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Abstract 
Background: Around 5000 patients undergo major lower limb amputation in the UK each 
year, commonly as a result of peripheral vascular disease.  Around 10% of these patients 
die before hospital discharge, and 30% die within a year of surgery.  Despite this, 
evidence for optimal management of these patients is weak.  The aim of this thesis is to 
develop tools which will direct future research and quality-improvement towards key 
interventions and outcomes for these patients. 
 
Methods: I used data from the UK National Registry to identify risk-factors for poor 
mortality and morbidity outcomes using rigorous statistical tools and developed a 
prognostic model for in-hospital mortality.  
I identified important outcomes for patients undergoing major lower limb amputation 
through systematic review of the literature and focus groups.  I then established 
consensus on core outcome sets for short- and medium-term studies recruiting these 
patients using a multi-round consensus survey followed by a face-to-face consensus 
meeting. 
 
Results: Independent risk-factors for in-hospital mortality were identified as emergency 
admission, bilateral operation, trans-femoral operation, age, American Society of 
Anesthesiologists grade, abnormal electrocardiogram and increased white cell count or 
creatinine, decreased albumin or patient weight. Previous revascularisation procedures 
were protective. 
I established consensus on 11 core outcomes for short-term studies and 11 core 
outcomes for medium-term studies.  Stump wound infection or healing, problems with 
the other leg and psychological morbidity were present in both sets. Outcomes related to 
death, additional healthcare, communication and pain relief were core for short-term 
studies.  Outcomes related to mobility, social re-integration, independence and quality of 
life were core for medium-term studies. 
 
Conclusions: I have identified contemporary risk-factors for peri-operative outcomes and 
defined core outcome sets for patients undergoing major lower limb amputation.  Future 
work should adopt these in order to design interventions which modify key risk-factors 
and use core outcomes as their key endpoints. 
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1 Introduction 
1.1 Background 
The prevalence of lower extremity peripheral arterial disease (PAD) is rising globally, with 
rates exceeding 10% of the population in people aged 65-69 years.1 The most significant 
risk factors for PAD are smoking and diabetes (of any type), so although rates of smoking 
are now gradually falling in many countries, high historical rates of smoking together with 
the rising prevalence of diabetes mellitus mean that this trend is likely to continue for the 
foreseeable future.2  The global increasing prevalence of diabetes, which has almost 
quadrupled over 34 years from 108 million people worldwide in 1980 to 422 million in 
2014,2 has been described as  ‘the biggest epidemic in human history.’ 3 
Despite advances in techniques for revascularisation, a small but significant proportion (1-
2%) of patients with PAD will progress to non-reconstructable or non-salvageable disease, 
and be faced with major lower limb amputation (MLLA).4  This risk is about 50% higher in 
patients who have diabetes-related PAD.5 This has led to approximately 5000 MLLAs 
being performed each year in the United Kingdom alone.6 
Poor outcomes after MLLA in the UK have been highlighted by a report from the National 
Confidential Enquiry into Patient Outcome and Death (NCEPOD).4 This showed a 12.4% 
30-day mortality rate, with more than 30% of patients dying in hospital within 90 days. 
This was worse than the 30-day mortality rate from a large study from the USA (9.1%).7  It 
was also significantly worse than the target of 5% 30-day mortality which was set by the 
original Vascular Society of Great Britain and Ireland Quality Improvement Framework 
(QIF) in 2010, which was revised to a target of less than 10% at 90 days in 2016.8  Major 
problems highlighted by the NCEPOD report included poor perioperative pain control and 
high short-term mortality. 
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In this context, the need for rigorous research is paramount.  There is a need to both gain 
a clearer understanding of the factors driving these poor outcomes, and to identify 
interventions which might improve matters. 
A recent systematic review and meta-regression of factors predictive of peri-operative 
mortality in patients undergoing MLLA for complications of PAD found 64 cohort studies  
with a total of 321,805 patients which examined this question.9  There were no 
randomised controlled trials which published either 30-day or in-hospital mortality rates.  
The majority of these studies were small and performed only simple univariate analyses, 
though five studies did use multivariate techniques to look for independent predictive 
factors.10-14  Only one of these studies went on to develop a prognostic model for peri-
operative mortality for use in clinical practice.12  Three other prognostic models of peri-
operative risk have been published.7,15,16  These were excluded from the above systematic 
review as they used slightly different definitions of peri-operative mortality.  These 
models use factors such as ‘impaired sensorium’ and ‘steroid use for a chronic condition’ 
which are not collected in routine health records in the UK,17 have poor discrimination, 
and there is no published evidence that any of the existing models have external validity. 
There is therefore a need for further work to explore risk factors for peri-operative 
mortality in patients undergoing MLLA. 
Once risk factors are identified, multivariate statistical techniques may be employed to 
develop prognostic models.  The development of prognostic models would also help with 
counselling of patients about the likely outcomes of surgery, informing the consent 
process and improving communication between the healthcare team and patients or 
carers.  Researchers must then identify interventions which may be beneficial and run 
interventional trials to assess their efficacy, effectiveness and implementation.   
These are well-trodden paths, which may result in improvements in a narrow set of 
outcomes.  However this approach has been challenged recently by organisations such as 
the Core Outcome Measures in Effectiveness Trials (COMET) initiative and the James Lind 
Alliance (a non-profit organisation which aims to identify the most important unanswered 
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questions in different areas of health or healthcare), who have highlighted the fact that it 
is both necessary to gain consensus on what is important and to engage fully with 
patients to gain a full understanding of their perspective.18,19  For example, while it may 
be clear to some that pain and perioperative mortality are important outcomes for 
patients undergoing MLLA for complications of PAD, this has not been formally assessed.  
It is entirely possible that these are not the most important outcomes from the patient’s 
perspective and that there are other key outcomes which deserve consideration.  
Investing time and resources on studies which focus on outcomes which may not be 
considered important by the majority of patients or healthcare professionals is both 
wasteful and unethical, as interventional trials potentially expose patients to the risks 
associated with interventions which have not previously been fully tested.  This is 
especially important in conditions such as MLLA, where there are large numbers of 
stakeholder groups. For example surgeons, physicians, anaesthetists, nurses, 
physiotherapists, occupational therapists, prosthetists and clinical psychologists all care 
for individuals having MLLA, so it is important to gain a broad perspective on the 
important outcomes. 
In response to the need to both gain an appreciation of patients’ perspectives and gain 
consensus on what the most important outcomes are, a growing number of “core 
outcome sets” have been developed.20  Core outcome sets aim to find consensus on 
which key outcomes should be reported for all studies involving a particular group of 
patients, presenting a minimum standard.  They aim to reduce research waste by 
directing research towards the most important outcomes and reduce the under-reporting 
of harms by listing the important harms which should be reported in clinical studies.  
Under-reporting of harms is an established problem in routinely collected health data,21 
and cherry-picking of outcomes to show a positive result is a known problem in both 
interventional trials and meta-analysis.22  The drive towards publication of core outcome 
sets has been led recently by the COMET initiative,18 which was launched in 2010, and 
core outcome sets have now been published for conditions as diverse as rheumatoid 
arthritis and head and neck cancer,23,24 with 1330 projects registered with the initiative as 
of December 2019.  With a rigorously developed core outcome set in place this should 
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enable researchers to do the right epidemiological studies to identify key drivers of these 
core outcomes and thus run the right interventional trials, which will make the biggest 
difference to our patients. 
The development of core outcome sets is therefore important for several reasons.  Firstly, 
consensus about the most important outcomes for these patients should direct research 
towards the key areas for improvement.  In a climate where research funding is in short 
supply, targeting research towards the most important outcomes becomes increasingly 
important.  Secondly, adoption of core outcome sets improves the efficiency of research.  
Systematic review with meta-analysis is the optimal strategy for pooling results from 
multiple studies, but many studies involving similar patient cohorts report similar but 
subtly different outcomes.25  This heterogeneity makes meta-analysis difficult, so that it is 
often impossible to generate pooled effect estimates.26  This can result in studies being 
excluded from analysis simply because their outcomes are not directly comparable. 
During the period where I was working on the projects in this thesis I was also a member 
of the trial management group for a randomised controlled feasibility study looking at an 
intervention designed to reduce post-operative pain following MLLA (the PLACEMENT 
trial).27  Though this is not covered in this thesis, the ethical approval for and the 
management of the projects in this thesis were undertaken in collaboration with the 
PLACEMENT trial management group. The work described in this thesis came about 
because while we (I and several others on the trial management group) were setting up 
the PLACEMENT trial we realised that there was a real need for high-quality tools to direct 
research and quality-improvement towards key interventions and outcomes for patients 
undergoing MLLA for complications of peripheral vascular disease. This group is therefore 
referred to multiple times throughout the thesis.  
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1.2 Assessment of peri-operative mortality risk factors 
The NCEPOD report highlighted the high perioperative mortality rate of patients 
undergoing MLLA, which was found to be 12.4% at 30 days.4 This makes MLLA the highest 
risk commonly performed Vascular Surgery operation other than ruptured abdominal 
aortic aneurysm (AAA) repair: higher than elective open AAA repair (3.0%) or lower limb 
bypass (3.0%).6 Despite this, it has historically been relatively overlooked by Vascular 
Surgeons, and the NCEPOD report found that around a third of cases were performed by 
unsupervised non-consultant grade surgeons.4  This is changing, with the 2016 Quality 
Improvement Framework recommending that a consultant vascular surgeon should be 
present in theatre for all major lower limb amputation cases. 
In the context of high-risk operations, quantification of risk is important for several 
reasons.  Firstly, it is important when counselling patients about the benefits and hazards 
of conservative management or surgical intervention.  Recent UK court rulings about 
patient consent have brought this to the fore for both patients and surgeons alike.28 This 
is an evolving area, but current advice is now that ‘surgeons are required to engage in a 
consenting process tailored to the individual patient with detailed, accurate and realistic 
explanations of the pros and cons of surgery.’29 In procedures such as MLLA where 
individual risk varies widely between patients, it is important to be able to quantify risks 
as accurately as possible. 
Secondly, the past few years have seen increasing publication of surgeon-specific or unit-
specific outcomes.  Some level of monitoring is important from a clinical governance 
point of view.  This potentially carries the benefit of improving outcomes via effects 
similar to the Hawthorne effect,30 which describes the now well-established research 
study effect where productivity or outcomes improve simply as a result of being 
monitored.  It does, however,  carry the risk of leading to risk-averse behaviour from 
surgeons if there is inadequate or inaccurate risk adjustment of these outcomes.31 Use of 
accurate, validated risk adjustment tools also helps to identify high-risk patients to 
clinicians, enabling them to target more intensive pre-operative work-up and 
  
6 
optimisation and higher post-operative levels of care to the appropriate patients.  There 
is increasing interest into the putative benefits of ‘prehabilitation’, with multiple on-going 
studies,32 though with little evidence of benefit at this time.33  This targeted care does, 
however, have the potential to lead to improvements in outcomes, and has been 
proposed as the major reason why outcomes in Cardiac Surgery improved dramatically 
after routine adoption of the European System for Cardiac Operative Risk Evaluation 
(EuroSCORE) into clinical practice.34 These factors have led to an explosion of published 
risk models in surgery, including an updated EuroSCORE II for cardiac surgery,35 and those 
used for laparotomy and abdominal aortic aneurysm repair,36,37 to name but a few. 
1.2.1 The UK National Vascular Registry 
The National Vascular Registry (NVR) is an audit database which is used for reporting 
short-term surgeon-specific outcomes for the two compulsory vascular index procedures 
(elective AAA repair and carotid endarterectomy).  In addition, data are collected for 
lower limb angioplasty, lower limb bypass and lower limb amputation, though data entry 
for these is voluntary rather than mandatory for surgeons practising within the UK 
National Health Services.  Due to the voluntary nature of reporting for the amputation 
dataset, case completion rates have historically been low, with only about 30% of cases 
recorded in 2009.  With talk of increasing the scope of compulsory reporting, this doubled 
to around 60% by the end of 2016.38   
With this improved case ascertainment, it is now appropriate to look again at the factors 
which predict peri-operative mortality in patients undergoing MLLA for complications of 
PAD in the UK.  While the missing 40% of cases may be systematically different from the 
remaining 60%, thus introducing an element of bias into any resulting analysis, with 
approximately 3,000 cases reported per year, I feel that analysis of this large number of 
cases will nonetheless provide useful insight into the risk factors for the majority of 
patients.  Given the improvements in outcome seen in other fields following the 
development of high-quality prognostic models of risk, it is also therefore appropriate to 
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generate new prognostic risk prediction tools based on improved (larger) datasets, to see 
if it is possible to improve upon existing models. 
Ideally, we would then move on to look at medium-term mortality as well as short- and 
medium-term morbidity.  Unfortunately, while it will be possible to briefly examine short-
term morbidity outcomes using data from the National Vascular Registry, as certain 
morbidity outcomes are reported, the data set has never been externally validated, so it 
is unclear how accurate the reporting of these outcomes will be.  It is well known that 
morbidity outcomes are under-reported in routinely collected data,21 so it is likely that 
morbidity outcomes in the National Vascular Registry are also under-reported.  It will 
therefore not be possible to quantify the risks of these outcomes with any degree of 
certainty from the National Vascular Registry.  Medium-term outcomes are not collected 
in the National Vascular Registry, so it will not be possible to examine these outcomes 
using this data source.  
1.3 Core outcome sets 
No core outcome set exists for major lower limb amputation.  Some more tightly focussed 
work has been done on factors influencing mobility in established amputee patients,39 
but there is no consensus about which outcomes are important to report for patients 
undergoing major lower limb amputation.  In this respect, vascular surgery in general is 
lagging behind many other specialties, such as oesophageal,40 colorectal41 and head and 
neck cancer surgery,24 where core outcome sets already exist.  In contrast, no core 
outcome set has been defined for any condition treated by or intervention delivered by 
vascular surgeons. 
Some additional complexity arises from the fact that recovery and rehabilitation after 
MLLA is a lengthy process, taking many months.  This means that there is a reasonable 
chance that the core outcomes for studies with short-term primary outcomes (where 
peri-operative complications, acute pain management, etc. may be key) may be different 
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from the core outcomes for studies with medium-term primary outcomes (where mobility 
and independence may be most important).  There is no agreed definition of what, 
precisely, is meant by ‘short-term’ or ‘medium-term’ in patients undergoing MLLA.  
Surgical audits often define short-term variously as within 30 days (as in the USA7), during 
the primary hospital admission (as in the National Vascular Registry17), or sometimes 
within 90 days (as in the UK national oesophago-gastric cancer audit).42  Medium-term is 
again a poorly defined term.  Reporting standards for abdominal aortic aneurysm repair 
define it as ‘up to 5 years after graft implantation’.43 
Given the poor outcomes highlighted by the NCEPOD report, it is imperative that we 
move forward in developing interventions to improve the care of patients undergoing 
MLLA.  However, as described above, to maximise the efficiency of this work it is vitally 
important that core outcome sets are developed.  Development of core outcome sets will 
aid the chain of research at multiple levels.  Firstly, core sets will guide epidemiological 
studies to consider which risk factors impact the core outcomes, leading to the 
development of risk models for those outcomes.  Secondly, they will guide researchers to 
investigate interventions designed to improve core outcomes, rather than investing 
valuable time and money pursuing interventions which are targeted at improving 
outcomes, but which might not be of central importance.  The efficacy and effectiveness 
of these interventions should then be assessed by measurement of core rather than non-
core outcomes in clinical trials, and by harmonising outcomes, data from multiple trials 
can better be subjected to meta-analysis in order to provide pooled estimates of 
treatment effects. 
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1.4 Thesis aims and objectives 
1.4.1 Aim 
The aim of this thesis is to develop tools which will direct future research and quality-
improvement towards key interventions and outcomes for patients undergoing MLLA for 
complications of peripheral vascular disease. 
1.4.2 Objectives 
  I will do this in two major ways. 
1.  
a. I will identify the principal risk factors for peri-operative mortality and 
morbidity in patients undergoing MLLA using routinely collected national 
data. 
b. Following on from this, I will use these risk factors to develop a prognostic 
model for peri-operative mortality, again using routinely collected national 
data. 
This work is presented in Chapter 2 of this thesis. 
2.  
a. I will develop an exhaustive list of outcomes for research and service 
evaluation involving patients undergoing major lower limb amputation as a 
result of complications of peripheral vascular disease.  
b. Following on from this, I will establish consensus on core outcome sets for 
both short-term and medium-term research and service evaluation 
involving patients undergoing MLLA for complications of peripheral 
vascular disease, using the list developed in 2.a. above as a starting point.   
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The development of core outcome sets for patients undergoing MLLA for complications of 
PAD is described in Chapters 3 and 4. 
The thesis concludes in Chapter 5 by giving an overview of the work, discussing the ways 
in which I have achieved the objectives I set out at the beginning of the project and 
including discussion of limitations and areas where further work is needed. 
Some of the work described in this thesis has been published in peer-review journals, and 
I have also presented much of the work at national and international conferences.  Details 
of these publications and presentations are given in Appendix B. 
  
  
11 
2 Assessment of peri-operative risk for 
people undergoing major lower limb 
amputation for complications of peripheral 
vascular disease: analysis of a three-year 
cohort from the UK National Vascular 
Registry 
2.1 Introduction 
Risk prediction for high-risk surgical procedures is of increasing importance 
internationally but has gained particular prominence within the United Kingdom as a 
result of three principal factors.  Firstly, population aging has resulted in an increasingly 
frail patient population, with multiple co-morbidities as well as functional decline.44,45  
Secondly, recent UK court rulings about patient consent have brought the issue of 
appropriate patient counselling prior to surgery to the fore for both patients and 
surgeons alike.28  Finally, the advent of surgeon-specific outcome publication in the 
United Kingdom has made the importance of appropriate risk adjustment a high priority 
for national audit.   
There is widespread concern that the publication of these data will lead to high risk 
patients being denied procedures which they might otherwise have chosen to undergo as 
a result of surgeons being more concerned about having an unfavourable statistic 
recorded next to their name than patients might be about experiencing those negative 
outcomes. 31  Appropriate risk adjustment reduces this issue by modifying the expected 
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number of adverse outcomes according to patients’ fitness for surgery and thus 
comparing a surgeon’s performance with a more appropriate standard. 
Major lower limb amputation is a high risk surgical procedure, with an in-hospital 
mortality rate in the UK of approximately 6% for below knee amputation and 12% for 
above knee amputation.6  These mortality rates make it the highest-risk lower limb 
procedure in Vascular Surgery in this country.  It is important, therefore, to identify the 
factors which contribute to these high mortality rates.  While it was appropriate in the 
last century to do this in a simple univariate manner from small single-centre studies, the 
adoption of national registries over the past two decades mean that there is an 
opportunity to use much more rigorous methodology, such as using multivariate 
techniques to identify whether predictors are independent or highly correlated.   
The earliest work of this type came from a Scottish study, published in 1999, and 
identified only age and sex as significant independent risk factors for mortality at 30 
days.10  More recently, work by Easterlin et al. from the USA using data from the National 
Surgical Quality Improvement Program database found several other predictors of 
mortality, going on to develop a predictive model to allow assessment of perioperative 
risk for an individual patient.12  Application of this work to data from UK audit is 
unfortunately hampered by the fact that several of the included variables, such as ‘steroid 
use for a chronic condition’, are not routinely collected in this country.  Work from Japan 
identified similar factors, but no risk model was developed to aid in presenting an 
accurate picture of the likely outcomes of surgery to patients, or in risk adjustment.14  
Table 2.1 lists the independent risk factors for peri-operative mortality identified in these 
studies.  In addition to the work of Easterlin et al. three other risk models exist for 
patients undergoing major lower limb amputation.  These are two versions of the 
Vascular Biochemistry and Haematology Outcome Model (VBHOM), as well as the 
Veterans Affairs model (VAM).15,16,46  These latter models were developed using quite 
small databases and do not report high levels of accuracy, even internally within the 
datasets used to generate the models. The second VBHOM model was developed in 
response to work attempting to externally validate the first VBHOM model, which found 
  
13 
it to have poor predictive power in terms of both discrimination and calibration.  There is 
no work which externally validated the second VBHOM model, the VAM or the model of 
Easterlin et al.  
 
Study Country Patients Independent Risk Factors 
Tang et al. 
2009 46 
UK 269 
Age, sex, emergency admission, urea, sodium, 
potassium, haemoglobin, white cell count, 
creatinine, urea/creatinine ratio 
Patterson et 
al. 201215 
UK 306 Age, sodium, creatinine, albumin, potassium 
Pell et al. 
199910 
UK 2759 Age, sex 
Easterlin et 
al. 201312 
USA 9244 
Age, dependent functional status, dialysis, 
steroid use for a chronic condition, dyspnoea, 
history of CHF, history of COPD, impaired 
sensorium, preoperative systemic sepsis, 
previous major cardiac surgery 
Yamada et 
al. 201614 
Japan 8565 
Age, sex, dependent functional status, 
malignancy, CRF, history of cardiac disease, level 
of amputation, emergency admission 
Feinglass et 
al. 200116 
USA 4061 
Age, smoking history, dyspnoea at rest, DNR 
status, dependent functional status, current 
pneumonia, ventilator dependent, COPD, 
previous revascularisation or amputation, 
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gangrene, hepatomegaly, hypertension 
requiring medications, current dialysis, 
cerebrovascular accident without neurological 
deficit, impaired sensorium, disseminated 
cancer, albumin, bilirubin > 1mg/dL, potassium < 
3.5mmol/L, BUN > 40mg/dL, WBC > 11, 
emergency operation, ASA grade 
Table 2.1: Risk factors for peri-operative mortality from previous multicentre studies employing 
multivariate modelling to identify independent risk factors.  All listed factors were significant at 
the 5% level.  CHF: congestive heart failure.  COPD: chronic obstructive pulmonary disease, CRF: 
chronic renal failure, DNR: do not resuscitate, BUN: blood urea nitrogen, WBC: white blood-cell 
count, ASA: American Society of Anesthesiology. 
 
Part of the reason for there being little work examining risk prediction in these patients 
may be a historical lack of availability of large clinical databases including patients 
undergoing major lower limb amputation.  As recently as 2009 for example, case 
ascertainment rates from the UK National Vascular Database were as low as 30%.  While 
this is not likely to improve dramatically until such a time as major amputation becomes 
subject to mandatory outcome reporting, many Vascular Surgeons in the UK believe that 
it is only a matter of time before the scope of mandatory reporting is widened to include 
these patients.  As a result, increasing numbers of amputations are being reported in 
national audit databases.  Case ascertainment estimates in the re-titled UK National 
Vascular Registry (NVR) rose to almost 60% in 2015.6  With well over 50% case 
ascertainment, it is now appropriate to begin thinking about the generation of risk 
prediction tools analogous to those already widely available for other high risk 
procedures such as cardiac surgery and abdominal aortic aneurysm repair.37,47   
The objectives of this chapter are 
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c. To identify the principal risk factors for peri-operative mortality and 
morbidity in patients undergoing MLLA using routinely collected national 
data. 
d. To use these risk factors to develop a prognostic model for peri-operative 
mortality, again using routinely collected national data. 
I will also compare the efficacy of the prognostic model to existing risk models and assess 
the model’s ability to predict morbidity outcomes such as length of stay and systemic 
peri-operative complications. 
Work from this chapter has been published in the European Journal of Vascular and 
Endovascular Therapy. 
2.2 Methods 
2.2.1 Data 
All patients recorded in the NVR as undergoing major lower limb amputation (below 
knee, through knee, above knee, hip disarticulation and hind quarter amputation) from 
January 2014 until December 2016 were included in the study.  Data were formally 
requested through and approved by the UK Healthcare Quality Improvement Partnership, 
who are the data controllers for English and Welsh data within the NVR; and through the 
Audit and Quality Improvement Committee of the Vascular Society of Great Britain and 
Ireland, who are the data controllers for Scottish and Northern Irish data within the NVR.  
Unfortunately, there was some delay in receiving the data, as there were some database 
issues which the data controllers needed to resolve prior to handing over the data. 
Data applications from the NVR are tightly controlled, and applicants are given only data 
which they can justify as important for the purpose of the project.  As one of the purposes 
of the project was to determine which factors were important for predicting outcome, I 
therefore applied for a reasonable number of parameters.  I also applied for a number of 
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outcome variables.  A list of the variables applied for and their type is given in Table 2.2.  
A full description of each of the data fields can be found in the NVR data dictionary, 
available from the NVR website. 
2.2.2 Outcomes 
As shown in Table 2.2, I requested several different outcome data fields.  It is therefore 
necessary to define, a priori, the primary outcome of interest, with the remainder being 
defined as secondary outcomes, in order to avoid being accused of selective reporting 
bias.  While all the outcomes requested are important in their own contexts, I chose in-
hospital mortality as the primary outcome.  This is coded in the NVR as ‘Discharge status’, 
with two possible values: alive or dead.  I have done this for two main reasons.  Firstly, it 
is a clear, categorical outcome which is not subject to significant recall bias.  This is 
important in work which relies on observational data, as it adds strength to any findings.  
Secondly, as it is not possible to submit records to the NVR without completing these 
data, it is unlikely that there will be significant missing data for this outcome. 
Other (secondary) outcomes available are return to theatre during admission, re-
admission to a higher level of care, length of stay (both post-operative and total), length 
of time from operation to last date of follow-up and last follow-up status (alive/dead – 
different from the primary outcome, which was in-hospital death as some patients do 
have later follow-up entered and whether this was ‘death’ or further clinical interaction), 
and post-operative complications, which are subdivided into several different categories: 
cardiac, respiratory, cerebral (stroke), renal failure, haemorrhage and limb ischaemia. 
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Data field Type Justification 
Age Predictor In order to take patient age into account in modelling 
Sex Predictor In order to take patient sex into account in modelling 
Deprivation 
index 
Predictor In order to look at whether social deprivation effects 
outcome 
Country of 
residence 
Predictor Required for Deprivation index analysis as these are 
country-specific 
Operation date Predictor In order to look at whether outcomes have changed 
over time, or with seasonal fluctuations 
Mode of 
admission 
Predictor In order to examine whether emergent or unplanned 
admissions are associated with worse outcomes 
compared with patients admitted electively 
Hospital status Predictor To examine whether there are differences between 
patients treated at major vascular centres and those 
who are not 
Side of 
indication 
Predictor To check for any difference in frequency between 
operative side, and the difference in outcome if 
bilateral amputation is performed in a single 
operation. 
Presenting 
problem 
Predictor To determine the effect that the underlying pathology 
leading to amputation has on outcomes. 
Previous 
ipsilateral 
treatment 
Predictor To determine the effect previous ipsilateral treatment 
has on outcome. 
  
18 
Comorbidities Predictor To look at the effect of comorbidities on outcome 
Smoking status Predictor To look at the effect of smoking status on outcome 
White cell count Predictor To look at the effect of blood parameters on outcome 
Sodium Predictor To look at the effect of blood parameters on outcome 
Potassium Predictor To look at the effect of blood parameters on outcome 
Creatinine Predictor To look at the effect of blood parameters on outcome 
Albumin Predictor To look at the effect of blood parameters on outcome 
Haemoglobin Predictor To look at the effect of blood parameters on outcome 
Glucose Predictor To look at the effect of blood parameters on outcome 
HbA1C Predictor To look at the effect of blood parameters on outcome 
Abnormal ECG? Predictor To look at the effect of cardiac conduction 
abnormalities on outcome 
ASA grade Predictor To look at the effect of ASA grade on outcome 
Ankle-brachial 
pressure index 
Predictor To look at the effect of degree of ischaemia at the 
ankle on outcome 
Medication Predictor To look at the effect of various medications (statins, 
ACE inhibitors/ARBs, beta blockers, antiplatelet 
agents, antibiotic prophylaxis, DVT prophylaxis) on 
outcome 
Weight Predictor To look at the effect of nutritional status on outcome 
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Height Predictor To enable us to calculate BMI and look at the effect of 
nutritional status on outcome 
Operation type Predictor To look at the effect of amputation level on outcome, 
and to make sure that all included cases were major 
amputations 
Method of 
wound closure 
Predictor To look at the effect of method of wound closure on 
outcome 
Destination 
after theatre 
Predictor To look at whether critical care admission after 
theatre is associated with outcome 
Critical care stay Predictor To look at whether duration of critical care admission 
after theatre is associated with outcome 
Return to 
theatre during 
admission 
Outcome To look both at whether return to theatre effects 
other outcomes and also whether other factors affect 
the likelihood of return to theatre during admission 
Re-admission to 
higher level of 
care 
Outcome To look both at whether re-admission to higher level 
of care effects other outcomes and also whether 
other factors affect the likelihood of re-admission to 
higher level of care 
Post-operative 
complications 
Outcome To look at the frequency of post-operative 
complications and what factors predict post-operative 
complications 
Discharge status 
(alive/dead) 
Outcome To look at what factors affect in-hospital mortality 
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Length of stay Outcome To look at what factors affect length of post-operative 
stay in hospital. 
Post-op length 
of stay 
Outcome To look at what factors affect length of post-operative 
stay in hospital. 
Length of time 
from operation 
to last date of 
follow-up 
Outcome To work out survival or censoring dates for the 
purposes of looking at what factors affect post-
operative survival. 
Last follow-up 
status 
(alive/dead) 
Outcome To indicate whether length of time from operation to 
last date of follow-up is a time to death or a time to 
censoring event. 
Table 2.2: Data requested from the NVR.  A full description of each of the above data fields can be 
found in the NVR data dictionary, which is available on the NVR website. 
 
2.2.3 Ethical approval and study registration 
The Health Research Authority give guidance in the UK about whether studies involving 
patients or their data should be defined as audit, service evaluation or research.  
Retrospective observational studies often fall under the banner of ‘service evaluation’, 
and thus do not require formal ethical approval.  The exception to this is when this work 
is designed to generate ‘generalisable or transferable findings’.48  The generation of a 
prognostic model for outcomes such as in-hospital mortality certainly falls into this 
category, and so the present work does require ethical approval.  I therefore added a 
description of the project as a sub-project to an existing project recruiting patients 
undergoing major lower limb amputation: the PLACEMENT trial.27  This was then 
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submitted as a substantial amendment to Wales Research Ethics Committee 3, and was 
approved (reference number 16/WA/0353). 
There is also a strong argument that observational studies, like randomised controlled 
trials, should be registered on a WHO-compliant trial registry (though these are not trials) 
to guard against selective reporting bias.49  This has been supported by multiple high-
profile journals including the BMJ and The Lancet.50  I therefore elected to register my 
project on one of the WHO-compliant registries which accept registration of 
observational studies.  I chose the Australia and New Zealand Clinical Trial Registry 
(ANZCTR) as it is free to use, accepts observational studies, and allows individual users to 
submit study registrations.  The project is registered as ACTRN12618000356268. 
2.2.4 Statistical methodology 
All statistical analysis was performed in the R statistical programming environment 
version 3.5.1.51  Missing data are a problem within all large clinical databases, so it is 
important that these are correctly handled.  Approaches which have been used in the 
past include ‘complete case analysis’, where only cases without any missing data items 
are included in analysis, single value imputation and multiple value imputation 
techniques.  Complete case analysis is often the method adopted where statistical 
analysis is restricted to univariate testing, as it allows all of the directly available data to 
be used.  The NVR includes many different parameters however, some of which have very 
poor completion rates, so a complete case analysis might inevitably result in exclusion of 
the vast majority of cases where multivariate analysis is performed.  This is a hugely 
wasteful approach, making this approach unacceptable where multivariate analysis is 
performed on large databases.  The situation is actually worse than this, however, as 
sometimes data may not be ‘missing completely at random’.  What this means is that 
data may be more likely to be missing in certain contexts.  One example of this is that 
data may be more likely to be missing if a patient dies.  This is known to be the case for 
patients operated on for abdominal aortic aneurysm who were entered into the UK 
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National Vascular Database, the precursor of the NVR.52  This can lead to bias in the 
results which we would hope to avoid.53 
Single value imputation methods (for example imputing the mean value where an item is 
missing) also lead to bias where data are not ‘missing completely at random’, so this is 
also an unacceptable option.54  Instead, I chose to use multiple imputation methodology 
to account for missing data.53  This has several key advantages.  First of all, it avoids 
discarding cases and thus uses as many of the data as possible.  Secondly, under quite 
weak conditions it is robust to cases where data are not ‘missing completely at random’.  
To be more precise, missing values may be systematically different from observed values, 
but this can be predicted by one of the other measured parameters.  This is referred to as 
data being ‘missing at random’ in the literature on missing data.53  Returning to the 
example above where data were more likely to be missing if a patient had died, this 
would be an example of the missing data being ‘missing at random’, as the predictor 
(death of the patient) is measured. 
Finally, multiple imputation is widely-available in the form of the ‘mice’ package version 
3.3.0 for the R statistical programming environment, which uses a chained equations 
approach to perform multiple imputation.55 Owing to its attractive properties and its wide 
availability, multiple imputation has also been recommended by prominent expert 
reviews for use in clinical studies where significant amounts of missing data are 
present.53,56  No method of handling missing data, no matter how good, can cope with the 
situation where the majority of data is missing, so I excluded parameters where more 
than 50% of values were not recorded.  Data were imputed using 45 replicates with 45 
iterations of the chained equations algorithm for each replicate.  This is both more 
replicates and more algorithm iterations than are recommended in order to be likely to 
remove significant bias due to initial values.54  In order to explore any differences which 
there might be between the imputed data and the unimputed data, a sensitivity analysis 
was done by performing univariate analysis using both complete case analysis and also 
the multiply imputed data. 
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Univariate analysis was performed using univariate logistic regression, together with 
application of Rubin’s rules to pool estimates for multiple imputation.53  Continuous 
variables were kept as such rather than dichotomised into ‘high’ and ‘low’ values. Odds 
ratios are given in the results per unit change in value.  Multivariate analysis was 
performed using multivariate logistic regression analysis to develop models using pre-
operative predictors.  Parameters were selected for inclusion in prognostic models using 
Information Criterion analysis in order to generate a parsimonious model which avoided 
over-fitting, by minimizing the Schwarz-Bayes Criterion.57  The Schwarz-Bayes Criterion 
(SBC) is a quantity which trades off model complexity against model fit, and is calculated 
using the formula 
SBC = k.loge(n) – 2.loge(L), 
where k is the number of parameters in the model, n is the sample size and L is the 
likelihood of the model given the data, where the values of the parameters have been 
chosen to maximise L.  In practice, I will have used a statistics package to estimate L.  As I 
have a large number of possible parameters it is not practical to calculate the SBC for all 
possible models, so I use a stepwise iterative process starting from a minimal model and 
then calculating the SBC for models with either a parameter added, or a parameter 
removed.   The model with the minimum SBC is then selected as the new model and the 
process repeats until the SBC is smaller for the current model than it is for any model with 
an additional parameter and any model with a parameter removed.  This was done 
separately for each of the 45 replicates and terms which were present in at least half of 
the replicates were retained.   
ROC curve analysis was used to assess model discrimination using the pROC package 
version 1.12.1.58  This plots the sensitivity against one minus the specificity for all possible 
cut-off values of a binary prediction model.  The area under this curve (also known as the 
C-statistic) is then used to assess the ability of the model to discriminate between cases 
where the outcome is positive and those where it is not.  A prediction model which is no 
better than chance will have a ROC curve which is a straight line at a 45-degree angle 
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from (0,0) to (1,1), with a C-statistic of 0.5. Standard statistical texts suggest that a C-
statistic of 0.6 implies average predictive power, 0.7 implies good predictive power and 
0.8 (or above) implies excellent predictive power.59  Another way of interpreting the 
meaning of the C-statistic is that it is the probability that the prediction model will give a 
higher score to a case where the outcome is positive than to one where the outcome is 
not.  The Delong method was then used to calculate confidence intervals for the C-
statistic and test whether performance was different to the estimated C-statistics of 
existing models.60 
The Hosmer-Lemeshow goodness of fit test was used to assess calibration of the 
models.59  This divides the data into several groups according to the predicted probability 
of the outcome, compares observed and expected counts and uses a c2 test to detect any 
significant mis-calibration. 
2.3 Results 
2.3.1 Demographics and outcomes 
There were 12,593 amputations entered into the registry during the study period 
(January 2014 to December 2016), of which 9549 were above the ankle joint and so 
comprised the study population.  Of these, 4516 (47%) were trans-tibial, 4369 (46%) 
trans-femoral, 442 (5%) through-knee, 32 (0.3%) hip disarticulation and 190 (2%) were 
simultaneous bilateral procedures.  Table 2.3 summarises the baseline characteristics of 
the study population, together with the amount of missing data for each parameter.  
Some of the parameters requested were not available due to database issues, so there 
are some differences between the list presented in Table 2.3 and those requested in 
Table 2.2. 
Overall, 865 patients (9.1%) died before leaving hospital.  There was also a high rate of 
post-operative morbidity in the cohort, with 6.6%, 9.7% and 4.3% of patients suffering 
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cardiac, respiratory and renal complications respectively.  Less than 1% of patients were 
recorded as having a post-operative stroke or bleeding complication, and 4.4% had a 
complication relating to limb ischaemia.  Ten percent (966/9546) of patients had an 
unplanned return to theatre, while four percent (363/9545) were re-admitted to critical 
care.  The median post-operative length of stay was 16 days (IQR 9—28 days, 1 missing 
value), with an overall median length of stay of 24 days (IQR 14—42 days, 1 missing 
value). 
 
 
Parameter Value Number missing (%) 
Age (median (IQR)) 70.3 (60.3—78.5) 5 (<1) 
Sex (Male : Female) 6729 : 2820 0 (0) 
Hospital type (teaching : non-teaching) 4544 : 5005 0 (0) 
Emergency admission (Y : N) 7489 : 2060 0 (0) 
Country (Eng:Sco:Wal:NI) 5875:494:439:358 2383 (25) 
Side (Left : Right : Bilateral) 4635 : 4724 : 190 0 (0) 
Previous intervention on same side (Y : N) 5902 : 3628 19 (<1) 
Comorbidities (Y : N) 
Diabetes 
Ischaemic heart disease 
Congestive heart failure 
 
5065 : 4467 
3788 : 5744 
1004 : 8528 
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Chronic lung disease 
Chronic kidney disease 
Hypertension 
Stroke 
1939 : 7593 
1968 : 7564 
5812 : 3720 
1085 : 8447 
17 (<1) 
Smoking (Never : Ex : Current) 1948 : 4721 : 2850 30 (<1) 
Pre-operative blood tests (median (IQR)) 
White cell count (109 cells/L) 
Haemoglobin (g/L) 
Sodium (mmol/L) 
Potassium (mmol/L) 
Creatinine (µmol/L) 
Albumin (g/L) 
 
11.7 (9.0—15.4) 
112 (97—148) 
136 (133—139) 
4.5 (4.1—4.9) 
81 (61—118) 
30 (24—35) 
 
14 (<1) 
3416 (36) 
38 (<1) 
18 (<1) 
11 (<1) 
2824 (30) 
Abnormal ECG (Y : N) 3672 : 4889 988 (10) 
ASA grade (1:2:3:4:5) 90:756:6164:2462:75 2 (<1) 
Pre-operative medications 
Antiplatelet agent 
Statin 
Beta-blocker 
ACE-inhibitor / ARB 
 
6783 : 2763 
6701 : 2845 
2560 : 6986 
3035 : 6511 
 
 
3 (<1) 
Weight (median (IQR)) 75 (63—87) 2607 (27) 
Table 2.3: Baseline characteristics of patients.  ACE – Angiotensin converting enzyme.  ARB – 
Angiotensin II receptor blocker. 
 
  
27 
2.3.2 Risk factors for post-operative mortality 
2.3.2.1 Univariate analysis 
Univariate analysis revealed that increased patient age; a history of ischaemic heart 
disease, congestive heart failure, chronic lung disease, chronic kidney disease or stroke; a 
raised pre-operative white cell count, raised pre-operative serum creatinine or low pre-
operative serum albumin; an abnormal ECG; increased American Society of 
Anesthesiologists (ASA) grade; emergency admission and pre-operative beta blocker 
therapy all increased the odds of in-hospital mortality.  Male sex, previous intervention 
on the same side, below knee amputation, current smoking, statin or ACEi/ARB therapy 
(Angiotensin Converting Enzyme inhibitor/Angiotensin II receptor blocker – a class of anti-
hypertensive medication), and increased weight all had protective effects, when using 
multiple imputation to handle challenges with missing data (Table 2.4). 
Parameter Multiple Imputation Complete Case 
Analysis 
O.R. 95% C.I. P-value O.R. 95% C.I. 
Age (per 10 year ­) 0.763 0.720—0.809 <0.0001 0.764 0.721—0.810 
Sex (Male vs. Female) 1.241 1.070—1.439 0.004 1.241 1.070—1.439 
Hospital type (teaching v. non-
teaching) 
1.034 0.899—1.190 0.637 1.034 0.899—1.190 
Emergency admission 0.263 0.203—0.342 <0.0001 0.263 0.203—0.342 
Previous intervention on same side 1.617 1.406—1.861 <0.0001 1.618 1.406—1.861 
Below knee amputation vs. higher 
level 
2.216 1.907—2.575 <0.0001 2.216 1.907—2.575 
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Comorbidities (Yes vs. No) 
Diabetes 
Ischaemic heart disease 
Congestive heart failure 
Chronic lung disease 
Chronic kidney disease 
Hypertension 
Stroke 
 
1.069 
0.634 
0.478 
0.690 
0.477 
0.867 
0.785 
 
0.930—1.230 
0.551—0.730 
0.397—0.576 
0.588—0.810 
0.411—0.555 
0.750—1.003 
0.640—0.963 
 
0.349 
<0.0001 
<0.0001 
<0.0001 
<0.0001 
0.054 
0.021 
 
1.069 
0.635 
0.479 
0.690 
0.477 
0.868 
0.785 
 
0.930—1.230 
0.552—0.731 
0.398—0.577 
0.588—0.811 
0.411—0.556 
0.750—1.003 
0.640—0.963 
Smoking – Current 1.208 1.031—1.415 0.019 1.206 1.030—1.413 
Pre-operative blood tests 
White cell count (per 109 cells/L ­) 
Haemoglobin (per g/L ­) 
Sodium (per mmol/L ­) 
Potassium (per mmol/L ­) 
Creatinine (per 10 µmol/L ­) 
Albumin (per g/L ­) 
 
0.968 
1.005 
0.995 
0.993 
0.973 
1.061 
 
0.961—0.975 
0.996—1.014 
0.980—1.010 
0.924—1.069 
0.968—0.977 
1.051—1.072 
 
<0.0001 
0.307 
0.507 
0.860 
<0.0001 
<0.0001 
 
0.968 
1.005 
0.995 
0.994 
0.973 
1.062 
 
0.961—0.975 
0.996—1.014 
0.980—1.010 
0.924—1.069 
0.968—0.977 
1.051—1.072 
Abnormal ECG 0.411 0.353—0.478 <0.0001 0.400 0.343—0.467 
ASA grade (per grade ­) 0.248 0.219—0.282 <0.0001 0.248 0.219—0.282 
Pre-operative medications 
Antiplatelet agent 
Statin 
Beta-blocker 
 
1.113 
1.258 
0.718 
 
0.957—1.295 
1.086—1.459 
0.619—0.834 
 
0.166 
0.002 
<0.0001 
 
1.113 
1.259 
0.719 
 
0.957—1.295 
1.086—1.459 
0.619—0.834 
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ACE-inhibitor / ARB 1.169 1.002—1.363 0.047 1.169 1.002—1.364 
Weight (per 10kg ­) 1.085 1.042—1.129 <0.0001 1.088 1.043—1.134 
Table 2.4: Univariate analysis showing odds ratios of being discharged alive according to different 
risk factors for patients undergoing major lower limb amputation in the UK National Vascular 
Registry. The last two columns present a sensitivity analysis using complete cases only.  Numbers 
greater than one indicate greater odds of being discharged alive.  O.R. – Odds Ratio. C.I. – 
Confidence Interval.  ACE – Angiotensin converting enzyme.  ARB – Angiotensin II receptor blocker.  
The  ­ symbol is used to indicate an increase in value, for example ‘per 10 year ­’ indicates that 
the odds ratios are those associated with a ten-year increase in age. 
 
Analysis was repeated using complete case analysis to assess sensitivity to the imputation 
methodology.  Results were almost identical to the multiple imputation analysis, giving 
confidence that the imputation methodology had not introduced any unwanted bias 
(Table 2.4). 
2.3.2.2 Multivariate modelling 
Multivariate regression modelling revealed that independent factors associated with in-
hospital mortality were emergency admission (Odds Ratio (OR) 2.47, 95% Confidence 
Interval (C.I.) 1.89-3.24), bilateral operation (OR 2.19, 95% C.I. 1.48-3.25), age (OR per 10 
year increase 1.21, 95% C.I. 1.13-1.29), ASA grade (OR per unit increase 2.60, 95% C.I. 
2.27-2.98), abnormal ECG (OR 1.52, 95% C.I. 1.28-1.79), and increased white blood cell 
count (OR per 109 cells/L increase 1.02, 95% C.I. 1.01-1.03) or serum creatinine (OR per 10 
µmol/L increase 1.02, 95% C.I. 1.02-1.03).   
Independent protective factors included trans-tibial operation (OR 0.61, 95% C.I. 0.52-
0.72), increased serum albumin (OR per g/L increase 0.97, 95% C.I. 0.95-0.98), previous 
procedures to the amputated limb (OR 0.79, 95% C.I. 0.68-0.92), and increased patient 
weight (OR per 10kg increase 0.95, 95% C.I. 0.91-0.99). 
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2.3.3 Development of a prognostic model of post-operative mortality 
One of the benefits of logistic regression analysis is that the model allows quantification 
of the probability of the specified outcome occurring (in-hospital mortality in this case).  
This model can be calculated using the formula  
P = 1 / (1 + eA) 
where  
• A is the fitted model formula, in this case 
A = 6.736 - 0.784 x (Bilateral operation) + 0.491 x (Trans-tibial operation) - 0.904 x 
(Emergency admission) - 0.019 x (Patient Age) - 0.410 (ECG abnormal) + 0.036 x (Albumin) 
- 0.958 x (ASA grade) - 0.002 (Creatinine) - 0.020 (White Cell Count) + 0.005 (Patient 
Weight) + 0.231 (Previous Ipsilateral Intervention) 
•  the logical variables (bilateral, trans-tibial, emergency, ECG abnormal, previous 
intervention) are replaced by one if they are true and zero if they are false; age is 
in years, albumin is measured in grams per litre, creatinine in micromoles per litre, 
white cell count in 109 per litre and patient weight in kilograms. 
The parameters used in the prognostic model above are all of the predictors found to be 
significant independent risk factors for in-hospital mortality in the previous section.  As 
described in the Methods in Section 2.2.4, we used the Schwarz-Bayes Criterion to 
determine whether the improved fit from retaining a parameter was sufficient to offset 
the increased complexity of adding the parameter to the model. 
When developing a model to predict outcome, it is common to test whether the model 
successfully discriminates between patients, and whether it is well calibrated. 
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I subjected the multivariate model described above to ROC curve analysis to determine 
the power of the model to discriminate between patients who died in hospital and those 
discharged alive.  As discussed above in the Methods, the area under the ROC curve gives 
a good summary of the discrimination of a prognostic model, with a value of 0.5 
representing discrimination no better than chance, 0.6 regarded as average 
discrimination, 0.7 as good discrimination and 0.8 as excellent discrimination.59  This 
showed that the model has good (bordering on excellent) discrimination (area under ROC 
curve 0.79, 95% C.I. 0.77-0.80).  A plot of the ROC curve is shown in Figure 2.1. 
I also performed the Hosmer-Lemeshov goodness of fit test to assess the calibration of 
the model.  There was no evidence of model mis-calibration (P=0.348).  Table 2.5 shows 
observed and expected outcomes with the data divided into 10 groups according to the 
predicted probability of in-hospital mortality from the model.  This is shown graphically in 
Figure 2.2. 
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Figure 2.1: ROC curve for prognostic model. 
 
Figure 2.2: A comparison between the predicted proportion of patients not surviving until hospital 
discharge and the observed proportion according to the predictive model developed here.  The 
cohort has been divided into 10 subsets according to predicted risk of mortality.  These data are 
given in a tabular format in Table 2.5. 
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Observed 
deaths 
Expected 
deaths 
Number of 
patients 
Probability 
range 
7 7 954 0 – 1.2% 
14 16 955 1.2 – 2.2% 
20 25 955 2.2 – 3.2% 
37 35 955 3.2 – 4.3% 
44 47 955 4.3 – 5.6% 
62 61 955 5.6 – 7.3% 
75 81 955 7.3 – 9.9% 
117 114 955 9.9 – 14% 
193 169 955 14 – 22% 
295 309 954 > 22% 
Table 2.5: Model calibration table for the logistic regression model for in-hospital mortality.  The 
‘number of patients’ in each row is the number whose predicted probability of failing to survive to 
hospital discharge is in the range given in the final column. 
 
2.3.3.1 Comparison to existing models 
As mentioned above, there are several existing models for peri-operative mortality 
following major lower limb amputation.12,15,16,46  Comparison with these models is 
hampered by the fact that three of the four models include terms which are not recorded 
in the National Vascular Registry, so any estimation of the discriminatory power of these 
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models will be hampered by the fact that I can only set these parameters to default values.  
This will clearly also affect the calibration of the models, as I can only guess at the correct 
‘average’ values.  The revised VBHOM model (which I will refer to as ‘VBHOM2’) does not 
suffer from this problem, so comparison with this model can be viewed as ‘fair’.15 
The calculated areas under the ROC curve for each of the four models were 0.59 (95% C.I. 
0.56-0.61) for VBHOM, 0.65 (95% C.I. 0.63-0.67) for VBHOM2, 0.68 (95% C.I. 0.66-0.70) for 
VAM and 0.65 (95% C.I. 0.64-0.68) for the NSQIP model.  All four models showed inferior 
discrimination to the model I have developed (P<10-6 for all comparisons).  Figure 2.3 shows 
all five ROC curves on the same graph for comparison.  The NSQIP, VBHOM and VBHOM2 
models all failed the Hosmer-Lemeshov goodness of fit test (P<0.0001 in all cases), 
suggesting that they are also poorly calibrated for this patient cohort.  The intercept 
coefficient was not published for the VAM model, so it was not possible to assess 
discrimination for that model. 
2.3.3.2 Performance of the model for predicting secondary outcomes 
Although the primary purpose of the model is to predict peri-operative mortality, it is also 
of interest to determine whether it is predictive of other negative post-operative 
outcomes.  I again used ROC curve analysis, this time with the secondary outcomes.  The 
model was a good discriminator of cardiac, respiratory and renal complications (area 
under ROC curve 0.74, 0.69 and 0.74 respectively).  It also had some ability to predict the 
need for return to critical care (area under ROC curve 0.62).  However, it was a poor 
discriminator of the need to return to theatre (area under ROC curve 0.52).  The model 
was also not a good discriminator of prolonged post-operative length of stay (area under 
ROC curve 0.57). 
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2.3.4 Risk factors for secondary outcomes 
In addition to examining risk factors for the primary outcome, I also looked at several 
secondary outcomes: return to theatre during admission, re-admission to a higher level of 
care, length of stay (both post-operative and total) and post-operative complications, 
which are subdivided into several different categories: cardiac, respiratory, cerebral 
(stroke), renal failure, haemorrhage and limb ischaemia.  The length of time from 
operation to last date of follow-up and last follow-up status (alive/dead) were very poorly 
completed, with missing data rates of 60% and 76% respectively, so these were not 
analysed.  Multivariate regression parameters for each of the secondary outcomes are 
presented in Table 2.6, and these analyses are discussed in some detail in the following 
subsections. 
Figure 2.3: ROC curve for prognostic model, with best estimates of the VAM, VBHOM and NSQIP 
models.  Some parameters from the other models were not available in the NVR dataset so these 
are conservative estimates of the true discrimination of these models. 
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2.3.4.1 Return to theatre during admission 
As stated above, 10% of patients had an unplanned return to theatre during their index 
admission.  Multivariate regression modelling revealed that there were seven 
independent predictors of return to theatre: bilateral operation (OR 2.58, 95% C.I. 1.61—
4.14), amputation below knee level (OR 0.673, 95% C.I. 0.544—0.832), history of diabetes 
(OR 1.44, 95% C.I. 1.16—1.78), emergency operation (OR 2.18, 95% C.I. 1.55—3.08), 
serum albumin (OR per g/l increase 0.951, 95% C.I. 0.936—0.965), increased patient age 
(OR per year increase 0.996, 95% C.I. 0.989—1.004) and increased white blood cell count 
(OR per unit increase 1.015, 95% C.I. 1.005—1.025). 
A model using these factors to predict cardiac complications had only average 
discrimination (C-statistic 0.64), though this was significantly better than the ability of the 
mortality model described in Section 2.3.3 to predict unplanned return to theatre (C-
statistic 0.52, P<0.0001). 
2.3.4.2 Re-admission to a higher level of care 
As stated in Section 2.3.1, 10% of patients had an unplanned return to theatre during 
their index admission.  Multivariate regression modelling revealed that there were only 
three independent predictors of readmission to critical care: ASA grade (OR per level 
increase 2.40, 95% C.I. 2.02—2.87), increased serum creatinine (OR per micro g per l 
increase 1.0035, 95% C.I. 1.0029—1.0040) and serum albumin (OR per g/l increase 0.958, 
95% C.I. 0.943—0.973).  
A model using these factors to predict re-admission to a higher level of care had only 
average discrimination (C-statistic 0.63), which was not significantly better than the ability 
of the mortality model described in Section 2.3.3 to predict readmission to critical care (C-
statistic 0.62, P=0.274). 
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 Complications 
Parameter Return 
to 
theatre 
Re-
admission 
to critical 
care 
Prolonged 
length of 
stay 
Cardiac Respiratory Renal Limb 
ischaemia 
Stroke Bleeding 
Age 0.996 
(0.989-
1.004) 
   1.015 
(1.010-
1.022) 
    
Emergency 2.18 
(1.55-
3.08) 
 1.74 
(1.57-
1.93) 
1.94 
(1.47-
2.57) 
1.40 
(1.14-1.71) 
1.96 
(1.38-
2.77) 
1.89 
(1.39-
2.58) 
  
Bilateral 2.58 
(1.61-
4.14) 
 1.65 
(1.22-
2.23) 
2.09 
(1.36-
3.21) 
     
Trans-tibial 0.673 
(0.544-
0.832) 
 1.18 
(1.08-
1.29) 
0.719 
(0.602-
0.858) 
0.729 
(0.629-
0.846) 
 1.73 
(1.40-
2.13) 
  
Previous 
procedures 
    0.784 
(0.680-
0.903) 
0.704 
(0.573-
0.864) 
   
White cell 
count 
1.015 
(1.005-
1.025) 
   1.017 
(1.010-
1.025) 
    
Creatinine  1.0035 
(1.0029-
1.0040) 
1.0009 
(1.0005-
1.0013) 
1.0010 
(1.0005-
1.0016) 
 1.0026 
(1.0019-
1.0032) 
   
Sodium     1.029     
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(1.014-
1.043) 
Albumin 0.951 
(0.936-
0.965) 
0.958 
(0.943-
0.973) 
0.986 
(0.980-
0.992) 
0.971 
(0.959-
0.983) 
0.972 
(0.962-
0.982) 
0.965 
(0.950-
0.980) 
  0.957 
(0.923-
0.989) 
ASA grade  2.40 
(2.02-
2.87) 
1.15 
(1.07-
1.23) 
2.23 
(1.91-
2.59) 
1.82 
(1.61-2.06) 
2.20 
(1.84-
2.63) 
1.48 
(1.26-
1.74) 
  
Diabetes 1.44 
(1.16-
1.78) 
 0.843 
(0.772-
0.921) 
   0.718 
(0.580-
0.888) 
  
Chronic 
kidney 
disease 
     2.06 
(1.63-
2.61) 
  2.70 
(1.69-
4.33) 
Congestive 
heart failure 
   1.48 
(1.19-
1.84) 
     
Chronic lung 
disease 
    1.94 
(1.67-2.26) 
    
Stroke        4.05 
(2.53-
6.48) 
 
Statin   1.15 
(1.05-
1.26) 
      
Beta-blocker    1.38      
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(1.16-
1.65) 
Abnormal 
ECG 
   1.84 
(1.52-
2.23) 
     
Chronic 
ischaemia 
      0.490 
(0.367-
0.654) 
  
Neuropathy       0.114 
(0.016-
0.406) 
  
Tissue loss       0.472 
(0.366-
0.608) 
  
Uncontrolled 
infection 
      0.289 
(0.206-
0.406) 
  
C-statistic 0.64 0.63 0.59 0.75 0.71 0.78 0.67 0.61 0.66 
Table 2.6: Multivariate odds ratios (95% confidence intervals) for morbidity outcomes for 
parameters found to be significant independent predictors using minimisation of the Schwarz-
Bayes criterion.  The last row gives the respective C-statistics of the models.  Prolonged length of 
stay was defined as a length of stay longer than the median value (16 days). 
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2.3.4.3 Length of stay 
I chose to focus on post-operative length of stay rather than overall length of stay, which 
includes the time spent in hospital prior to major lower limb amputation, as I felt that in 
addition to patient-related factors, overall length of stay was likely to be influenced by a 
number of unmeasured non-patient related factors such as the efficiency of the inpatient 
referral system and theatre capacity.  To simplify the analysis, I defined ‘prolonged post-
operative length of stay’ as a length of stay which was longer than the median value, 
which was 16 days.  Multivariate regression modelling revealed that there were eight 
independent predictors of prolonged post-operative length of stay: bilateral operation 
(OR 1.65, 95% C.I. 1.22—2.23), amputation below knee level (OR 1.18, 95% C.I. 1.08—
1.29), history of diabetes (OR 0.843, 95% C.I. 0.772—0.921), emergency operation (OR 
1.74, 95% C.I. 1.57—1.93), serum albumin (OR per g/l increase 0.986, 95% C.I. 0.980—
0.992), ASA grade (OR per level increase 1.15, 95% C.I. 1.07—1.23), increased serum 
creatinine (OR per micro g per l increase 1.0009, 95% C.I. 1.0005—1.0013) and whether 
the patient was on statin therapy (OR 1.15, 95% C.I. 1.05—1.26). 
A model using these factors to predict prolonged post-operative length of stay had poor 
discrimination (C-statistic 0.59), though this was significantly better than the ability of the 
mortality model described in Section 2.3.3 to predict prolonged post-operative length of 
stay (C-statistic 0.57, P=0.006). 
2.3.4.4 Cardiac complications 
Multivariate regression modelling revealed that there were nine independent predictors 
of cardiac complications: bilateral operation (OR 2.09, 95% C.I. 1.36—3.21), amputation 
below knee level (OR 0.719, 95% C.I. 0.602—0.858), history of congestive cardiac failure 
(OR 1.48, 95% C.I. 1.19—1.84), emergency operation (OR 1.94, 95% C.I. 1.47—2.57), 
abnormal ECG (OR 1.84, 95% C.I. 1.52—2.23), serum albumin (OR per g/l increase 0.971, 
95% C.I. 0.959—0.983), ASA grade (OR per level increase 2.23, 95% C.I. 1.91—2.59), 
increased serum creatinine (OR per micro g per l increase 1.0010, 95% C.I. 1.0005—
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1.0016) and whether the patient was on beta-blocker therapy (OR 1.38, 95% C.I. 1.16—
1.65). 
A model using these factors to predict cardiac complications had good discrimination (C-
statistic 0.75), but this was not significantly better than the ability of the mortality model 
described in Section 2.3.3 to predict cardiac complications (C-statistic 0.74, P=0.140). 
2.3.4.5 Respiratory complications 
Multivariate regression modelling revealed that there were nine independent predictors 
of respiratory complications: previous procedures to the amputated limb (OR 0.784, 95% 
C.I. 0.680—0.903), amputation below knee level (OR 0.729, 95% C.I. 0.629—0.846), 
history of chronic lung disease (OR 1.94, 95% C.I. 1.67—2.26), emergency operation (OR 
1.40, 95% C.I. 1.14—1.71), increased patient age (OR 1.015, 95% C.I. 1.010—1.022), 
serum albumin (OR per g/l increase 0.972, 95% C.I. 0.962—0.982), ASA grade (OR per 
level increase 1.82, 95% C.I. 1.61—2.06), increased serum sodium (OR per mmol per l 
increase 1.029, 95% C.I. 1.014—1.043) and increased white blood cell count (OR 1.017, 
95% C.I. 1.010—1.025). 
A model using these factors to predict cardiac complications had good discrimination (C-
statistic 0.71), but this was not significantly better than the ability of the mortality model 
described in Section 2.3.3 to predict respiratory complications (C-statistic 0.69, P=0.072). 
2.3.4.6 Renal complications 
Multivariate regression modelling revealed that there were six independent predictors of 
renal complications: history of chronic kidney disease (OR 2.06, 95% C.I. 1.63—2.61), 
emergency operation (OR 1.96, 95% C.I. 1.38—2.77), previous procedures to the 
amputated limb (OR 0.704, 95% C.I. 0.573—0.864), serum albumin (OR per g/l increase 
0.965, 95% C.I. 0.950—0.980), ASA grade (OR per level increase 2.20, 95% C.I. 1.84—
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2.63), ) and increased serum creatinine (OR per micro g per l increase 1.0026, 95% C.I. 
1.0019—1.0032). 
A model using these factors to predict cardiac complications had good discrimination (C-
statistic 0.78), which was significantly better than the ability of the mortality model 
described in Section 2.3.3 to predict renal complications (C-statistic 0.74, P=0.011). 
2.3.4.7 Complications related to limb ischaemia 
Complications related to limb ischaemia occurred in 4.4% of patients.  Multivariate 
regression modelling revealed that there were only five independent predictors of this: 
amputation below knee level (OR 1.73, 95% C.I. 1.40—2.13), emergency operation (OR 
1.89, 95% C.I. 1.39—2.58), ASA grade (OR per level increase 1.48, 95% C.I. 1.26—1.74), 
history of diabetes (OR 0.718, 95% C.I. 0.580—0.888) and the indication for the operation 
(OR compared to acute ischaemia 0.490, 95% C.I. 0.367—0.654 for chronic ischaemia; 
0.114, 95% C.I. 0.016—0.828 for neuropathy; 0.472, 95% C.I. 0.366—0.608 for tissue loss; 
and 0.289, 95% C.I. 0.206—0.406 for uncontrolled infection). 
A model using these factors to predict ischaemic complications had only average 
discrimination (C-statistic 0.67), though this was significantly better than the ability of the 
mortality model described in Section 2.3.3 to predict ischaemic complications (C-statistic 
0.56, P<0.0001). 
2.3.4.8 Stroke 
Stroke was an uncommon complication, reported after only 0.8% of amputations.  The 
only predictive factor was a previous history of stroke (OR 4.05, 95% C.I. 2.53—6.48). 
2.3.4.9 Bleeding 
Bleeding was again a rare complication, also reported after 0.8% of amputations.  
Multivariate regression modelling revealed that a history of chronic kidney disease (OR 
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2.70, 95% C.I. 1.69—4.33) and serum albumin (OR per g/l increase 0.957, 95% C.I. 0.923—
0.989) were independent predictors of bleeding complications. 
A model using these factors to predict bleeding complications had only average 
discrimination (C-statistic 0.66), which was not significantly better than the ability of the 
mortality model described in Section 2.3.3 to predict bleeding complications (C-statistic 
0.62, P=0.228). 
2.4 Discussion 
I have shown that morbidity and mortality after major lower limb amputation in the UK 
remain high.  While modelling has revealed some potentially modifiable factors, most 
predictors, such as age and ASA grade, are difficult or impossible to modify.  I have also 
developed an accurate predictive model for in-hospital mortality risk to aid patient 
counselling prior to surgery, which it would be possible to deploy in the form of a 
smartphone app or web-based calculator.  I have made a web-based calculator which 
shows how this can be done.  It is available from http://www.ambler.me.uk/Vascular and 
could easily be converted into a smartphone app for offline use.  Predicting morbidity 
outcomes proved more difficult, though the model for mortality did provide good 
discrimination of whether patients would develop cardiac and renal complications. 
As mentioned in the Introduction to this Chapter, there is some prior work looking at 
independent risk factors for peri-operative mortality following major lower limb 
amputation.  Several of the factors I found are similar to those found in previous work.  
Increasing age was found to be an independent predictor of mortality in almost all 
studies, including my own.  Emergency admission and level of amputation were also 
found to be predictive of mortality in several other studies, including work from large 
administrative databases in Japan and the USA.14,16 Evidence of systemic sepsis in the 
form of a raised pre-operative white cell count has also been identified as a significant 
factor in previous studies.12,46  In contrast, bilateral procedures have not been previously 
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shown to have a worse outcome than unilateral procedures, and increased patient weight 
has never been identified as an independent protective factor previously.  There is little 
evidence in the literature that any of the previously developed models have been used in 
clinical practice – the only work on external validation I could identify was for the first 
VBHOM model, showing that discrimination and calibration for this model were poor.15  
The model I have presented has shown discrimination which is an improvement on 
previously published models (Figure 2.3 on page 35). 
Strengths of this work include the large, national database used as a data source, the 
rigorous statistical methods used both to handle missing data and also the information 
criterion approach to reduce the chances of overfitting.   
Weaknesses of this study include the fact that in many vascular surgical centres, surgeons 
enter their own data into the NVR and these data are not subject to rigorous external 
validation.  However, as the national audit does not link cases to individual surgeons, 
there is little reason for surgeons to be selective about which cases are entered.  A 
further weakness with the NVR is that the case completion rate is also known to be only 
around 60%, so it is also possible that the missing cases, if present, would provide some 
further insight into risk factors for adverse outcomes.  It is also possible that the missing 
40% of cases are systematically different from the completed cases, so it is possible that 
other risk factors are better predictors of outcome in this unmeasured cohort, or that the 
degree to which the risk factors we have identified predicts outcomes could be different.  
There is, unfortunately, no way of knowing this with certainty.  Current case 
ascertainment rates are a dramatic improvement over the situation 10 years ago, when 
only around 30% of cases were entered.  The UK National Vascular Registry reports for 
the past two years have highlighted the fact that case ascertainment rates vary widely 
between Vascular Networks, with some Networks reporting no major limb amputations, 
and others reporting all cases.17,38  I am therefore optimistic that many of the missing 
data relate to institutional and administrative factors rather than patient-related factors.  
The patient-related factors I have identified as predictive of outcome should therefore be 
reliable. 
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The presence of missing items within otherwise completed cases is also a weakness.  I 
used multiple imputation to account for this missing data, and a sensitivity analysis using 
only complete cases gave very similar results (Section 2.3.2.1, Table 2.4, page 29), even 
for parameters with a significant amount of missing data, so there is no evidence that 
these missing values have introduced significant bias. 
A further weakness of this study is due to the limitations of the data recorded in the NVR 
during the study period.  It is increasingly recognised that frailty is an important risk factor 
for peri-operative complications, including mortality.45  Indeed, dependent functional 
status has been shown in other work to be important for predicting mortality in this 
cohort.12  Unfortunately, until recently, no measure of frailty or functional status (such as 
mobility or independent living) was recorded in the NVR.  While a measure of frailty has 
now been added to NVR dataset, this did not happen in time for the study period, so it 
was not possible to assess its predictive power in this cohort.   
Some subgroups of patients were present in only small numbers in the data, for example 
hip disarticulations and simultaneous bilateral procedures.  Estimates of the significance 
of these factors will therefore be subject to imprecision.  Despite this, it was identified 
that patients having simultaneous bilateral procedures represented a significantly higher 
risk cohort, so I feel that it was appropriate to include these patients in the analysis. 
A final weakness is that although the model I have generated has good internal validity, I 
have not tested performance on external data.   
I think that a knowledge of the factors which predict poor outcomes for patients provides 
significant opportunities to develop interventions which may have a positive impact on 
clinical practice.  Firstly, it will encourage surgeons to do what they can to modify 
negative factors where this is possible.  Secondly, many of the factors predicting poor 
outcome, such as emergency admission and a raised white cell count, are linked to 
management of patients at a late stage in their disease and may reflect late presentation 
or recognition.  This highlights the critical rôle of healthcare staff to recognise the 
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deteriorating foot in the community, and robust in-hospital systems and teams to treat 
patients quickly. Earlier recognition will reduce the number of patients undergoing 
amputation as an emergency when they are septic, with increased risk of both kidney and 
cardiac dysfunction, often following a period of chronic low-grade foot sepsis resulting in 
malnutrition and low albumin.  Amputation is often followed by long periods in hospital.  
In my experience, much of this time is as a result of social or organisational factors, 
including the need to assess a patient’s home for wheelchair suitability and carry out any 
necessary modifications.  Earlier recognition would allow amputation to be handled in a 
more elective manner, so that this could be done ahead of time, facilitating shorter 
hospital admissions and thus reduced healthcare costs.  Such systems are already in place 
for many patients in the form of the diabetic foot service and could be rolled out to all 
patients with chronic limb-threatening ischaemia.  The present work highlights the fact 
that limb salvage must not be the only measure of the success of ‘limb-salvage’ clinics.  
Early recognition that limb salvage is unlikely to succeed will facilitate early discussion 
about the options and outcomes of amputation.  This will in turn improve the outcomes 
of those patients who decide to have an amputation rather than continuing to pursue 
further fruitless efforts at limb salvage.   
I have also developed a model which could be used to aid counselling and decision-
making, either in clinic or at the bedside, by quantifying the probability of the patient 
surviving to hospital discharge.  I have developed a web calculator for easy use in clinic 
which is available from http://www.ambler.me.uk/Vascular.  This could be converted into 
a standalone smartphone app for offline use.  By having a model which can more reliably 
predict mortality, discussions about options can be more fully explored with patients, 
enhancing shared decision-making.61  Multiple previous studies have shown that surgeons 
systematically underestimate the chances of a patient surviving an operation.62,63 As the 
choice between amputation and conservative management is sometimes the choice 
between amputation and palliation, it is critically important that these discussions are 
conducted in the context of reliable risk estimates.  
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Ten percent of patients returned to theatre during their index admission.  This is quite a 
high proportion, and it would have been good to get an idea of the reasons for these 
returns to theatre.  Unfortunately, no detail is given in the dataset so some of these 
patients will have had a minor debridement procedure, some will have returned for 
bleeding or evacuation of a haematoma, and some will have had a major revision of 
amputation level.  This may be the reason why it was difficult to generate a model with 
good discriminatory power for this outcome. 
Further studies are required to identify whether attempts to modify any of the factors 
actually have a clinically relevant impact on outcome.  Firstly, improvements might be 
made through quality improvement programmes designed to facilitate earlier 
identification and treatment of patients for whom further attempts at limb salvage are at 
high risk of failure.  Increased patient weight and serum albumin have similar, though 
smaller, protective effects, so it is possible that a pre-operative dietary intervention might 
also be helpful for patients with stable but un-reconstructable arterial disease in this 
patient population.  Improved shared decision-making using risk quantified by these data 
should be encouraged, perhaps supported by a decision aid.64 Secondly, there are more 
speculative options which would require testing in prospective interventional studies. 
One unexpected factor was that previous procedures to the amputated limb reduced 
mortality rates.  While it is possible that having had previous procedures is simply a 
surrogate for ‘fitness’ in some way, it may also be that intervention to facilitate healing at 
a trans-tibial rather than trans-femoral level might have multiple benefits, both in terms 
of improved short-term outcomes and also in terms of the improvement in long-term 
functional outcomes.  Increased patient weight and serum albumin have similar 
protective effects, so it is possible that pre-operative dietary intervention or other ‘pre-
habilitation’ might also be helpful for patients with stable but un-reconstructable arterial 
disease.  There is increasing interest into the putative benefits of ‘pre-habilitation’, with 
multiple on-going studies,32 though little concrete evidence of benefit at this time.33 
As mentioned above, further work is also needed to externally validate the predictive 
model.  This was highlighted within Vascular Surgery recently with the publication of the 
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draft National Institute for Health and Care Excellence (NICE) guidelines for the treatment 
of Abdominal Aortic Aneurysm,65 which found that none of the models which had been 
subjected to external validation were found to have good discriminatory power.  The 
models examined were all generated some time ago from relatively small cohorts using 
simplistic statistical methodology for both model fitting and handling missing data, so 
there are reasons to be optimistic that the model developed here will not be as 
susceptible to these problems. 
In conclusion, I have detailed independent risk factors for mortality and morbidity 
following major lower limb amputation and developed a prognostic model for in-hospital 
mortality with good predictive power.  Further work is required to validate this model and 
investigate whether interventions targeted at the identified factors might improve 
outcomes for this cohort. 
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3 Development of core outcome sets for 
people undergoing major lower limb 
amputation for complications of peripheral 
vascular disease. Part 1: background, 
systematic review and focus groups 
3.1 Introduction 
This chapter describes the process of generating a “long-list” of outcomes to be 
considered for inclusion in a core outcome set for patients undergoing major lower limb 
amputation (MLLA).  The background and justification for development of the core 
outcome set have been described in Chapter 1.  The process begins with a systematic 
review, and then involves focus groups with a range of stakeholders, to ensure that the 
outcomes/outcomes measures which have been reported in previous studies capture the 
full extent of key issues facing this patient cohort.  This exhaustive list of outcomes or 
measures is reduced to a shorter list, where similar outcomes are grouped together.  In 
Chapter 4 this shorter list is then used as the basis for a Delphi consensus survey, where 
consensus is established on which outcomes are ‘core’ and a three phase Delphi 
consensus survey followed by a face-to-face meeting. 
During development of this project, it became apparent that core outcomes for patients 
undergoing MLLA might be different depending on whether a study was focussed on 
short-term or longer-term issues.  For example, as the process of rehabilitation with a 
prosthesis is a lengthy one, which can take over a year to complete, level of mobility may 
not be considered core for studies focussed on issues around the acute post-operative 
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phase.  In contrast, acute post-operative complications such as pneumonia or peri-
operative myocardial infarction may not be considered core for studies focussed on 
patients’ return to independence following surgery, as this would generally require much 
longer follow-up and may not be materially influenced by such issues.  I therefore decided 
that it would be best to develop two separate but complementary core outcome sets: 
one for short-term studies, which I defined as up to 30 days; and one for medium-term 
studies, considering issues up to two years after MLLA.  The former definition was chosen 
to line up with common surgical outcome publications, where 30 days is the standard 
interval during which post-operative outcomes are recorded in Vascular Surgery.  The 
latter limit was chosen following discussions with colleagues in rehabilitation, who stated 
that they would regard patients two years after their amputation as ‘established’ 
amputee patients.  While this argument justifies the development of separate core sets 
for outcomes of studies with primary outcomes measured at different time scales, it does 
not justify pre-judging which outcomes are most important at these timescales.  I 
therefore decided to collect a single exhaustive list of outcomes and use the consensus 
process to determine which of these to include in each of the two core sets. 
Secondly, I considered whether to include all patients undergoing MLLA, or to restrict the 
cohort according to the indication for amputation.  The common indications for MLLA in 
adults are peripheral vascular disease, encompassing patients with conventional 
atherosclerotic disease, acute limb ischaemia and diabetes as well as the rarer cohort of 
patients with large vessel vasculitis; trauma; and neoplastic disease.  Peripheral vascular 
disease patients comprise well over 80% of patients undergoing MLLA in the developed 
world.66,67  Patients undergoing MLLA for complications of peripheral vascular disease are 
generally older and have significant comorbidities such as ischaemic heart disease or 
diabetes.  Patients undergoing trauma or tumour related MLLA often have little in the 
way of comorbid disease and so recover and rehabilitate more quickly and completely. It 
was therefore felt that core outcomes for these two subgroups might be different, with 
those with peripheral vascular disease likely to have significantly worse outcomes, so I 
ultimately decided to restrict attention to the high-risk majority of patients undergoing 
MLLA with peripheral vascular disease. 
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The objective of this chapter is therefore to present the process of generating an 
exhaustive list of outcomes for research and service evaluation involving patients 
undergoing major lower limb amputation as a result of complications of peripheral 
vascular disease.  This is then reduced to a shorter ‘long-list’ of outcomes suitable for 
consideration in a consensus process. This shorter list should: 
1. Be short enough to be practical in an online Delphi survey. 
2. Be comprehensive, in that firstly all relevant outcomes in the long-list could be 
represented by these broad outcome areas, and secondly all of the outcome 
categories developed by Dodd et al.68 (described below in Section 3.2.1.5) for 
which there were outcomes in the exhaustive list would also be included in the 
shorter list. 
3. Be understandable by lay individuals (patients and carers) taking part in the 
survey. 
The following chapter (Chapter 4) will present the process by which consensus was gained 
on which of the outcomes should be included in the core outcome sets. 
3.2 Methods 
The process for development of a core outcome set is now established, and has been 
described in The COMET Handbook.69  This involves a mixed-methods approach, utilising 
both quantitative and qualitative aspects.70  The initial stages of the process are designed 
to create an exhaustive list of outcomes, to be considered subsequently by the consensus 
panels (to be described in Chapter 4).  The first stage is a systematic review to identify 
existing published outcomes.  This is followed by focus groups involving a broad range of 
stakeholders. 
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3.2.1 Phase I: Systematic review 
The systematic review process which underpins core outcome set development differs 
somewhat from the standard approach to systematic review as the goal of the process is 
different.  Classical systematic review involves a structured assessment of the strength of 
evidence for a particular intervention.71  As a result, assessment of the quality of evidence 
extracted from each source, and for each outcome, is critical.  Systematic review when 
performed as part of the core outcome set development process, by contrast, is designed 
to generate as complete a list as possible of the outcomes to be considered when 
evaluating interventions in a particular patient cohort.  Thus, I felt that elimination of low-
quality reports was inappropriate, as this might cause the reviewers to miss important 
outcomes which simply have not been adequately addressed in high quality research, 
thus seriously undermining the validity of the core outcome sets.  It is therefore 
inappropriate to follow established standards in systematic review to the letter.  These 
standards do, however, provide a useful framework for the general process of systematic 
review, so where appropriate I follow the Preferred Reporting Items for Systematic 
reviews and Meta-Analysis (PRISMA) standards.71 
The objective of this review is to identify all short- (defined as up to 30 days) and 
medium-term (defined as up to 2 years) outcomes reported in published work involving 
patients undergoing MLLA for complications of peripheral vascular disease.  I have 
registered the review in the PROSPERO registry of systematic reviews (ID: 
CRD42017059329). 
3.2.1.1 Criteria for considering studies 
All clinical studies reporting at least one short- (within 30 days) or medium-term (up to 2 
years) outcome involving human subjects undergoing major lower limb amputation (i.e. 
amputation of the lower limb above the ankle) as a result of peripheral vascular disease 
were included.  This included non-interventional studies (e.g. case series, cohort and 
qualitative studies), case-control studies and non-randomised and randomised 
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interventional trials.  Study reports describing the same patient sample were included if 
they reported different outcomes, but outcomes which were duplicated were only 
counted once in the quantification of the frequency of outcome reporting.  Studies 
reporting only patients undergoing amputation for non-ischaemic disease such as trauma, 
tumour, chronic non-ischaemic pain or congenital malformations were excluded.  
Systematic reviews found by the electronic search were used as a source of additional 
references which might have been missed by the electronic search, but outcomes were 
not extracted from the reviews themselves, as this would duplicate work from the source 
references.  Non-systematic reviews, commentaries, editorials and articles which discuss 
general principles rather than patient cases were excluded.  Cross-sectional studies 
recruiting established amputee patients were also excluded as we were interested in 
outcomes for patients undergoing amputation rather than those living with amputation.  
Non-English language clinical studies were included if there was a publicly available 
translation of either the abstract or full study, and data extraction was limited to what 
was available in the English language. 
3.2.1.2 Outcomes 
All outcomes described as either primary or secondary outcomes from included studies 
were reported. When more than a single study reported an outcome, the number of 
studies reporting that outcome was reported. 
3.2.1.3 Search strategy 
MEDLINE and EMBASE were searched through Ovid using the terms given in Table 3.1. 
Titles were screened initially, then abstracts of potentially relevant articles were retrieved 
and screened.  Finally, full text articles of potentially suitable studies were retrieved, and 
a final decision made on suitability for inclusion in the study.  Reference lists of included 
studies were also screened, and a search using the ‘Related Articles’ function in PubMed 
was used to capture any further relevant papers. Two individuals independently screened 
studies for inclusion.  Disagreements were resolved through discussion and consensus 
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with a generally inclusive policy: since the aim of the review was to identify all reported 
outcomes, inclusion of borderline studies was felt to be preferable, as it was felt that non-
relevant outcomes were likely to be removed by the consensus process. 
Item 
number 
Search item 
1 exp Peripheral Vascular Diseases/di [Diagnosis] 
2 Arterial Occlusive Diseases/di [Diagnosis] 
3 exp Arteriosclerosis/di [Diagnosis] 
4 exp Atherosclerosis/di [Diagnosis] 
5 exp Peripheral Arterial Disease/di [Diagnosis] 
6 (atherosclero* or arteriosclero* or PVD or PAOD or PAD).ti,ab. 
7 (arter$ adj4 ($occlus$ or steno$ or obstruct$ or lesio$ or block$ or 
obliter$)).ti,ab. 
8 (vascular adj4 (occlus* or steno* or obstruct* or lesio* or block* or 
obliter*)).ti,ab. 
9 (vein* adj4 (occlus* or steno* or obstruct* or lesio* or block* or 
obliter*)).ti,ab. 
10 (veno* adj4 (occlus* or steno* or obstruct* or lesio* or block* or 
obliter*)).ti,ab. 
11 (peripher* adj4 (occlus* or steno* or obstruct* or lesio* or block* or 
obliter*)).ti,ab. 
12 (peripheral adj3 dis*).ti,ab. 
13 arteriopathic.ti,ab. 
14 CLI.ti,ab. 
15 dysvascular*.ti,ab. 
16 (leg adj4 (obstruct* or occlus* or steno* or block* or obliter*)).ti,ab. 
17 (limb adj4 (obstruct* or occlus* or steno* or block* or obliter*)).ti,ab. 
18 (lower adj3 extrem* adj4 (obstruct* or occlus* or steno* or block* or 
obliter*)).ti,ab. 
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19 1-18 combined with OR 
20 amputee$.tw. 
21 Amputees/ 
22 (knee adj3 (disarticulat$ or exarticulat$)).tw. 
23 (amputat$ adj3 (transfemoral or transtibial or lower limb or lower extremity 
or above knee or below knee or through knee)).tw. 
24 Disarticulation/ 
25 Amputation/ 
26 20-25 combined with OR 
27 (transfemoral or transtibial or lower limb or lower extremity or knee).tw.  
28 exp Leg/ 
29 27 OR 28 
30 26 AND 29 
31 19 AND 30 
32 Remove duplicates from 31  
Table 3.1: Search strategy for systematic review. 
 
3.2.1.4 Data extraction 
A standardised data collection proforma was used and is shown in Table 3.2.  Extracted 
data included the participant details (number and demographics: age, gender and study 
country), study type (for example randomised or non-randomised controlled trial, cohort 
study, case series, qualitative), interventions (if any), stated outcomes presented in the 
methods (both primary and secondary), and reported outcomes.  Outcomes were 
extracted verbatim where possible.  As this study focuses on which outcomes are 
reported rather than the value of those outcomes, neither study quality nor risk of bias 
was relevant so were not assessed. Data were extracted from 10% of studies by two 
independent reviewers. Concordance between reviewers was maximised by discussing in 
detail this 10% and coming to a consensus decision.  Following this, the next 10% was also 
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extracted independently and concordance was then assessed by calculating Kendall’s τ 
(tau) statistic for the number of extracted outcomes.  Provided that the concordance 
between reviewers was high (i.e. a 95% confidence interval for the value of τ excluded 
zero), I decided (and the published protocol stated) that the remainder of studies would 
be extracted by a single reviewer.72 If concordance were poor, the discrepancies would 
have been investigated and a further 10% of studies would have been double-extracted. If 
concordance were high at this point, the remainder of studies would be single extracted, 
otherwise double extraction and consensus discussion would continue.  This third round 
of double extraction was not necessary (see Results in Section 3.3.1.4 below).   
Reference details 
Patient 
demographics 
Study 
details Outcomes 
Re
fe
re
nc
e 
nu
m
be
r  
Au
th
or
s  
Ti
tle
 
Ab
st
ra
ct
 
Jo
ur
na
l  
Y e
ar
 
Vo
lu
m
e 
Pa
ge
s  
Nu
m
be
r o
f p
at
ie
nt
s  
M
e(
di
)a
n 
ag
e  
Ag
e 
m
ea
n 
or
 m
ed
ia
n?
 
Pr
op
or
tio
n 
m
al
e  
In
te
rv
en
tio
ns
 
St
ud
y 
co
un
tr
y 
/ c
ou
nt
rie
s  
St
ud
y 
ty
pe
 
Pl
an
ne
d  
Nu
m
be
r P
la
nn
ed
 
Pr
es
en
te
d  
Nu
m
be
r P
re
se
nt
ed
 
                   
Table 3.2: Data extraction template. 
 
3.2.1.5 Results synthesis and reduction to a shorter list 
The principal outcome of the systematic review is an exhaustive list of outcomes, with 
frequencies of reporting.  Following generation of this list, outcomes were grouped into 
appropriate domains in order to draw out common themes for consideration in 
qualitative focus groups, discussed below, and to take forward to a consensus process 
(described in Chapter 4).  There are no clear guidelines on the way in which an exhaustive 
list of outcomes should be reduced to a more manageable list which is suitable for 
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inclusion in a Delphi survey.  Dodd et al. performed a systematic review of published core 
outcome sets, finding 99 which included a systematic review to identify a long-list of 
outcomes.68  Of these, only 28 used a formal system to aid in classifying the outcomes, 21 
of which were developed by the authors during the  development process.  Dodd et al. 
developed a generic system for classification of outcomes into five main areas, which are 
subdivided into a total of 38 domains.68  Their classification system was based on a 
simpler 12-domain classification by Smith et al.73  I believe that that the use of such 
generic classification systems improves the reproducibility and transferability of research, 
so the outcomes were divided into these 38 domains.  This is important, as a core 
outcome set is supposed to describe the core concepts which should be measured, with 
the precise timing or means of measuring the outcome left for further study.  This also 
makes the consensus process more practical, as it results in a more manageable list of 
outcomes to be rated in a subsequent Delphi process.   
While I agree with the authors that using such a system to classify outcomes is helpful as 
it reduces the potential for important topics to be missing from a core outcome set, I feel 
that the categories – which consist largely of single-word summaries of an area such as 
‘physical’ or ‘social’ – are too broad to be used directly in a Delphi consensus process.  
The terminology used is also quite medical (for example ‘hepatobiliary outcomes’), 
making the categories quite inaccessible to many patients.  In addition, some of the 
domains included several quite distinct outcome groups. 
Following this classification, I therefore developed a list of more descriptive outcome 
groups within each domain.  For example, in the ‘social’ domain I grouped the three 
outcomes ‘self-reported frequency of sexual activity’, ‘desire for sexual activity’ and 
‘importance of sexual activity to satisfaction with life’ together as the outcome ‘sexual 
activity’.  The six outcomes ‘effect on home and work capacity’, ‘return to work’, 
‘Reintegration into Normal Living (RNLI)’, ‘community participation at 12 months’, ‘social 
integration at 12 months’ and ‘low social functioning at 6 months’ were grouped together 
as the outcome ‘participation in work and social activities’.  I felt that these would be 
much easier for participants to rate in the Delphi survey.  Next, some of the outcomes 
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measured cannot be viewed as ‘core’ as they are only relevant to a subset of patients.  
For example, acute kidney transplant rejection will only be relevant to patients who have 
a kidney transplant.  Outcomes such as these were then removed from the shorter list. 
The terminology used for outcomes can, at times, be confusing, and is applied 
inconsistently.  Some authors refer to the outcomes extracted from the systematic review 
as ‘outcome measures’, as in most cases what is reported in the literature is a specific 
way of measuring an underlying concept, or outcome.  Unfortunately, this is not always 
the case – in some studies the precise definition of a measure is not given, and what is 
described is an outcome, measured in a way which is incompletely described.  In addition, 
some authors refer to the shorter list of consolidated outcomes, where similar measures 
are grouped together, as a list of ‘domains’.  Others (such as Dodd et al.) use ‘domain’ to 
mean an even more generic list which may be used to group outcomes together. In order 
to improve the readability of this thesis, I have taken the following pragmatic decision, 
which is applied consistently for the remainder of the thesis. 
• To refer to ‘outcomes’ or ‘outcome measures’ extracted from the systematic 
review as ‘outcome measures’, even though many of these are not well specified 
measures. 
• To refer to the shorter list of consolidated outcomes as ‘outcomes’, as this is the 
list from which the core outcome sets will be selected. 
• To refer to the categories specified by Dodd et al. as ‘domains’. 
The results of the short-listing were refined at study management group meetings (where 
trials managers, statisticians, qualitative researchers, vascular surgeons and lay 
representatives were present) after having been sent round via email for comments and 
suggestions ahead of time in order to ensure that this process had been handled in a 
reasonable way.  The two lay representatives and the non-medically trained members of 
the study group also commented on the wording of the outcomes to ensure that they 
were as clear as possible for non-medical participants in the subsequent consensus 
process. 
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3.2.2 Phase II: Qualitative focus groups 
The primary purpose of running focus groups was to ensure that published outcomes 
adequately capture the outcomes which are most important to patients undergoing 
amputation, as well as those who care for them, both informally and professionally.  This 
is important for two reasons.  Firstly, it is entirely possible that outcomes which are 
viewed as important by patients or their informal carers may not have been given due 
consideration in the scientific literature, as research is dominated by clinical practitioners.  
There are documented examples of this happening during the development of other core 
outcome sets.  An example of this is that during the development of core outcome sets in 
Rheumatoid Arthritis, patients described ‘sleeping better’ as an important outcome, 
though at the time of the study it had not been described in any study in the Rheumatoid 
Arthritis literature.74  Conversely, it is possible that healthcare professionals will raise 
outcomes which patients are hesitant to discuss and which, because of perceived 
difficulties in recruitment for such studies, are also not well represented in the 
literature.75 
These two challenges highlight the rationale for qualitative research which engages with 
both patients and carers and also with healthcare professionals in order to reduce the risk 
of missing important outcomes.  I therefore decided to perform focus groups which 
recruited both sets of individuals.  Following discussions with qualitative researchers and 
others with prior core outcome set experience, participants were divided into three 
groups: one for patients and carers, one for nurses and allied healthcare professionals 
and one for medically trained professionals.  Participants in the two healthcare 
professional groups were allowed to cross over into the other group if necessary, in order 
to improve participation, and separate interviews were held where a key stakeholder 
group invitee was unable to attend any of the group sessions. 
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3.2.2.1 Sampling strategy – Healthcare professionals 
A purposive sampling strategy was used when recruiting participants of the major 
professions and specialties who regularly care for patients with major lower limb 
amputation in order to achieve broad representation of different viewpoints.  Where 
individuals responded to say that they were unavailable, or failed to respond, we invited 
other individuals from that profession/specialty in order to try to be as inclusive as 
possible.  A list of those invited is given in Table 3.6 in Section 3.3.2.1 on page 91 of this 
chapter.  Neither of the physiotherapists who agreed to come was able to attend the 
focus groups due to last-minute diary conflicts, so I arranged and LB-H held a separate 
interview with those individuals as I felt that it was very important to obtain input from 
physiotherapists with experience in looking after patients who have undergone MLLA. 
3.2.2.2 Sampling strategy – Patients and carers 
Previous experience with focus groups with amputee patients led me to believe that it 
might be difficult to get many individuals to engage with the study.  I therefore invited ten 
participants from a concurrently running randomised controlled feasibility trial (the 
PLACEMENT trial)76, along with six amputee patients who had had their amputations at 
least one year before the date of the focus group.  The former had already consented to 
contact from the research team for the purpose of engagement in focus groups as this 
was included on the PLACEMENT trial consent form.  The latter were approached by the 
usual care team and agreed verbally to be contacted by the research team.  All invited 
patients were encouraged to invite their carers to the group, whether or not they were 
willing or able to participate themselves. 
3.2.2.3 Data collection 
Owing to a lack of experience with running focus groups, these were facilitated by an 
experienced qualitative researcher (LB-H) working at the Cardiff Centre for Trials 
Research.  I organised the focus groups, including arranging the location and inviting 
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participants, attended and made notes.  A flexible, semi-structured topic guide was used, 
and the groups began with an open discussion about the care of patients undergoing 
MLLA, the level of importance participants place on these issues, and how these issues 
may change over time (i.e. over the short- and medium-term time periods).  The first part 
of the interview was guided by participants themselves, and the areas identified in the 
systematic review were not revealed. However, after this open discussion, prompts from 
the list of outcomes developed in the systematic review were used if areas had not 
naturally occurred.  
The facilitator (LB-H) used these prompts to explore whether the outcomes revealed by 
the systematic review were relevant to the real-life experiences and attitudes of the focus 
group participants and whether they were comprehensive to the concerns and needs of 
patients with lower limb amputations. Participants were encouraged to initiate and 
elaborate on topics most important to them and to respond directly to other participants’ 
responses in order to generate a group discussion. Focus groups lasted around 90—120 
minutes and were audio-recorded and transcribed verbatim, with references to 
identifiable personal details removed.  Brief demographic details of participants were 
taken by the facilitator.  Field notes were made by me and following the focus groups the 
facilitator reflected on the process, made overall observations and documented relevant 
contextual details.  The data were managed using qualitative coding software (NVivo 
qualitative analysis software; QSR International Pty Ltd. Version 11).  Data were coded, 
stored and analysed at the Centre for Trials Research, and kept on encrypted storage 
devices. 
3.2.2.4 Analysis 
Thematic analysis of the focus group transcripts and field notes was performed.77  
Following familiarisation with the data, the qualitative researcher (LB-H) developed a way 
of categorising the data into themes and subthemes (the analytical framework). An 
inductive approach was used, where the themes were identified directly from the focus 
group data, without referring to the domains identified in the systematic review. I 
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discussed the framework with the qualitative reviewer, and we agreed a framework. The 
qualitative researcher then systematically coded the focus group data, using the 
qualitative data analysis software NVivo, according to these themes (data topics that 
were common in the dataset), but also looking for contradictory views (negative cases). I 
then coded a proportion of the dataset independently (one of the three focus groups) and 
met with the qualitative researcher to discuss discrepancies in coding until consensus was 
reached. Any refinements were made to the analytical framework and reapplied to the 
data. The qualitative researcher then interpreted the coded data, taking into 
consideration the stakeholder group (i.e. themes according to patient, carer, healthcare 
professional type). The next, and final stage of analysis then involved considering this 
interpretation of the focus group data against the outcomes identified in the systematic 
review. The qualitative researcher and I then identified: (i) areas where themes in the 
focus group data were similar to or corresponded to those identified in the systematic 
review; (ii) areas where new themes were initiated by focus group participants but were 
not found in the systematic review; and (iii) areas where themes were found in the 
systematic review but not present in the focus group data. By bringing these elements 
together we produced a list of outcomes to be taken forward to the consensus study. 
As we used an inductive approach, in which the data take centre stage, the theoretical 
framework was not predetermined, so that the description was derived from the data 
itself.  We took a phenomenological approach to attempt to uncover the meaning of the 
‘lived experience’ of groups of individuals — people who have undergone MLLA and their 
carers, and a range of healthcare professionals involved in the management of patients 
who have undergone amputation — on the phenomenon (issues or outcomes of 
importance to patients after undergoing MLLA). As Tavallaei and Talib describe “the 
major aim of phenomenology is to ‘reduce’ the experience individuals have about a 
certain phenomenon” so that finally the description of the universal essence is created 
which means, as VanManen has described, “to grasp the very nature of the thing”.78,79  
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3.3 Results 
3.3.1 Phase I: Systematic Review 
3.3.1.1 Results of the search 
MEDLINE and EMBASE were searched on 20th April 2017 using the search protocol 
detailed in Table 3.3.  The search revealed 4288 studies after removal of duplicates. 
 
Item 
number 
Search item Number of 
results 
1 exp Peripheral Vascular Diseases/di [Diagnosis] 218253 
2 Arterial Occlusive Diseases/di [Diagnosis] 6766 
3 exp Arteriosclerosis/di [Diagnosis] 35693 
4 exp Atherosclerosis/di [Diagnosis] 18165 
5 exp Peripheral Arterial Disease/di [Diagnosis] 22699 
6 (atherosclero* or arteriosclero* or PVD or PAOD or 
PAD).ti,ab. 
385166 
7 (arter$ adj4 ($occlus$ or steno$ or obstruct$ or lesio$ or 
block$ or obliter$)).ti,ab. 
233846 
8 (vascular adj4 (occlus* or steno* or obstruct* or lesio* or 
block* or obliter*)).ti,ab. 
62629 
9 (vein* adj4 (occlus* or steno* or obstruct* or lesio* or 
block* or obliter*)).ti,ab. 
30643 
10 (veno* adj4 (occlus* or steno* or obstruct* or lesio* or 
block* or obliter*)).ti,ab. 
34079 
11 (peripher* adj4 (occlus* or steno* or obstruct* or lesio* 
or block* or obliter*)).ti,ab. 
39183 
12 (peripheral adj3 dis*).ti,ab. 85949 
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13 arteriopathic.ti,ab. 462 
14 CLI.ti,ab. 4890 
15 dysvascular*.ti,ab. 405 
16 (leg adj4 (obstruct* or occlus* or steno* or block* or 
obliter*)).ti,ab. 
1394 
17 (limb adj4 (obstruct* or occlus* or steno* or block* or 
obliter*)).ti,ab. 
4192 
18 (lower adj3 extrem* adj4 (obstruct* or occlus* or steno* 
or block* or obliter*)).ti,ab. 
3557 
19 1-18 combined with OR 966305 
20 amputee$.tw. 11024 
21 Amputees/ 44444 
22 (knee adj3 (disarticulat$ or exarticulat$)).tw. 538 
23 (amputat$ adj3 (transfemoral or transtibial or lower limb 
or lower extremity or above knee or below knee or 
through knee)).tw. 
11473 
24 Disarticulation/ 446 
25 Amputation/ 50788 
26 20-25 combined with OR 100428 
27 (transfemoral or transtibial or lower limb or lower 
extremity or knee).tw.  
359281 
28 exp Leg/ 391890 
29 27 OR 28 610534 
30 26 AND 29 28531 
31 19 AND 30 5849 
32 Remove duplicates from 31  4288 
Table 3.3: Numbers of results from systematic review database search. 
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GKA and NV independently screened titles and abstracts for inclusion, excluding 3878 as 
not relevant (25 of which were duplicates not excluded by the automatic system on Ovid), 
the majority because amputation was discussed as an outcome of other treatment rather 
than being the subject of the study.  This left 410 studies potentially suitable for inclusion, 
12 of which were systematic reviews, so useful as a source of additional studies which 
might have been missed by the search protocol. Thirty-eight more were excluded after 
review of the full text, leaving 360 studies available for extraction of outcomes.  A further 
153 studies were identified by screening reference lists.  Of these, 63 were excluded after 
screening abstracts, and a further 10 were excluded after review of the full text, leaving a 
further 80 studies suitable for extraction of outcomes.  A flow chart conforming to the 
format suggested by PRISMA is shown in Figure 3.1. 
3.3.1.2 Included studies 
Four-hundred and forty studies from 42 different countries were included in the review.  
Studies came most frequently from the USA (167 studies) or the United Kingdom (79 
studies).  Table 3.4 gives a breakdown of the number of studies included from each 
country.  This included sixteen case reports, 292 retrospective case series or cohort 
studies, 100 prospective cohort studies, two studies which included both prospective and 
retrospective cohorts, nine non-randomised controlled trials, 20 randomised controlled 
trials and one qualitative study.  The median number of patients included in the studies 
was 84 (range 1-186338).  Three hundred and twenty-three (73.4%) of the studies 
reported the proportion of male and female patients included.  The overall proportion of 
male patients was 61.2% (243493/397783) in studies where this was reported (range 0-
100%).  Four hundred and eighteen (95%) studies reported the mean or median age of 
participants.  In those reporting the mean age, the overall mean age was 73.5 years 
(range 34-93.5 years). 
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(n = 60) 
Studies included in 
qualitative synthesis 
(n = 440) 
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n = 440) 
Additional records identified 
through other sources 
(n = 153) 
Records after duplicates removed 
(n = 4416) 
Records screened 
(n = 4416) 
Records excluded 
(n = 3916) 
Full-text articles 
assessed for eligibility 
(n = 500) 
Excluded studies: 
12 Systematic reviews. 
13 Cross-sectional studies. 
21 Amputation the outcome 
       not the intervention. 
9 Indication not vascular. 
2 Minor amputations only. 
2 Opinion/Commentary. 
1 Second report on same 
cohort, without presentation 
of new outcomes. 
Figure 3.1: Flow diagram of article selection for systematic review. 
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Country Number of studies 
Argentina 1 
Australia 14 
Brazil 5 
Canada 12 
China 4 
Croatia 1 
Czechoslovakia 3 
Denmark 21 
Finland 8 
France 5 
Germany 18 
Ghana 1 
Greece 1 
Hong Kong 1 
Hungary 3 
Ireland 3 
Israel 5 
Italy 4 
Japan 11 
Lebanon 1 
Malaysia 1 
Netherlands 18 
New Zealand 1 
Norway 1 
Poland 3 
Portugal 2 
Russia 9 
Singapore 4 
Slovenia 2 
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South Africa 3 
South Korea 1 
Spain 1 
Sri Lanka 1 
Sweden 9 
Switzerland 7 
Taiwan 4 
Thailand 1 
Turkey 2 
Ukraine 1 
UK 79 
USA 167 
Uzbekistan 1 
Total 440 
Table 3.4: Country of origin of studies included in the systematic review. 
 
3.3.1.3 Excluded studies 
Forty-eight	studies	were	excluded	after	review	of	the	full	text	of	the	paper	as	it	was	not	possible	to	assess	suitability	for	inclusion	on	the	basis	of	the	abstract	alone.		Of	these,	13	studies	were	excluded	as	they	recruited	a	cross-section	of	patients	who	had	undergone	MLLA	at	some	point	in	the	past,	rather	than	patients	who	underwent	amputation	or	acute	post-amputation	rehabilitation,	the	majority	of	whom	had	undergone	their	amputation	several	years	in	the	past.		A	further	21	studies	examined	predictors	of	amputation,	rather	than	looking	at	the	outcomes	of	patients	undergoing	amputation	so	reported	no	outcome	measures.		Nine	studies	concerned	patients	whose	amputations	were	performed	for	cancer	or	trauma,	not	peripheral	vascular	disease.		Two	of	the	studies	included	only	minor	amputations	at	the	level	of	the	toes,	foot	or	ankle.	Two	studies	were	opinion-based	articles	which	reviewed	principles	of	managing	patients	requiring	amputation	and	included	no	patients.		Finally,	one	study	
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was	a	second	report	on	the	same	cohort	of	patients	as	another	included	study	and	reported	no	new	outcome	measures	which	were	not	reported	in	the	first	study. 
3.3.1.4 Extraction of reported outcome measures 
Papers found during the search were divided into 10 approximately equal batches for 
analysis.  JARJ and I independently screened and extracted data from the first batch, 
going through the results and coming to a consensus decision as described in the 
Methods.  Both then screened and extracted from the next batch and compared the 
number and type of outcome measures.  Outcome measures appeared to be similar and 
calculation of Kendall’s τ statistic revealed that the correlation was 0.66 (95% bootstrap 
confidence interval with 1000 replicates 0.463-0.827) for planned outcomes and 0.57 
(95% confidence interval 0.314-0.782) for presented outcomes.  As this met the criterion 
for continued independent extraction, a decision was made to continue extraction 
independently.  Three-hundred and ninety-eight studies were reviewed in this phase, of 
which 38 were excluded (see Excluded Studies in Section 3.3.1.3 on page 68 above for 
details).  I extracted from a total of seven batches and JARJ extracted from a total of five 
batches.  Following extraction from the studies retrieved from the search, I compiled a list 
of potential studies from references of included studies and screened and extracted from 
these additional studies.  A further 90 studies were identified in this way, of which 10 
were excluded after review of the full text (see Excluded Studies in Section 3.3.1.3 on 
page 68 above for reasons for exclusion). 
The 440 included papers reported 1447 outcome measures, giving an average number of 
outcomes per study of 3.29.  There were 444 discrete outcome measures.  The most 
frequently reported outcome measures were ‘mortality’ and ‘wound healing’, which were 
each reported in 93 studies.  Two hundred and eighty-one discrete outcome measures 
were only reported by a single study.  A complete list of the outcome measures reported, 
along with the frequency of reporting, is given in Table 3.5. 
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3.3.1.5 Division of outcome measures into main domain and reduction to a list of 
outcomes 
There is considerable overlap across the 444 outcome measures reported in the 
literature.  Some of this relates simply to the use of different synonyms by study authors: 
for example, 93 study authors reported ‘mortality’, whereas eight reported ‘death’.  In 
addition, some relates to the timing of measurement: there were 46 studies reporting 30-
day mortality, six reporting 6-month mortality, eleven reporting 12-month mortality, etc.  
It is impractical to propose a Delphi survey which asks respondents to rate the relative 
importance of all 444 of these overlapping and sometimes semantically identical outcome 
measures, so it is appropriate to reduce them to discrete concepts. 
The outcome measures are presented in Table 3.5, classified using the system described 
by Dodd et al.68  In addition, as described in the Methods, the outcome measures have 
been grouped into outcomes.  This reduced the list of 444 outcome measures to a list of 
48 distinct outcomes.  Three of the outcomes were felt not to be relevant to the majority 
of patients undergoing a major lower limb amputation for complications of peripheral 
vascular disease so were not taken forward to the Delphi survey.  These were ‘Problems 
with transplant in patients with kidney transplants’ and ‘Transplant rejection in patients 
with organ transplants’, which were eliminated as the vast majority of patients 
undergoing major lower limb amputation would not have an organ transplant; and 
‘Peripheral vascular disease’, as all patients undergoing a major lower limb amputation 
for complications of peripheral vascular disease would already have peripheral vascular 
disease.  After removing these three outcomes we were left with 45 outcomes from the 
systematic review to take forward to the Delphi survey. 
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Domain ‘Death’ 
Outcome Outcome Measures N 
Death within a specified 
period of time after 
operation, or survival 
time after the operation 
6-month mortality 6 
mortality 93 
30-d mortality 46 
Death 8 
inpatient death in rehab 2 
in-hospital mortality 12 
in-hospital death 2 
perioperative mortality 19 
mortality at 3 years 2 
mortality at 5 years 5 
mortality at 12 months 11 
mortality at 3 months 2 
mortality at 2 years 6 
death before discharge 1 
death after discharge 1 
died within 2 years of amputation 1 
postoperative early mortality 1 
postoperative mortality 3 
Early mortality rate (within 14 days) 3 
total mortality 2 
postoperative death 2 
all-cause mortality 1 
8-year mortality 1 
90-day mortality 2 
died within 1 week 1 
died before healing 1 
patient survival at 1 year 1 
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1-year survival 3 
5-year survival 1 
2-month survival 1 
24-month survival 1 
3-year survival 1 
survival 63 
long term patient survival 1 
additional amputation free survival 1 
contralateral amputation-free survival 2 
Cause of death cause of death 19 
cause of in-hospital death 1 
mortality from purulent and necrotic complications 1 
Domain: Blood and lymphatics 
Outcome Measures N 
Bleeding or need for 
blood transfusion after 
surgery 
blood loss 2 
transfusion 2 
post-operative haemoglobin 3 
bleeding requiring 4 units blood within 72 hours of 
surgery 
1 
haematoma 1 
bleeding complications 2 
haemorrhage 1 
seroma/hematoma 1 
wound bleeding 1 
Domain: Cardiac 
Outcome Measures N 
Heart related problems 
during surgery or follow-
up 
medical stability 1 
cardiac arrhythmias 3 
cardiac event 1 
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heart complications 1 
cardiac complications 2 
cardiac arrest 2 
angina 1 
ECG changes 1 
resting heart rate, HRmax, %predicted HRmax, BPmax, 
Artificial oxygen saturation 
1 
MI 15 
MI within 1 year 1 
Late MI 1 
time to readmission with acute coronary syndrome 1 
CK-B level 1 
congestive heart failure 3 
Domain: Endocrine 
Outcome Measures N 
Problems related to 
control of diabetes 
during surgery or 
follow-up diabetic complications 1 
Domain: Gastrointestinal 
Outcome Measures N 
Nausea 
nausea 1 
post-operative antiemetic use 1 
Upper gastrointestinal 
tract problems perforated duodenal ulcer 1 
Constipation* GI tract complications 1 
Domain: General 
Outcome Measures N 
pain characterization and intensity over time 1 
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Pain in residual 
limb/amputation stump 
highest pain score for 6 postoperative days 1 
pain intensity/frequency 1 
Successful pain control 1 
perioperative pain scores 1 
average pain scores per day 1 
post-operative pain 3 
Post-amputation chronic pain 2 
pain at 6 months 2 
pain intensity in first 24 hours 1 
pain at 3 months 1 
post-operative wound pain intensity 1 
prolonged limb pain 1 
chronic stump pain 2 
stump pain 9 
stump pain in first 30 days, at 3 months and at 6 months 1 
effective pain relief 1 
McGill Pain Questionnaire at 6 months 2 
Pain at 3-6 months 1 
stump allodynia 2 
Pain threshold 2 
Satisfaction with treatment of pain 1 
stump pain at 12 months 2 
VAS on days 1 and 3 1 
96-hour mean NRS pain score 1 
temporal summation of pain 1 
mean VAS intensity of stump and phantom pain after 1 
week and 3, 6 and 12 months 1 
NRS pain score in first 3 days 1 
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McGill Pain Questionnaire at 8 days, 6 weeks and 3 
months 1 
Neuropathic Pain Scale 1 
Quantitative sensory testing 1 
reflex sympathetic dystrophy in stump 1 
nerve complications 1 
Domain: Immune system 
Outcome Measures N 
Transplant rejection in 
patients with organ 
transplants biopsy-proven acute rejection 1 
Domain: Injury/poisoning 
Outcome Measures N 
Falls Falls 1 
Domain: Metabolism/nutrition 
Outcome Measures N 
Nutritional status 
(weight loss, 
malnourishment, 
obesity, etc.) BMI 1 
Domain: MSK/connective tissue 
Outcome Measures N 
Joint contractures 
Contracture of knee joint 1 
flexion contractures 1 
Frequency and degree of contractures 1 
Domain: Nervous system 
Outcome Measures N 
Effectiveness of pain 
relief 
Successful surgery after peripheral nerve blockade 9 
onset time of nerve block 1 
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analgesic time from beginning of block 1 
Duration of analgesia 1 
block related complications 1 
time until first analgesia 1 
paresthesia and injection pain during injection 1 
pain relief with peripheral block 1 
intraoperative pain in the sciatic nerve distribution 1 
PCA prescriptions 1 
opioid consumption 5 
total morphine equivalents per day 1 
Morphine equivalents in first 72 hours 1 
post-operative opioid requirement 1 
amount of narcotics used for pain relief post-
operatively 1 
need for narcotic analgesics 1 
morphine requirements 1 
opioid consumption in first 3 postoperative days 1 
Morphine equivalents on days 1 and 3 1 
opioid consumption at 30 days and 6 months 1 
oxycodone use in first 3 days 1 
analgesic medications 1 
NSAID consumption 1 
duration and dosage of ketamine 1 
amitriptyline prescription 1 
Phantom sensations or 
pain 
phantom limb pain 15 
postoperative phantom pain intensity 1 
phantom pain at 1 year 1 
Sherman's phantom limb questionnaire 1 
phantom limb sensation 5 
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phantom limb sensation in first 3 postoperative days, at 
6 months and at 12 months 1 
kinetic sensations, kinesthetic sensation, exteroceptive 
sensations, super-added sensations, all at 6 months 1 
Stroke 
stroke 13 
haemorrhagic stroke rate 1 
Stroke within 1 year 1 
Late stroke 1 
CVA 1 
coma 24 hours 1 
Domain: Renal/urinary 
Outcome Measures N 
Problems with kidneys 
acute renal failure 6 
creatinine level 1 
renal insufficiency 1 
renal complications 1 
new onset dialysis 2 
renal/urological complications 1 
Problems with urinary 
tract 
urinary retention 1 
urinary tract infection 4 
Problems with 
transplant in patients 
with kidney transplants 
Delayed renal graft function 1 
primary nonfunction 1 
graft loss 1 
long term graft survival 1 
Domain: Psychiatric 
Outcome Measures N 
Drowsiness 
sedation 2 
mean sedation score over first 96 hours 1 
sedation on a 1-5 NRS in first 3 days 1 
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Anxiety or depression 
Rate of suicidal ideation 1 
PHQ-9 1 
depression at 6 months 1 
low mental health at 6 months 1 
Beck Depression Inventory while inpatient, in rehab, 
and after discharge from rehab 1 
Hospital Anxiety and Depression Score 1 
Domain: Respiratory/thoracic/mediastinal 
Outcome Measures N 
Pneumonia pneumonia 11 
Breathing problems 
post-op ventilatory support 1 
respiratory/pulmonary complications 2 
re-intubation 1 
ventilator dependence 1 
pneumothorax 1 
aspiration 1 
Prolonged mechanical ventilation requiring 
tracheostomy 1 
unplanned intubation for respiratory/cardiac failure 1 
prolonged intubation (48 hours) 1 
Domain: Skin/subcutaneous tissue 
Outcome Measures N 
Problems with 
amputation stump 
healing 
skin irritation at 6 months 1 
wounds from prosthesis use at 6 months 1 
Stump irritation 1 
requirement for skin graft 1 
skin maceration 1 
Stump defects and type 1 
pressure sore incidence 2 
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decubitus ulcer 1 
stump related complications 1 
Wound occurrence 2 
wound complications 15 
local wound complications 2 
soft tissue complications 1 
resting TcpO2 post therapy 1 
leg oedema 1 
Stump volume reduction 1 
synovial effusion 2 
wound dehiscence 2 
Postoperative stump necrosis 4 
Wound healing 93 
primary healing rate 6 
healing rate 1 
time to wound healing 6 
mode of wound healing 1 
stump healing 8 
Delayed wound healing 4 
failed primary healing 2 
failure to heal 1 
secondary healing 1 
healing after revision 1 
healing after re-amputation to AKA 1 
not healed at follow-up 1 
Stump wound infection 
surgical site infection 1 
Wound infection 15 
Superficial wound infection 1 
deep wound infection 1 
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stump infection 3 
wound infection requiring reoperation 1 
sepsis 5 
fever 1 
Expression of CD3, 4, 8, 19, 25, 69, IFNgamma, IL-4, 
phagocytosis burst capacity, oxidative burst capacity 1 
Lipid peroxidation processes 1 
Domain: Vascular 
Outcome Measures N 
Blood clots in deep 
veins or lungs (venous 
thromboembolism) 
VTE (DVT/PE) 7 
PE 8 
DVT requiring therapy 1 
DVT 6 
ipsilateral DVT 1 
contralateral DVT 1 
VTE at 14 days and in first 8 weeks 1 
Peripheral vascular 
disease peripheral vascular disease 1 
Physical 
Outcome Measures N 
Patients supplied with a 
temporary or definitive 
prosthetic limb 
successful fitting with prosthesis 66 
prosthetic prescription rate 5 
rate of prosthetic fitting at 1 year 1 
prosthetic device acquisition 1 
Prosthetic prescription within 1 year of amputation 2 
progress to definitive prosthesis 1 
unsuitable for prosthesis 1 
referral for prosthetic rehabilitation 1 
use of prosthesis on discharge 1 
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Prosthetic limb use, 
comfort and fitting 
prosthetic use at 12 months 3 
Rates of abandoning prosthesis use 3 
prosthetic use at 6 months 3 
prosthetic use at 6 weeks and 4 months 1 
self-reported hours of prosthetic use at 6 months 1 
Achievement of prosthetic use 5 
Daily hours of prosthetic use 1 
prosthetic use at follow-up 5 
Daily hours of prosthetic wear at 12, 18 and 24 months 1 
Prosthetic wearing at follow-up 1 
Houghton score of prosthetic use 1 
prosthesis comfort at 6 months 1 
need for socket changes 1 
COP (Centre of pressure) trajectories and time functions 1 
distribution of reaction forces between the two legs 1 
inclination angles obtained through second order 
regression analysis using stabilogram data 1 
cadence 1 
velocity 1 
step time 1 
step length 1 
Level of independent 
mobility or function 
achieved (may include 
use of mobility aids) 
Prosthetic Limb Users Survey of Mobility (PLUS-M) 1 
prosthesis evaluation questionnaire-mobility section 1 
walking in prosthesis at 6 weeks, 4 months and 12 
months 1 
function with a prosthesis at 1 year 2 
Independent fitting of prosthesis 1 
prosthetic restoration 1 
mobility with temporary prosthesis 1 
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walking with pneumatic walking aid 1 
Locomotor Capabilities Index 5-level scale at 12 months 7 
Functional Independence Measure (FIM) total score 5 
FIM-M score 2 
LCI-5 at 6 weeks & 4 months 1 
ability to use parallel bars/walkers/crutches on 
discharge 1 
Ambulation 2 
K-levels 1 
2-minute walk 3 
timed up and go at 6 months 4 
5-metre gait speed 1 
patient-specific functional scale 1 
Groningen activity restriction scale at 12 months 2 
appearance and gait at 6 months 1 
Minimum Data Set Activities of Daily Living Long Form 
Score 1 
discharge functional status 4 
Mobility in the home at discharge from rehab 2 
independent walking/ambulation 3 
return to pre-morbid functional status 1 
Special Interest Group in Amputee Medicine (SIGAM) 
mobility grade at 6 months 3 
Functional independence while inpatient and in rehab 1 
Functional independence after discharge from rehab 2 
LCI while inpatient and in rehab 1 
LCI after discharge from rehab 2 
LCI at 6 months 2 
mobilized without crutches 1 
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timed up and go at 12 months 1 
Barthel Index effectiveness at discharge 3 
mobility at 1 year 2 
maintenance of ambulation 4 
functional measure for amputees at 1 and 6 months 1 
LCI at 1 month 1 
Satisfactory ambulation measured by the Walking 
Ability Index 2 
rehabilitation success 11 
locomotor performance after prosthesising 1 
mobility unaided without wheelchair 1 
functional ambulation level 7 
Independent mobility with prosthesis 1 
mobility level 16 
Walking speed 2 
mobility with prosthesis 11 
rehabilitation status 1 
rehabilitation outcome 4 
successful maintained level of rehab at follow-up 1 
Distance walked 2 
functional outcome 2 
mobility score 1 
successful ambulation with prosthesis 6 
independence of ADL 1 
mobility aids used at follow-up 2 
degree of rehabilitation 6 
wheelchair use (dependence) 2 
method of ambulation at discharge 1 
means of ambulation 1 
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walking ability at follow-up 3 
satisfactory walking results 1 
functional independence at 1 year 1 
functional activity level at 12, 18 and 24 months 1 
Stanmore Harold Wood Mobility Grade 1 
rehabilitation accomplishments 1 
Mobility at 6 months 2 
improvement of physical function at rehabilitation 
discharge 1 
10 metre walk velocity 1 
prosthetic gait (mobile in or outdoors with prosthesis) 1 
Rivermead mobility index 1 
walking aids used on discharge 5 
need for mobility aids at 6 months 1 
use of early walking aids 1 
use of mobility aids at 12, 18 and 24 months 1 
Development of 
problems with the other 
leg 
major amputation of the contralateral lower limb 15 
contralateral limb preservation 2 
time to contralateral amputation 1 
contralateral limb survival 1 
Domain: Social 
Outcome Measures N 
Participation in work 
and social activities 
effect on home and work capacity 1 
return to work 1 
Reintegration into Normal Living (RNLI) 1 
community participation at 12 months 1 
social integration at 12 months 1 
low social functioning at 6 months 1 
Sexual activity self-reported frequency of sexual activity 1 
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desire for sexual activity 1 
importance of sexual activity to satisfaction with life 1 
Domain: Rôle 
Outcome Measures N 
Independent living 
independence 2 
maintenance of independent living 6 
independent living status 1 
Experiences of living with an amputation 1 
discharge supports 2 
home care arrangements 1 
social service use 1 
discharge with assistance 1 
Psychological/wellbeing 
Outcome Measures N 
Coping strategies and 
psychological 
adaptation 
  
Coping Strategies Questionnaire at 6 months 1 
Psychological adaptation to limb loss 2 
low emotional functioning at 6 months 1 
Domain: Cognitive 
Outcome Measures N 
Cognitive function or 
confusion 
Digit span 1 
list learning 1 
list recall 1 
semantic fluency 1 
short portable mental status questionnaire 1 
right-left foot recognition 1 
delirium 1 
Domain: Global Quality of Life 
Outcome Measures N 
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Quality of life 
quality of life 3 
EQ5D 1 
SF-36 Subscales 2 
SIP-68 1 
Domain: Perceived Health Status 
Outcome Measures N 
Satisfaction with health 
status 
Satisfaction with mobility at 12 months 1 
Satisfaction with life at 12 months 1 
Body Image Questionnaire while inpatient, in rehab, 
and after discharge from rehab 1 
Domain: Personal circumstances 
Outcome Measures N 
Residential status 
discharge home 3 
discharge to independent living 2 
ultimately returned home 1 
living environment 1 
proportion returned to previous living conditions at 1 
year 1 
discharge destination 16 
change of residence 1 
discharge disposition 3 
discharge setting 1 
discharge placement 1 
disposition of patients 1 
residential status at discharge 1 
discharge to nursing home care 1 
institutionalization 1 
Economic 
Outcome Measures N 
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Cost of treatment 
resource utilization 1 
acute medical costs 1 
postacute medical costs 1 
hospital charges 2 
expenses 1 
hospital costs 1 
cost analysis 1 
financial burden of prosthesis 1 
rehabilitation charges 1 
Number and class of hypertension medications 1 
Hospital use 
Outcome Measures N 
Time in operating suite 
operative time 2 
time in the recovery room 1 
Time taken to complete 
rehabilitation 
Duration required to complete rehabilitation 6 
number and duration of physio treatments during early 
walking aid/prosthesis use 1 
time until definitive prosthesis 5 
initial prosthetic casting 1 
time to prosthetic fitting 4 
time to reach prosthetic casting 1 
readiness for prosthetic fitting 1 
rate of progression through temporary prostheses 1 
time to walking with prosthesis 2 
time to temporary prosthetic fitting 1 
days until patella tendon bearing cast 1 
weeks to achieve maximum benefit 2 
time to mobilisation 2 
LOS in ITU 1 
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Length of time in 
intensive care/acute 
hospital/rehabilitation 
LOS 51 
rehabilitation LOS 11 
total hospital stay 1 
time to discharge 1 
admission to HDU/ICU 1 
prolonged hospital stay 1 
Need for re-admission 
to hospital after 
discharge 
Occurrence of transfer back to acute service 1 
proportion having readmission 4 
Compliance with 
guidelines for care 
QIF compliance 1 
use of compression therapy 1 
Domain: Need for further intervention 
Outcome Measures N 
Need for additional 
operations 
additional amputation rate 3 
stump revision rate 9 
Revision to AKA 24 
Ipsilateral reamputation 1 
Revision at same level 1 
revision at more proximal level 3 
time from amputation to revision 1 
need for surgical revision 1 
reamputation rate 40 
reamputation level 1 
reamputation timing 1 
reamputation at 12 months 1 
late revision or reamputation 1 
final amputation level 3 
revision rate 26 
reamputation/revision to higher level 12 
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revision or reamputation within 30 days 2 
debridement of stump 1 
further procedures 1 
Domain: Adverse events/effects 
Outcome Measures N 
Side effects of 
medication side effect occurrences 1 
Overall perioperative 
complications 
Perioperative systemic complications 4 
morbidity 3 
cardiorespiratory complications 1 
postoperative complications 4 
major morbidity 1 
Table 3.5: Outcomes from the systematic review, grouped into the Domains recommended by 
Dodd et al.68  N: Number of times reported.  *Constipation was an outcome raised in focus groups.  
While not directly measured by any of the studies, it can be considered a ‘GI tract complication’, 
which is why it appears in this table.  Prior to incorporating insights from the focus groups, we had 
a single GI tract complication outcome from the systematic review, but due to the importance 
placed on this outcome by focus group participants we split this into ‘upper gastrointestinal tract 
problems’ and ‘constipation’.  Outcomes in red were felt not to be relevant to a core outcome set 
for patients undergoing MLLA for complications of peripheral vascular disease so were excluded 
from the Delphi.  Some of the outcomes were difficult to categorise or could be put into several 
categories.  For these outcomes we checked that all of the alternative categories were also 
included in the Delphi.  The classification was approved at formal trial management group 
meetings. 
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3.3.2 Phase II: Qualitative focus groups 
The focus groups took place on 15th September (Mixed healthcare professionals; group 1), 
28th September (patients and carers; group 2) and 6th October 2017 (doctors; group 3).  A 
further interview with two physiotherapists specialising in the care and rehabilitation of 
amputee patients took place on 1st December 2017 (group 4), as it was felt to be 
important to get input from physiotherapists and none of the invited physiotherapists 
was able to make it to any of the focus groups. 
3.3.2.1 Focus group participants 
A list of the professions/specialties invited, along with those who agreed to attend and 
those who actually did attend is given in Table 3.6. 
 
 
Profession/specialty Number 
invited 
Number 
accepted 
invitation 
Number 
attended 
Doctors    
Anaesthetists 1 1 1 
Vascular surgeons 4 3 2 
Orthopaedic surgeons 2 0 0 
Diabetologists 1 1 1 
Wound care specialists 1 0 0 
Rehabilitation physicians 4 1 0 
GP (special interest in 
rehabilitation) 
1 1 1 
Subtotal 14 7 5 
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Nurses    
Vascular specialist nurse 2 2 1 
Vascular care practitioner 1 1 1 
Pain specialist nurse 1 1 1 
Rehabilitation specialist nurse 1 1 0 
Tissue viability specialist nurse 1 0 0 
Community nurse 3 0 0 
Operating theatre nurse 2 1 0 
Vascular ward nurse 2 1 1 
Subtotal 13 7 4 
Allied health professionals    
Physiotherapist 2 2 0 
Occupational therapist 1 1 1 
Dietician 2 0 0 
Podiatrist 2 2 2 
Clinical psychologist 1 1 1 
Prosthetist 2 2 2 
Operating department 
practitioner 
2 1 0 
Subtotal 12 9 6 
Total 39 23 15 
Table 3.6: Focus group participants: healthcare professionals. 
 
One non-medically trained healthcare professional (the clinical psychologist) attended the 
focus group intended for medically trained healthcare professionals.  No medically 
trained healthcare professional attended the focus group intended for non-medically 
trained healthcare professionals. 
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In addition to the patients and carers whose invitation I described above, I also invited 
one individual who was known to the study team owing to her participation as lay 
representative on the PLACEMENT trial management group, whose father had had a 
major limb amputation.  There were 10 unilateral and 6 bilateral amputee patients.  Of 
the unilateral amputee patients, seven had below the knee amputation and three had 
above knee amputations.  Of the bilateral amputee patients, three had bilateral above 
knee amputations, one had bilateral below knee amputations and the other two had one 
below and one above knee amputation.  Eleven male and five female amputee patients 
were invited.   Five amputee patients and five carers agreed to participate, and three 
amputee patients and three carers actually attended.  Of the three amputee patients who 
attended, one (female) had a unilateral below knee amputation, one (male) had bilateral 
below knee amputations and one (male) had one below knee and one above knee 
amputation.  The three carers who attended all cared for people with above knee 
amputation, none of whom attended the focus group. 
3.3.2.2 Thematic framework 
The qualitative researcher (LB-H) developed a thematic framework from analysis of the 
three focus groups and the additional interview (described collectively as ‘groups’ below).  
This revealed 19 themes which were covered in the discussions.  Some themes were only 
raised in one of the four groups, some in two, some in three and some in all four.  The full 
framework is presented in Appendix A, and the themes are discussed below. 
1. Quality of life 
This theme was discussed in groups 1, 2 and 3.  All three groups touched on issues 
of functional independence here.  Group 3 also related it to issues of body image 
and comfort.   Group 1 also discussed the way social functioning related to quality 
of life, highlighting the difficulty of separating different themes.  
2. Social functioning 
This theme was discussed extensively by all groups.  There was much discussion of 
goal setting in this context, and the satisfaction associated with successful return 
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to pre-morbid levels in relation to activities such as being able to go to the toilet 
without assistance or go and get a glass of water.  Hobbies, holidays and family life 
were discussed, as was the importance of the social support network and the 
strain which amputation placed on relationships, with one amputee patient 
remarking ‘I wasn’t a nice person to know’ when discussing the early period 
following amputation.  Group 1 also discussed the importance of sexual activity, 
but only after seeing this item in the results of the systematic review. 
3. Psychological and biopsychosocial factors. 
This theme was again discussed by all groups.  Groups 1 and 3 discussed managing 
patient and carer expectations and helping them to know what to expect from 
rehabilitation, as well as the importance of psychological support.  Both negative 
(grief, anger, regret, guilt, fear for the future, anxiety and depression to name a 
few) and positive (hope, elation, self-belief, confidence) factors were discussed by 
groups 1, 2 and 4. 
4. Illness representations. 
These were covered by groups 1, 2 and 3.  Patient beliefs around what had 
happened to them were explored, including the positive experiences of no longer 
having to deal with a smelly chronic wound, or chronic pain, with some amputee 
patients wishing they had had their amputation earlier.  Negatives such as the 
question of whether the amputation could have been avoided and being treated 
like ‘’an invalid’’ and dealing with other people’s reactions and stigma were also 
discussed. 
5. Communication. 
This was discussed by all groups.  The importance of the communication 
relationship, both between the patient and the care team and also within the care 
team, was highlighted in terms of shared decision-making, ensuring that everyone 
was working towards common goals and also the continuity of care. 
6. Financial issues. 
Group 3 discussed return to work and the impact that this might have on financial 
issues as well as the consequence that this might have on mood and 
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independence.  Groups 1 and 2 discussed the negative aspects of patients possibly 
losing their home and the costs of adapting the home. 
7. Amputation type. 
Groups 1 and 3 discussed technical aspects of amputation type and the impact 
that this might have on prosthetic fitting and function.  These issues were not 
discussed by the patients and carers group or the amputee physiotherapists. 
8. Wound healing. 
Groups 1 and 4 discussed delayed wound healing, healing of the deep or 
superficial tissues, scarring and removal of sutures. 
9. Pain. 
This was discussed by all groups.  It is possible that this was discussed 
disproportionately as the PLACEMENT trial, which looked at an intervention 
designed to reduce postoperative pain in amputee patients, was ongoing at the 
time of the focus groups and some of the participants were involved in the 
running of this trial.  Outcomes discussed included the level of severity of the pain, 
pain in the residual limb, phantom limb pain, chronicity of pain, medication use to 
control pain and the use of additional, unprescribed things to control pain, such as 
cannabis, massage or mirror box therapy. 
10. Rehabilitation. 
This was discussed by groups 1, 3 and 4.  Issues around realistic goal setting, time 
out of bed, the importance of peer support and relationship building (continuity of 
care) were raised within this context. 
11. Prosthesis. 
Issues related to prosthesis fitting or function were discussed by all groups, 
including issues related to comfort, look, function and satisfaction as well as issues 
related to equipment such as the supply of suitable footwear, early walking aids 
and walking frames.  Goal setting was again discussed in this context. 
12. Mobility aids other than prosthesis. 
Supply of equipment to facilitate independence was discussed by all groups.  This 
included wheelchairs, shower adaptations, beds and walking frames. 
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13. Returning home. 
Groups 1 and 3 discussed the barriers to getting patients home when they were 
medically fit for discharge.  This again included supply of appropriate equipment 
but also the management of wounds as an outpatient. 
14. Falls. 
Patients and carers (group 2) also discussed the problems with falling, which was 
recognised to be a common problem among amputee patients, both because of 
problems with balance and also simply because patients sometimes forget that 
their leg is no longer there and try to stand on it. 
15. Readmissions. 
Groups 1 and 3 discussed the problem of readmissions, both because of problems 
with the residual limb (amputation stump) and also for other reasons, as this 
patient cohort are often highly co-morbid. 
16. Clinical state compared to pre-operative state. 
This theme was discussed by all groups.  Groups 1, 2 and 3 discussed the fact that 
patients may be in a better state after surgery than before, as they may have been 
septic or in chronic pain.  Patients also reflected on the fact that without their 
amputation they might not be alive anymore.  All groups reflected on the fact that 
the period leading up the amputation was often long and so often patients were 
quite ‘de-conditioned’ (the phrase used in multiple groups, meaning that 
individuals had lost muscle mass due to immobility due to problems with their 
limb) by the time they had their amputation.  This, together with comorbidities 
often led to quite a prolonged rehabilitation phase afterwards.  Group 4 also 
mentioned that the extra energy and co-ordination required to mobilise after 
amputation could unmask problems which had previously been hidden such as the 
impact of stroke or cognitive impairment or could trigger other problems such as 
heart attacks due to the increased strain. 
17. Fate of the other limb. 
This was discussed by groups 1, 3 and 4.  The risk to the other limb of decubitus 
ulcers and disease progression which could lead to amputation of the other limb 
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was considered important.  Additional strain on the contralateral hip and knee 
were also discussed. 
18. Risk reduction behaviour. 
Groups 3 and 4 discussed the importance and impact of smoking cessation, 
diabetic control, drug abuse and homelessness on amputee patients and their 
rehabilitation. 
19. Mortality. 
Group 3 discussed the importance of mortality as an outcome as it was recognised 
that many amputee patients do not live a year after amputation. 
3.3.2.3 Conversion of the thematic framework from focus groups into outcomes 
The thematic framework developed by LB-H, the study qualitative researcher, was 
reviewed and I converted the themes into outcomes to line-up with those developed in 
the systematic review.  I presented these to the PLACEMENT Trial Management Group via 
email and discussed face-to-face at a meeting in order to get consensus on how best to 
translate these into meaningful outcomes.  Most themes were felt to have already been 
covered by outcomes from the systematic review, but there were four themes which 
were felt not to have been covered by the outcomes from the systematic review.  One of 
these themes (communication) was felt to be broad enough that two additional 
outcomes needed to be defined.  Table 3.7 presents these additional themes and the 
outcomes derived from them. 
For the purpose of keeping similar outcomes together in the Delphi survey, these five 
additional outcomes were also grouped using the Domains of Dodd et al.68  Impact on 
family/loved ones was placed into the ‘Social’ domain, Shared decision making and 
Communication between healthcare team and patient/carers were placed into the 
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‘Delivery of Care’ domain, Use of drugs or therapies which have not been prescribed was 
placed into the ‘Need for further intervention’  domain and Number of outpatient 
appointments was placed into the ‘Hospital use’ domain. 
 
Theme Suggested sub-
themes 
Comments Outcomes 
Psychological/ 
biopsychosocial 
factors 
3.5 Family 
perspective 
• How will family cope Impact on 
family/loved ones 
Communication  5.1 Patient and 
health 
professional 
communication 
 
• In terms of patient: being 
listened to, involved in 
decision making, given 
opportunity to ask 
questions, interaction with 
surgical team, being 
‘understood’ and 
understanding what was 
going to happen, 
empowering patient 
• Individual patient goal 
setting (theory of care 
owners’ model) 
• Terminology - asking the 
patient what they want to 
call the residual limb  
• Empathy from health care 
professionals 
Shared decision 
making. 
Effective 
communication 
between 
healthcare team 
and 
patient/carers 
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• Continuity of care (‘knowing’ 
the patient) 
• Will depend on whether 
elective vascular or 
orthopaedeic patient 
Pain 9.11 Pain 
management: 
non-
medication 
• Are patients supplementing 
due to pain (e.g. cannabis 
use) 
• Other ways of handling pain 
e.g. handling techniques, 
massage, laser or mirror box 
therapy 
Use of drugs or 
therapies which 
have not been 
prescribed 
Readmissions  
 
15.2 Reduction 
in other 
hospital visits  
• Difficult having to go to so many 
different appointments 
Number of 
outpatient 
appointments 
Table 3.7: Additional outcomes derived from focus groups.  Blue text: themes discussed in the 
mixed healthcare professionals focus group; red text: themes discussed in the patients and carers 
focus group; black text: themes discussed in the medically trained healthcare professionals focus 
group; red text: themes discussed in the patients and carers focus group; black text: themes 
discussed in the medically trained healthcare professionals focus group; green text: themes 
discussed in the physiotherapists group. 
3.4 Discussion 
Both systematic review and qualitative research have revealed a large number of 
outcomes facing patients undergoing amputation as a consequence of peripheral vascular 
disease.  Many of these overlap to a large degree, but it is interesting to reflect on the 
fact that some of the themes discussed in the focus groups, such as the problems with 
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communication (for example shared decision-making) have not been the subject of 
significant research within the scientific literature for this patient cohort. 
This finding, where qualitative research reveals outcomes of importance to patients 
which have received little attention previously in the research literature, has previously 
been reported by Sanderson et al. in other work on core outcome sets.74 The work of 
Sanderson et al. highlighted the importance of involving patient stakeholders in the 
development of a long-list of potential core outcomes.  The importance of shared 
decision-making, however, was highlighted in all of the focus groups, so this was clearly 
recognised as important by a diverse group of both patients and healthcare professionals, 
despite having failed to appear in the results of the systematic review.  This may reflect 
the under-researched nature of major lower limb amputation or may reflect the fact that 
searching the scientific literature is not sufficient even to develop a list of outcomes 
which healthcare professionals will recognise as complete. 
One of the strengths of this work is the mixed methods approach I adopted, with 
quantitative research in the form of a systematic review being complemented by 
qualitative research to develop a full appreciation of the breadth of issues which are 
important to a patient cohort.  This benefits from the advantages of both approaches to 
developing a long-list of outcomes, so is less likely to miss out factors which could take on 
an important rôle in the later phases of core outcome set development.  The principal 
disadvantage of this approach is that it does add considerable work to the process, as 
both the systematic review and the organisation, running and analysis of focus groups are 
lengthy processes.  Not only this, but after both are complete there is then a requirement 
to combine the results into a single list of topics for the subsequent consensus survey. 
The large list of distinct outcome measures obtained from the systematic review 
highlights the fact that research in this area has historically been highly inefficient in two 
respects.  Firstly, it is not likely that all of the outcomes underlying these outcome 
measures would be considered core by patients, carers and healthcare professionals.  It 
would be more efficient to direct work mainly towards the outcomes which matter the 
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most.  Secondly, as there is such a diverse range of outcome measures, it is difficult to 
pool the results of multiple studies to compare and contrast the effects of different risk 
factors or interventions. 
It could be argued that one could dispense with the systematic review phase when 
developing a long-list.  Our systematic review revealed 444 outcome measures, across 26 
different domains.  While the approach of dispensing with the systematic review has 
been adopted by some core outcome set developers, I believe that it is unlikely that a 
small number of focus groups would capture the full breadth of possible outcomes 
encountered in a full systematic review.  One example of this is the fact that sexual 
activity was only discussed in one of the focus groups, and this only happened in the final 
phase of the focus group upon reviewing the results of the systematic review. 
I have developed a long-list of outcomes from our systematic review, and a further 
collection of themes from stakeholder focus groups.  The next steps for developing core 
outcome sets now involve identification of the most important outcomes from the 
combined list of outcomes I have identified.  There are two further stages necessary for 
the completion of core outcome sets.  The first is to perform a multi-round consensus 
survey involving a broad pool of stakeholders.  Secondly, I need to ratify the results of the 
consensus survey at a multi-stakeholder face-to-face meeting.  These steps will be 
discussed in the next chapter. 
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4 Development of core outcome sets for 
people undergoing major lower limb 
amputation for complications of peripheral 
vascular disease. Part 2: Delphi and face to 
face consensus meeting 
4.1 Introduction 
In this chapter I describe a Delphi consensus survey and present the results of a face-to-
face meeting where consensus was established on the final core outcome sets. 
My objective was to establish consensus on the most important outcomes for studies 
focussed on short-term or medium-term outcomes through a three-round Delphi process, 
followed by a consensus meeting to ratify the results of the Delphi survey and address 
any perceived deficiencies in the outcomes rated as core by this process.   
4.2 Methods 
4.2.1 Delphi survey 
Following synthesis of results from the systematic review and qualitative focus groups, 
stakeholders (patients, carers and health and social care workers) were surveyed to 
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determine which outcomes should comprise the core outcome set for studies of lower limb 
amputation for Peripheral Arterial Disease.  All individuals who participated in focus groups 
were invited to take part in the survey, as were all patients recruited in the PLACEMENT 
trial who had agreed to be contacted for this purpose. Several amputee patients who the 
team came across during routine clinical practice were also invited.  Amputee patients were 
also encouraged to ask their carers to participate.  In addition, the survey was advertised 
via multiple national and international groups including the Vascular Society of Great 
Britain and Ireland, the British Society for Endovascular Therapy, the European Society for 
Vascular Surgery Vascunet collaboration, the British Association of Chartered 
Physiotherapists in Amputee Rehabilitation, the Douglas Bader foundation and Blesma (the 
limbless veterans charity). 
  The survey was a three-round Delphi consensus process and used the DelphiManager 
software from Liverpool University. This was supplemented with paper surveys for several 
amputee patients who said that they would prefer to complete a paper survey. 
There is little consensus on how to conduct a Delphi process.  Firstly, I had to decide on the 
method by which outcomes are either rated or ranked.  As discussed in the COMET 
handbook,69 the Grading of Recommendations Assessment, Development and Evaluation 
(GRADE) working group recommend a 9-point Likert-like scale, with 1-3 categories, with 7-
9 labelled as “essential” (must be reported in all trials), 4-6 as “desirable”, and 1-3 as “not 
important”.  I chose this system as while some others have used alternative scales, such as 
a 5-point scale,80 this seems to be the most common approach, and is easily implemented 
with the DelphiManager software.  Stakeholders were also allowed to rate outcomes 
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‘unable to score’ if they felt that they did not have the experience or understanding to rate 
an outcome. 
There is no clear consensus on the way in which items are added or removed between 
rounds, or on the definition of ‘consensus’.  Diamond et al. performed a systematic review 
of Delphi processes, selecting a sample of 100 Delphi processes to examine the issue of 
defining consensus.81  Of these, 98 purported to be attempting to establish consensus, but 
consensus was only defined in 72 of these, of which only 43 defined it a priori.  The most 
common way of defining consensus was by the percentage of respondents agreeing, and 
the median threshold for agreement was 75%.  The second commonest was a measure of 
central tendency, such as the mean or median score.  I therefore decided to use ‘over 75% 
of respondents scoring 7-9’ as the definition of consensus that the outcome was ‘core’ in 
the final round of the survey. 
There is some debate about the appropriateness of dropping items between Delphi rounds.  
The COMET handbook presents both sides of the argument,69 suggesting that where items 
are dropped between rounds there is likely to be less survey attrition, but that this runs the 
risk of eliminating items which might have gained more support in later rounds due to 
between-round feedback.  In order to attempt to tread the middle ground here, I decided 
to use a less stringent criterion to remove items between rounds. This would hopefully 
therefore reduce survey fatigue by shortening subsequent survey rounds, while also 
reducing the risk of dropping important outcomes due to ill-considered responses in early 
rounds. 
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Outcomes not achieving a mean score of greater than 6 by the respondents in round 1 were 
therefore eliminated.  Respondents were also given the opportunity to propose outcomes 
that they felt were essential but had been excluded from the first round.  These proposed 
outcomes were reviewed by the study management group and any outcomes which were 
significantly different from outcomes already due to be ranked in round 2 were added to 
the list. 
In the second round, stakeholders were again asked to rate the putative outcomes as 
essential (7-9), desirable (4-6) or not important (1-3).  Stakeholders were given feedback at 
this stage in the form of a prompt highlighting the score they gave the outcome in the 
previous round, and histograms showing how other respondents had rated the outcomes.  
Two histograms were displayed, one showing how healthcare professionals had rated the 
outcome, and one showing how patients and carers had rated the outcome. 
Outcomes not achieving a mean score of at least 7 in the second round were eliminated (a 
more stringent requirement than that used in round 1, but less stringent than requiring 
over 75% of respondents rating the outcome 7-9).  The process then proceeded to a third 
round of voting. 
In the third round, stakeholders were again asked to rate the putative outcome measures 
as essential (7-9), desirable (4-6) or not important (1-3), and feedback on ratings from the 
previous round was given.  Outcomes voted ‘essential’ (7-9) by over 75% of the 
respondents in this final round were considered ‘core’. 
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At each stage, participants were asked to rate outcomes separately for short-term and 
medium-term studies.  This is because it was recognised that some outcomes may be 
considered more or less important depending upon the timing of the study.  For example, 
stakeholders might consider the rate of post-operative pneumonia very important for short 
term studies but less important for medium term studies, whereas the rate of prosthetic 
limb prescription might be considered very important for medium term studies but less 
important for short term studies. 
4.2.2 Face-to-face consensus meeting 
The ultimate goal of this research was to define core sets of short and medium-term 
outcomes for reporting by research studies on patients undergoing major lower limb 
amputation for peripheral vascular disease.  The results of the consensus survey were 
therefore discussed at a face-to-face meeting of key stakeholders and a nominal group 
technique applied to rank a list of short-term outcomes and a second list of medium-term 
outcomes which would represent the core outcome sets.  Stakeholders included 
members of the PLACEMENT Trial Management Group, along with individuals from 
professions or specialties not represented by the Group, who participated in the focus 
groups in phase II.   
I invited stakeholders from the following groups: 
1. Patients 
2. Carers 
3. Nursing 
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4. Surgery 
5. Anaesthetics/Pain Medicine 
6. Medicine (rehabilitation, diabetes, care of the elderly) 
7. Physiotherapy 
8. Occupational therapy 
9. Prosthetics 
10. Clinical psychology 
11. Trials management 
Participants from all professional stakeholder groups agreed to attend the meeting.  I 
invited eight amputee patients as previous experience had led me to believe that it would 
be difficult to get engagement from patients.  Five amputee patients and one carer 
agreed to attend. 
A Nominal Group technique was used rather than a straightforward vote to either accept 
or reject the results of the consensus survey because of the risk that by choosing 
somewhat arbitrary levels at which to eliminate outcomes during the Delphi process, it 
was possible to arrive at either a core outcome set with an enormous number of items, or 
a core outcome set with only a very small number of items.  The members of the face-to-
face meeting had the opportunity to present potential solutions to these problems, rather 
than simply voting to reject the result of the Delphi if they felt that there were problems.  
These could then be discussed and voted on by the panel members.  For consistency with 
the Delphi survey, 75% of voting members were required to agree on a modification of 
the Delphi results for that modification to be adopted in the final core sets. 
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4.3 Results 
4.3.1 Delphi survey 
The Delphi Survey commenced in August 2018 and round 3 was completed in December 
2018. 
4.3.1.1 Round 1 
One hundred and forty people participated in round 1, and 123 completed the round.  In 
addition to rating the existing 100 outcomes, there were 67 new outcomes suggested in 
round 1. Some of these were very similar to each other, so were amalgamated these into 
single outcomes. Some were very similar to existing outcomes, so I (in collaboration with 
the PLACEMENT trial management group) felt that adding these would add to the work of 
completing the survey while adding little to the resulting set - at this stage of the project I 
was trying to establish a list of broad concepts which should be measured rather than the 
best way to measure these concepts. After looking through all of these and considering 
each of them carefully, 20 new items were added to the list of outcomes. 
There were 30 outcomes which were given low scores and so were removed from the 
survey, so 90 outcomes were carried forward to round 2.  In this round, outcomes rated 
less than 6 on average were excluded, unless one of the two stakeholder groups (either 
healthcare professionals or patients/carers) gave the outcome an average rating of at 
least 8.  Short-term and medium-term outcomes carried forward to Round 2 are shown in 
Table 4.1 and Table 4.2 respectively. 
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 Mean score 
Percentage 
rated 
Outcome HCP P/C Overall 1-3 7-9 
Death within a specified period of time after 
operation; or survival time after the operation 
8.04 9.10 8.13 1.56 85.94 
Cause of death 7.53 9.00 7.64 4.69 78.91 
Bleeding or need for blood transfusion after 
surgery 
5.51 8.40 5.73 14.06 32.03 
Heart related problems during surgery or follow-
up 
6.69 8.30 6.82 3.91 62.50 
Problems related to control of diabetes during 
surgery or follow-up 
6.22 9.00 6.44 7.81 53.91 
Pain in residual limb/amputation stump 7.19 7.70 7.23 0.78 71.88 
Falls 6.80 7.40 6.84 6.25 61.72 
Nutritional status 6.11 6.80 6.17 7.94 43.65 
Joint contractures 6.62 7.40 6.68 10.32 64.29 
Effectiveness of pain relief 7.10 7.60 7.14 2.38 73.02 
Phantom sensations or pain 6.81 7.50 6.87 3.97 65.08 
Stroke 6.57 8.10 6.69 7.14 57.14 
Problems with kidneys 5.78 8.10 5.97 13.49 45.24 
Anxiety or depression 6.74 7.90 6.83 3.97 65.87 
Pneumonia 6.72 8.30 6.84 6.35 65.87 
Breathing problems 6.22 8.40 6.39 8.73 52.38 
Problems with amputation stump healing 8.15 8.50 8.18 0.00 94.40 
Stump wound infection 8.10 8.90 8.17 0.00 94.40 
Blood clots in deep veins or lungs (venous 
thromboembolism) 
7.26 8.80 7.38 0.80 72.80 
Patients supplied with a temporary or definitive 
prosthetic limb 
6.60 8.10 6.72 11.20 57.60 
Prosthetic limb use; comfort and fitting 6.30 8.10 6.45 12.00 52.80 
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Level of independent mobility or function 
achieved 
6.83 7.30 6.87 5.60 63.20 
Development of problems with the other leg 7.04 8.50 7.16 4.80 68.80 
Impact on family/loved ones 6.43 7.20 6.50 5.60 54.40 
Independent living 6.23 7.20 6.31 8.13 44.72 
Coping strategies and psychological adaptation 6.58 6.70 6.59 5.69 53.66 
Cognitive function or confusion 6.57 7.10 6.61 4.88 56.10 
Quality of life 6.85 8.10 6.95 3.25 60.98 
Satisfaction with health status 6.47 7.70 6.57 4.07 47.97 
Effective communication between healthcare 
team and patient/carers 
7.07 8.10 7.15 6.50 69.92 
Shared decision-making 6.93 8.20 7.03 8.13 65.85 
Compliance with guidelines for care 6.80 8.10 6.90 7.32 63.41 
Residential status 6.18 8.20 6.34 9.76 47.97 
Cost of treatment 6.37 8.50 6.54 8.13 48.78 
Time in operating suite 5.44 8.30 5.67 17.89 36.59 
Length of time in hospital 6.66 7.00 6.69 4.88 54.47 
Need for re-admission to hospital after discharge 7.21 8.00 7.28 3.25 73.17 
Need for additional operations 7.44 8.20 7.50 3.25 80.49 
Side effects of medication 5.75 8.00 5.93 17.89 43.90 
Overall perioperative complications 7.73 8.80 7.81 2.44 84.55 
Table 4.1. Short-term outcomes carried forward from round 1 to round 2 of the Delphi survey.  
HCP: Healthcare professionals; P/C: patients or carers. 
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 Mean score 
Percentage 
rated 
Outcome HCP P/C Overall 1-3 7-9 
Death within a specified period of time after 
operation; or survival time after the operation: 
1-2 years after surgery 
7.36 6.70 7.31 4.69 70.31 
Cause of death: 1-2 years after surgery 6.66 7.30 6.71 7.03 57.03 
Pain in residual limb/amputation stump: 1-2 
years after surgery 
7.37 6.70 7.32 1.56 74.22 
Joint contractures: 1-2 years after surgery 6.47 6.10 6.44 7.94 57.14 
Phantom sensations or pain: 1-2 years after 
surgery 
7.04 6.50 7.00 2.38 65.87 
Anxiety or depression: 1-2 years after surgery 6.79 6.40 6.76 3.97 61.90 
Problems with amputation stump healing: 1-2 
years after surgery 
7.39 7.80 7.42 4.00 77.60 
Stump wound infection: 1-2 years after surgery 7.03 7.80 7.10 5.60 72.80 
Blood clots in deep veins or lungs (venous 
thromboembolism): 1-2 years after surgery 
5.63 8.20 5.83 15.20 44.80 
Patients supplied with a temporary or definitive 
prosthetic limb: 1-2 years after surgery 
7.67 8.30 7.72 1.60 80.80 
Prosthetic limb use; comfort and fitting: 1-2 
years after surgery 
7.70 8.80 7.78 0.80 85.60 
Level of independent mobility or function 
achieved: 1-2 years after surgery 
7.95 7.70 7.93 0.00 86.40 
Development of problems with the other leg: 1-2 
years after surgery 
7.20 7.60 7.23 4.80 68.80 
Participation in work and social activities: 1-2 
years after surgery 
7.35 7.30 7.34 1.60 77.60 
Impact on family/loved ones: 1-2 years after 
surgery 
6.72 6.20 6.68 7.20 59.20 
  
111 
Independent living: 1-2 years after surgery 7.68 6.90 7.62 1.63 80.49 
Coping strategies and psychological adaptation: 
1-2 years after surgery 
7.04 6.80 7.02 4.07 65.04 
Cognitive function or confusion: 1-2 years after 
surgery 
6.19 6.60 6.22 8.13 48.78 
Quality of life: 1-2 years after surgery 7.95 7.40 7.90 0.00 90.24 
Satisfaction with health status: 1-2 years after 
surgery 
7.18 6.80 7.15 4.07 69.92 
Effective communication between healthcare 
team and patient/carers: 1-2 years after surgery 
6.21 7.60 6.33 12.20 52.03 
Shared decision-making: 1-2 years after surgery 6.16 7.10 6.24 16.26 52.03 
Compliance with guidelines for care: 1-2 years 
after surgery 
6.41 7.30 6.48 10.57 55.28 
Residential status: 1-2 years after surgery 7.04 7.60 7.09 5.69 60.98 
Cost of treatment: 1-2 years after surgery 6.53 8.30 6.67 7.32 52.03 
Time taken to complete rehabilitation: 1-2 years 
after surgery 
6.46 7.60 6.55 9.76 57.72 
Need for re-admission to hospital after 
discharge: 1-2 years after surgery 
6.10 7.00 6.17 13.82 51.22 
Need for additional operations: 1-2 years after 
surgery 
6.91 7.80 6.98 4.88 67.48 
Side effects of medication: 1-2 years after 
surgery 
5.52 8.10 5.73 18.70 35.77 
Overall perioperative complications: 1-2 years 
after surgery 
6.50 7.90 6.61 12.20 58.54 
Table 4.2. Medium-term outcomes carried forward from round 1 to round 2 of the Delphi survey.  
HCP: Healthcare professionals; P/C: patients or carers. 
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4.3.1.2 Round 2 
Ninety-nine of the 123 people participating in round 1 also participated in round 2.  Of the 
90 outcomes rated in round 2, there were 63 outcomes which were given low scores and 
so were removed from the survey, leaving 27 outcomes to rate in round 3.  None of the 
outcomes added to the survey after they were suggested in feedback from round 1 of the 
survey met this threshold, so all of these additional outcomes were removed at this stage.  
Fourteen of the highly-rated outcomes were for studies focused on short-term outcomes 
(up to approximately 30 days after surgery – Table 4.3) and 13 were for studies focused 
on medium-term outcomes (up to 2 years after surgery – Table 4.4). 
Outcome 
Mean 
score 
Rated 1-3 
(%) 
Rated 7-9 
(%) 
Death within a specified period of time after 
operation; or survival time after the operation 
8.354 0.00 92.71 
Cause of death 8.032 1.05 88.42 
Pain in residual limb/amputation stump 7.215 0.00 74.19 
Effectiveness of pain relief 7.290 2.15 76.34 
Problems with amputation stump healing 8.333 0.00 95.70 
Stump wound infection 8.312 0.00 93.55 
Blood clots in deep veins or lungs (venous 
thromboembolism) 
7.281 0.00 73.03 
Development of problems with the other leg 7.304 4.35 72.83 
Quality of life 7.044 3.30 65.93 
Effective communication between healthcare 
team and patient/carers 
7.143 6.59 70.32 
Shared decision-making 7.044 6.67 67.78 
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Need for re-admission to hospital after 
discharge 
7.389 2.22 80.00 
Need for additional operations 7.478 2.22 81.11 
Overall perioperative complications 7.955 2.25 88.76 
Table 4.3. Short-term outcomes carried forward from round 2 to round 3 of the Delphi survey. 
 
Outcome 
Mean 
score 
Rated 1-3 
(%) 
Rated 7-9 
(%) 
Death within a specified period of time after 
operation; or survival time after the operation 
7.417 2.08 72.92 
Pain in residual limb/amputation stump 7.473 2.15 77.42 
Problems with amputation stump healing 7.710 1.08 78.49 
Stump wound infection 7.108 4.30 76.34 
Patients supplied with a temporary or definitive 
prosthetic limb 
8.011 1.09 85.87 
Prosthetic limb use; comfort and fitting 8.109 0.00 89.13 
Level of independent mobility or function 
achieved 
8.185 0.00 89.13 
Development of problems with the other leg 7.478 2.17 75.00 
Participation in work and social activities 7.283 1.09 77.17 
Independent living 7.846 1.10 84.62 
Quality of life 8.066 1.10 92.31 
Satisfaction with health status 7.099 4.40 71.43 
Residential status 7.100 3.33 64.44 
Table 4.4. Medium-term outcomes carried forward from round 2 to round 3 of the Delphi survey. 
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4.3.1.3 Round 3 
Ninety-one of the 99 people participating in round 2 also completed round 3.  Of the 27 
outcomes rated in round 3, 18 received high enough support to be considered ‘core’ 
according to the rules laid out in the project protocol.72  Seven of the participants were 
patients or carers and the remainder were from healthcare professionals, representing 
the fields of occupational therapy, physiotherapy, prosthetics, nursing, vascular surgery, 
diabetology, and clinical psychology.  Table 4.5 lists the nine short-term outcomes 
receiving a high level of support, together with their average scores, the percentage of 
respondents rating the outcome 1-3 and the percentage of respondents rating the 
outcome 7-9.  Table 4.6 lists the same information for the nine medium-term outcomes 
receiving a high level of support.  Table 4.7 lists the same information for the nine 
outcomes rated in round 3 which did not receive high levels of support.  Figure 4.1 shows 
the distribution of ratings for the short-term outcomes rated as ‘core’.  Figure 4.2 shows 
the distribution of ratings for the medium-term outcomes rated as ‘core’.  Figure 4.3 
shows the distribution of ratings for the outcomes not rated as ‘core’ in the final round of 
the Delphi survey. 
 
 
 
 
  
115 
Outcome 
Mean 
score 
Rated 1-3 
(%) 
Rated 7-9 
(%) 
Problems with amputation stump healing  8.647 0 97.8 
Stump wound infection 8.604 0 96.7 
Death within a specified period of time after 
operation; or survival time after the operation 
8.549 0 95.6 
Cause of death 8.330 1.10 90.1 
Effectiveness of pain relief 7.253 2.20 76.9 
Effective communication between healthcare 
team and patient/carers 
7.253 6.59 75.8 
Need for re-admission to hospital after 
discharge 
7.578 1.11 83.3 
Need for additional operations 7.611 1.11 85.6 
Overall perioperative complications 8.202 2.25 92.1 
Table 4.5. Short-term outcomes rated as ‘core’ by the Delphi survey. 
  
Outcome 
Mean 
score 
Rated 1-3 
(%) 
Rated 7-9 
(%) 
Problems with amputation stump healing 7.917 1.10 78.5 
Stump wound infection 7.710 1.08 78.5 
Pain in residual limb/amputation 
stump/phantom 
7.407 1.10 77.4 
Patients supplied with a temporary or 
definitive prosthetic limb 
8.122 0.00 85.9 
Prosthetic limb use, comfort and fitting 8.178 0.00 89.1 
Level of independent mobility or function 
achieved 
8.264 0.00 89.1 
Participation in work and social activities 7.253 1.10 77.2 
Independent living 7.857 1.10 84.6 
Quality of life 8.267 1.11 92.3 
Table 4.6. Medium-term outcomes rated as ‘core’ by the Delphi survey. 
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Figure 4.1: Ratings of the 9 short-term outcomes receiving a high level of support from the Delphi survey. 
  
  
117 
   
   
   
Figure 4.2: Ratings of the 9 medium-term outcomes receiving a high level of support from the Delphi survey. 
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Figure 4.3: Ratings of the 9 outcomes not receiving a high level of support from the Delphi survey.
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Outcome 
Mean 
score 
Rated 1-3 
(%) 
Rated 7-9 
(%) 
Death within a specified period of time after 
operation; or survival time after the operation: 
1-2 years after surgery 
7.374 1.10 72.5 
Pain in residual limb/amputation stump: within 
1 month 
7.176 4.40 71.4 
Stump wound infection: 1-2 years after surgery 6.780 5.49 71.4 
Development of problems with the other leg: 
within 1 month 
7.275 5.49 72.8 
Development of problems with the other leg: 
1-2 years after surgery 
7.517 3.30 75.0 
Quality of life: within 1 month 6.890 3.30 59.3 
Satisfaction with health status: 1-2 years after 
surgery 
6.889 5.56 68.9 
Shared decision-making: within 1 month 6.945 8.79 67.0 
Residential status: 1-2 years after surgery 7.111 3.33 64.4 
Table 4.7. Outcomes rated in the third round which were not rated as ‘core’ by the Delphi survey. 
  
4.3.2 Face-to-face consensus meeting 
The final part of the core outcome sets development project was a face-to-face meeting 
to discuss the results of the Delphi survey and ratify the findings.  This included discussion 
of all the outcomes rated in the final round of the survey and voting on inclusion or 
exclusion of these outcomes from the final published set.  The meeting took place on 
Friday 12th April 2019 in College House, Cardiff. 
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Unfortunately, two days prior to the event, two of the amputee patients withdrew for 
personal reasons.  On the day, the diabetologist, the rehabilitation physician and the 
specialist nurse who had all agreed to come did not attend the meeting.  In addition, two 
of the amputee patients who had said that they would come when contacted the 
previous day did not attend.  The final consensus group was comprised of two vascular 
surgeons, one vascular surgical trainee (myself), one anaesthetist, one physiotherapist, 
one occupational therapist, one clinical psychologist, one prosthetist, one clinical trials 
manager, one amputee patient and one person who had been a carer for an amputee 
patient. 
4.3.2.1 Short-term outcomes 
The meeting was divided into two halves.  In the first half, we discussed short-term 
outcomes.  I began by presenting the results of the Delphi survey.  We then moved to the 
discussion phase, with each member in turn being given the opportunity to raise concerns 
or outcomes of interest.  After each member had spoken, the group then spent time 
discussing the points raised, and once everyone was happy that these points had been 
adequately discussed, we moved on to the next member of the group to give them their 
opportunity to raise any concerns or outcomes of interest, which were then discussed in 
turn.  There was some initial discussion about terminology, with the prosthetist 
suggesting that the term ‘residual limb’ was preferred to the term ‘stump’.  There was 
strong disagreement from the amputee patient about this, who said that this was 
‘political correctness’ and that he preferred the term ‘stump’.  The carer raised the point 
that she was confused when people said ‘residual limb’ as she wondered whether the 
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term referred to the non-amputated limb.  The group therefore decided to keep the 
nomenclature used in the Delphi survey. 
The clinical psychologist said that he was disappointed that there was no measure of 
psychological morbidity such as depression or anxiety in the final set of outcomes.  I 
pointed out that it had been in the original set of outcomes rated, but that it had not 
received sufficient support.  There was, however, broad support from participants at the 
meeting that psychological morbidity was very important in amputee patients.  It was 
suggested that there may have been too few clinical psychologists completing the Delphi 
survey to give adequate weight to this outcome. 
Both the physiotherapist and the prosthetist suggested that the omission of contralateral 
limb deterioration (as it had not quite achieved sufficient support from the survey to be 
included in the final list of outcomes) should be reconsidered.  There was concern that 
omission of this outcome might have been due to the slightly arbitrary decision about the 
cut-off score to use in the final round. 
The carer made the suggestion that length of stay was important as getting home quickly 
was important to patients and extra nights in hospital were expensive for the health 
service.  Others contributed that it was a very easy thing to measure and given this 
perhaps it should be considered a core outcome despite not receiving sufficient support 
from the Delphi survey. 
Finally, the anaesthetist raised the concern that he was not sure how best to measure 
‘Effective communication between healthcare team and patient/carers’ and he did not 
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think this belonged in an outcome set.  There was a lot of disagreement with this 
viewpoint as it was viewed as very important by many people in the room. 
We then proceeded to the voting phase.  Nine participants voted to add a measure of 
psychological morbidity to the outcome set, with one against.  Eight participants voted to 
add deterioration of the other leg to the outcome set, with two against.  Six participants 
voted to add length of stay to the outcome set, with five against.  Two people voted to 
remove ‘Effective communication between healthcare team and patient/carers’ from the 
core outcome set, with nine disagreeing with this suggestion. 
4.3.2.2 Medium-term outcome 
I again began by presenting the list of outcomes which reached the threshold for 
acceptance in the third round of the Delphi survey and those which did not (Tables 4.3 
and 4.4).  The prosthetist raised the point that stump healing and infection are similar 
issues, and that both affect prosthetic outcome, agreeing that these were very important 
for medium-term outcomes.  There was then some discussion about whether these 
outcomes should be combined into a single outcome.  The vascular surgeons commented 
that while infection was one reason for poor healing, a more common reason was poor 
blood supply.  There was subsequent recognition that because of this, they should be 
kept separate in the list of outcomes.  There was some surprise expressed that mortality 
had not reached the threshold for inclusion.  There was quite a lot of support for adding 
this to the list brought forward from the Delphi, so it was decided to vote on this at the 
end of the discussion.  The concern about omission of problems with the contralateral 
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limb was again raised by the physiotherapist, who suggested that this should again be 
added to the list of outcomes from the Delphi.  It was again decided that this should be 
voted on at the end of the discussion.  The anaesthetist suggested that he was surprised 
that no mention was made of phantom pain in the list of outcomes in Round 3.  I 
explained that phantom pain had been a separate item in the Delphi but had not received 
enough support in Round 2 to make it into the Round 3 voting.  It was suggested that 
perhaps it would have been better to have a single ‘pain’ outcome which included all 
types of painful sensations, and that this could be done by changing the outcome ‘Pain in 
residual limb/amputation stump’ to ‘Pain in residual limb/amputation stump/phantom’.  
This was supported by several people, so again it was decided that this should be voted 
on at the end of the discussion. 
The psychologist again expressed concern that no real measure of psychological 
morbidity was included in the final set, again suggesting that this was because of the 
small number of psychologists completing the survey.  It was commented that 
psychological morbidity is covered to some extent in quality of life measures.    It was 
recognised that this was true, but several expressed the feeling that it was important in 
its own right, so again it was decided that this should be voted on at the end of the 
discussion. 
The carer asked whether the patient returning to their own home or going to a 
nursing/residential home might be important.  I mentioned that this was one of the other 
outcomes in the Delphi but that it had not been given enough support to come through 
as ‘core’. 
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Finally, I asked if anyone thought any of the items highlighted by the Delphi were not 
important and should be removed due to poor support by either professionals or 
patients/carers.  One person suggested that perhaps quality of life should be removed, as 
it received less support from the panel of patients and carers.  Others disagreed, saying in 
their view it was helpful for health economic analysis and is a good thing to incorporate 
into patient reported outcome measures, being a measure of overall success of the whole 
operation, clinical care and rehabilitation package. 
We then proceeded to the voting phase.  Seven participants voted to add mortality to the 
outcome set, with three against, so this was not added, as it failed to meet the 
requirement of 75% of voting members agreeing the change.  Nine participants voted to 
add deterioration of the other leg to the outcome set, with one against.  Eight 
participants voted to add a measure of psychological morbidity to the outcome set, with 
two against.  None of the participants voted to add residential status to the outcome set.  
Finally, all 11 participants voted to change the outcome ‘Pain in residual limb/amputation 
stump’ to ‘Pain in residual limb/amputation stump/phantom’. 
4.3.3 Final core outcome sets 
Adopting the same selection threshold as used in the third round of the Delphi (over 75% 
of participants rating the outcome as critical), the final core outcome set for studies 
focussed on short-term outcomes is as follows: 
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1. Death within a specified period of time after operation; or survival time after the 
operation 
2. Cause of death 
3. Problems with amputation stump healing  
4. Stump wound infection 
5. Development of problems with the other leg 
6. Effectiveness of pain relief 
7. Psychological morbidity 
8. Effective communication between healthcare team and patient/carers 
9. Need for re-admission to hospital after discharge 
10. Need for additional operations 
11. Overall perioperative complications 
I have organised and illustrated these in Figure 4.4.   
Figure 4.4: Short-term core outcome set for patients undergoing major lower limb amputation 
for complications of peripheral vascular disease. 
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For studies focussed on medium-term outcomes, the core outcome set contains the 
items: 
1. Problems with amputation stump healing 
2. Stump wound infection 
3. Development of problems with the other leg 
4. Pain in residual limb/amputation stump/phantom 
5. Psychological morbidity 
6. Quality of life 
7. Patients supplied with a temporary or definitive prosthetic limb 
8. Prosthetic limb use, comfort and fitting 
9. Level of independent mobility or function achieved 
10. Participation in work and social activities 
11. Independent living 
I have organised and illustrated these in Figure 4.5. 
Figure 4.5: Medium-term core outcome set for patients undergoing major lower limb 
amputation for complications of peripheral vascular disease. 
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4.4 Discussion 
I have developed core outcome sets for studies recruiting patients undergoing major 
lower limb amputation for complications of peripheral vascular disease with both short-
term and medium-term focus.  Four outcomes are shared between both short-term and 
medium-term sets, while the remaining seven outcomes in each set were felt to be ‘core’ 
for only one time period.  To my knowledge, this is the first time that core outcome sets 
for studies of patients with the same condition but for different durations have been 
developed.   
Broad ranges of outcomes are present in both short- and medium-term sets, including 
local stump-related problems (healing, infection, pain); further health and healthcare 
(readmissions, re-operations, complications, problems with the other leg); psychosocial 
problems (psychological morbidity, work/social re-integration, communication); mobility, 
independence and quality of life all featuring.  There are objective ‘hard’ outcomes such 
as mortality, which are easily captured in routinely collected data, but there are also 
multiple outcomes which require patient reported outcome measurement (PROM) 
instruments.  To our knowledge there are no PROM tools that holistically capture 
mobility, pain, anxiety and depression, etc. in amputee patients. 
No other work has defined core outcome sets for patients undergoing lower limb 
amputation, though there has been some work using the International Classification of 
Functioning, Disability and Health to classify factors influencing mobility in established 
amputee patients.  While not a true core outcome set, this work did like our work find 
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that problems of pain, mobility, functional independence and participation in work and 
social activities were important for these patients.39 
There are other examples where during the development of core outcome sets it was 
discovered that outcomes which are viewed as important by patients or their informal 
carers had not been given consideration in the scientific press, as research is dominated 
by clinical practitioners, highlighting the importance of this step.74  Conversely, it is 
possible that healthcare professionals will identify outcomes which patients are hesitant 
to discuss and which, because of perceived difficulties in recruitment for such studies, are 
also not well represented in the literature.75 
A strength of this work is that I had input from patient and carer representatives 
throughout the work. A patient and a carer on the study team reviewed all patient-facing 
material including information leaflets and the wording of the Delphi survey to ensure 
that wording was in plain English.  I also used focus groups of patients, carers and 
healthcare professionals to ensure that outcomes important to individuals who would be 
unlikely to contribute to the research literature were also considered.  This was clearly 
important, as I added five outcomes from the focus groups, two of which made it to the 
final consensus survey round , and one (effective communication between healthcare 
team and patient/carers) is part of the final core outcome sets, described by one of the 
patients as the most important outcome in the short-term set.   
A weakness of the study is that we did not manage to get as many patients and carers to 
participate in the consensus survey or face-to-face meeting as we intended.  This was not 
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for a lack of trying: I personally invited over 40 amputee patients to participate in the 
survey, advertised the survey through two amputee charities and encouraged clinicians 
participating in the survey to advertise it to their patients.  I also contacted all participants 
from the previous round of the survey, encouraging them to complete subsequent rounds 
and extending the completion deadline if necessary, in order to receive as many 
responses as possible.  Having had six patient/carer participants who had agreed to come 
to the consensus meeting I was disappointed that only two attended despite contacting 
scheduled participants in the few days before the meeting to remind them and arrange 
transportation. 
The development of core outcome sets represents an important step forward in 
improving the efficiency of further research.  Results of the systematic review highlighted 
the inefficiency of previous research in this area, with 444 different outcomes reported in 
the 440 included studies.  Having established consensus on the most important outcomes 
for these patients, future research can be more focused, and meta-analysis will be more 
feasible.  This is discussed further in Chapter 5. 
Core outcome sets also have the potential to improve the quality of observational 
research in the form of registry studies. If national registries adopt the outcome sets then 
results from different registries may be pooled, improving the power of such analyses.  
Standardisation will also be possible, allowing appropriate correction at scale for 
confounding factors to be performed in a uniform way across multiple registries.  Work 
has already begun in this direction in vascular surgery, though not for patients undergoing 
amputation.82 
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I have developed core outcome sets for short- and medium-term studies recruiting 
patients undergoing major lower limb amputation. Further work is required to explore 
how best to measure these outcomes, and to develop and validate patient-reported 
outcome measurement tools which capture outcomes such as pain, communication, 
mobility, psychological morbidity and quality of life. 
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5 Discussion 
 
The aim of this thesis was to develop tools which could direct future research and quality 
improvement towards key interventions and outcomes for patients undergoing MLLA for 
complications of peripheral vascular disease.  In this chapter I will outline the main results 
of this work and highlight the ways in which I have achieved this aim.  No research is 
performed in isolation, so I will also discuss the results in the context of other work in the 
area.  There are limitations to the work I have done, and I will discuss these before 
moving on to talk about further research which is needed and draw conclusions about the 
body of work as a whole. 
5.1 Summary of findings 
5.1.1 Predictors of peri-operative risk 
I used data from the National Vascular Registry (NVR) to examine risk-factors for peri-
operative complications following major lower limb amputation.  Data were applied for 
through the UK Healthcare Quality Improvement Partnership and the Audit and Quality 
Improvement Committee of the Vascular Society of Great Britain and Ireland, and ethical 
approval was granted by Wales Research Ethics Committee 3.  The study was registered 
prospectively on the Australia and New Zealand Clinical Trials Registry.  The primary 
outcome was in-hospital mortality and secondary outcomes included length of stay and 
other standard peri-operative complications such as renal failure and return to theatre.  
Multiple imputation methodology was used to handle missing data for variables with 
missing data rates less than 50%. Variables with missing data rates greater than 50% were 
excluded from the analysis.  I performed both univariate and multivariate logistic 
regression to look for predictors of the primary outcome.  For the secondary outcomes I 
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performed only multivariate analysis in order to look for significant independent 
predictors once measured confounders had been taken into account. 
Multivariate analysis revealed that bilateral operation; emergency admission; increased 
age, creatinine, white blood cell count or American Society of Anesthesiologists (ASA) 
grade; and ECG abnormalities were all associated with an increased risk of in-hospital 
mortality.  Protective factors included trans-tibial amputation, previous procedures on 
the amputated limb and increased patient weight or serum albumin.  In addition to these 
factors, univariate analysis also suggested that male sex; a history of ischaemic heart 
disease, congestive heart failure, chronic lung disease or stroke; current smoking; and 
statin, beta-blocker or ACE-inhibitor/angiotensin-receptor-blocker therapy were also 
significant predictors of higher in-hospital mortality when considered in isolation.  A 
sensitivity analysis using complete case analysis revealed no unexpected differences with 
the analysis using the multiply imputed datasets, providing confidence that the multiple 
imputation procedure had not introduced unexpected bias. 
A range of different variables was predictive of the different secondary outcomes (Table 
2.6 on page 39).  Emergency admission, trans-tibial amputation, low serum albumin and 
high ASA grade were all predictive of more than half of the adverse secondary outcomes.  
Chronic heart, kidney and lung disease were also predictive of cardiac, renal and 
respiratory complications respectively. 
5.1.2 A prognostic model of risk 
The parameters which were found to be independently associated with increased risk of 
in-hospital mortality were included in a logistic regression model, allowing quantification 
of the probability of a given patient not surviving until discharge.  These parameters were 
selected by stepwise minimisation of the Schwarz-Bayes criterion in order to develop a 
parsimonious model, reducing the risk of overfitting.  Model discrimination was assessed 
using ROC curve analysis, and this was compared to the discrimination of other available 
models.  Calibration of the model was assessed using the Hosmer-Lemeshow goodness of 
fit test.  The discriminative power of the model for predicting the secondary outcomes 
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was also assessed by calculating the C-statistic (the area under the ROC curve) and 
comparing this to the C-statistic of models designed specifically to predict each secondary 
outcome. 
The C-statistic for the model developed was 0.79 (95% C.I. 0.77-0.80), suggesting good, 
bordering on excellent discrimination.  The Hosmer-Lemeshow goodness-of-fit test found 
no evidence of mis-calibration (P=0.348).  This test found significant evidence of mis-
calibration for all the other models I found in the literature (page 33).  The C-statistic for 
each of these models was also significantly lower than the C-statistic for the model I 
developed, suggesting that the discrimination of these models was inferior to the model I 
developed.  The model was also a good discriminator of cardiac, respiratory and renal 
complications, though it was not a good discriminator of the other secondary outcomes. 
5.1.3 Core outcome sets – development of the ‘long list’ of outcomes 
I performed a systematic review, searching the MEDLINE and EMBASE databases for 
studies involving patients undergoing major lower limb amputation for complications of 
peripheral vascular disease.  The review compiled a list of all of the outcomes which were 
reported in these studies.  In order to capture as broad a range of outcomes as possible, I 
included both studies reporting high-level evidence, such as randomised controlled trials, 
and low-level evidence such as case reports.  I then grouped the outcomes using the 38 
domain classification system defined by Dodd et al.68 
The search identified 4288 references.  After screening, this was reduced to 360 studies.  
A further 153 potentially relevant studies were identified through screening reference 
lists, and after screening, 80 of these satisfied the inclusion criteria giving a total of 440 
included studies, from 42 different countries.  These studies reported a total of 1447 
outcomes, of which 444 were discrete (different from one another).  The most frequently 
reported outcomes were ‘mortality’ and ‘wound healing’ (each reported in 93 studies).  
After grouping together similar outcome measures such as ’30-day mortality’ and ‘in-
hospital mortality’, both of which measure the outcome ‘mortality’ and removing 
outcomes which were not relevant I was left with 45 distinct outcomes. 
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In addition, I organised four focus groups, which were led by a senior qualitative 
researcher, to explore outcomes which healthcare professionals, patients and carers felt 
were important to patients undergoing major lower limb amputation, or who had 
recently undergone major lower limb amputation.  One focus group was composed of 
patients and carers, one contained medically trained professions as well as a clinical 
psychologist, one contained allied healthcare professionals and one additional group 
contained two physiotherapists, as none of the invited physiotherapists had been able to 
attend any of the other groups and I felt that this was an important group to include.  A 
flexible semi-structured topic guide was used, and the groups started with open 
discussion, with the results of the systematic review revealed later in order to prompt 
further discussion around topics which might not have already been raised.  Thematic 
analysis was then performed by the qualitative reviewer to develop an analytical 
framework using an inductive approach.  The framework was discussed with me to 
ensure that it adequately captured the focus groups. The qualitative reviewer then coded 
all of the focus group transcripts, and I re-coded one of the groups to ensure 
consistency/reproducibility.  I then identified themes which were both similar and not 
similar to the outcomes from the systematic review.  The qualitative reviewer then went 
through what I had coded to ensure that she agreed with my assessments, to ensure that 
I had not misunderstood what she was attempting to express in the analytical framework. 
A broad range of healthcare professionals attended the focus groups, as well as three 
amputee patients and three people who cared for amputee patients.  The analytical 
framework divided the results of the focus groups into 19 themes, ranging from quality of 
life and social functioning to communication, readmissions and mortality.  Some of these 
were recognised as similar to outcomes found in the systematic review, while some, 
particularly those around communication, were quite different.  After mapping the 
analytical framework onto outcomes, I was left with five additional outcomes which were 
not covered by the results of the systematic review. 
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5.1.4 Core outcome sets – coming to consensus 
The 50 outcomes derived from the systematic review and focus groups were taken 
forward to a three-round Delphi consensus process, where participants were asked to 
rate each of the outcomes on a 9-point Likert-like scale.  In the first round, participants 
were also able to propose additional outcomes which they felt were missing from the list 
of rated outcomes.  As I was attempting to develop two core outcome sets – one for 
studies with short-term primary outcomes and one for studies with medium-term 
primary outcomes – participants were asked to rate each of the outcomes twice.  Short-
term was defined as ‘within 30 days or while in hospital’, while medium term was defined 
as up to two years following amputation. In the second and third rounds participants 
were given feedback on how others had rated an outcome in the previous round and 
reminded how they had rated that outcome in the previous round.  After the first round, 
outcomes with a mean rating of less than 6 were removed.  After the second round, 
outcomes with a mean rating of less than 7 were removed.  Outcomes rated 7-9 by over 
75% of participants in round three were taken forward to the consensus meeting for 
ratification as core outcomes. 
At the consensus meeting, the results of the third round of the Delphi survey were 
presented.  These were divided into short-term outcomes and medium-term outcomes.  
Participants were then asked to comment on what they thought of the proposed core set, 
and whether they thought that there were any outcomes which should also be 
considered core, despite not receiving sufficient support from the Delphi survey.  All 
participants were given the opportunity to speak.  Proposals for changes to the core set 
were then voted on, with a requirement that 75% of votes should be in favour of a 
change before the set of items proposed by the Delphi should be changed. 
There were 123 complete responses to round 1 of the Delphi survey.  Thirty outcomes 
received low scores so were removed from further rounds, and twenty additional 
outcomes were added in response to participants’ suggestions.  In round 2, 99 of the 
original 123 respondents completed the survey.  Following this, 63 outcomes received 
low scores so were removed from consideration, leaving 27 outcomes to rate in the final 
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round.  Ninety-one of the remaining 99 participants also completed round 3.  Nine short-
term and nine medium-term outcomes received sufficient support in the final round to be 
proposed as core at the consensus meeting.  These are shown in Table 4.5 and Table 4.6 
respectively on page 115. 
At the consensus meeting there were several proposals for changes to the core set, 
including adding development of problems with the other leg and a measure of 
psychological morbidity to both short- and medium-term sets, adding length of stay to 
the short-term set, removing ‘Effective communication between healthcare team and 
patient/carers’ from the short-term set, adding mortality  and residential status to the 
medium-term set. 
In the voting phase, both ‘development of problems with the other leg’ and 
‘psychological morbidity’ received over 75% support for both short- and medium-term 
sets so were added to the final core sets, which are given in full in Section 4.3.3. 
5.2 Context of other literature 
5.2.1 Predictors of peri-operative risk 
As mentioned in Chapter 2, there have been some previous studies which attempted to 
use multivariate statistical techniques to identify predictors of short-term mortality in 
patients undergoing major lower limb amputation.10,12,14  All of these, in common with my 
work, identified that patient age was a good predictor of mortality.  Beyond this common 
factor, however, results have been quite varied.  Studies from Scotland and Japan 
identified sex as an important factor.  This was predictive of outcome on univariate 
analysis in the NVR dataset, but not on multivariate analysis after taking other 
confounding influences into account.  Level of amputation (trans-tibial or trans-femoral) 
and emergency operation were found to be predictive of outcome in the study from 
Japan, in line with my work.14  
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Studies from the USA and Japan both identified dependent functional status as 
important.12,14  This is not a variable which was recorded in the NVR dataset so it was not 
possible for me to assess the significance of this factor in a UK dataset.  However it has 
been shown to be predictive of outcome following multiple other major vascular and 
general surgical operations, so it is likely that this is an important factor which is not 
presently recorded in the NVR.83  Both of these other studies also identified key co-
morbidities as being important predictors: cardiac disease in both studies; chronic renal 
disease and malignancy in the study from Japan;14 and dialysis and COPD in the study 
from the USA.12  In contrast, in my work while these were predictive of in-hospital 
mortality on univariate analysis, none of these were chosen as significant predictors in 
the multivariate model selection process.  This may be as a result of including the ASA 
grade as a predictor, as this will be highly correlated with comorbidity, since the 
definitions of grades 2-4 are ‘a patient with mild systemic disease’, ‘a patient with severe 
systemic disease’ and ‘a patient with severe systemic disease that is a constant threat to 
life’.84  In addition, pre-operative serum creatinine, included in my model, will be strongly 
correlated with a history of chronic renal disease/dialysis, again possibly removing the 
need for both to be included in the model. 
5.2.2 A prognostic model of risk 
The model I have developed has good apparent discrimination – and better than 
previously available models.12,15,16,46  This brings major lower limb amputation into line 
with other major vascular procedures such as abdominal aortic aneurysm repair, where 
rigorously developed risk calculators with good discrimination in UK datasets are already 
available.37,85  Previously available models were either developed using small UK 
samples,15,46 or using data from the USA – a quite different healthcare system.12,16  The 
models from the USA also suffer from the problem that they contain data items which are 
not routinely collected in healthcare data in the UK, making them difficult to apply in 
practice.12,16  I conclude that the model I have developed is therefore an important step 
forward in this field, as it is a valid tool for prognostication, can potentially be used for 
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discussion of options with patients and can be used for selecting patients who will have 
better outcomes with surgery. 
5.2.3 Core outcome sets – development of the ‘long list’ of outcomes 
I found 444 outcome measures in the systematic review from 440 studies, which I 
reduced to 45 outcomes for rating in a Delphi survey.  The number of outcome measures 
reported in studies which systematically record outcomes from previous studies as part of 
core outcome set generation is widely variable, from 83 in tooth decay in children,80 to 
370 in head and neck cancer,24 766 in colorectal cancer,86 and 901 in oesophageal cancer 
resection surgery.40  The number of outcomes which this is reduced to prior to 
consideration in a Delphi process is also highly variable: 24, 370, 7 and 68 in the studies 
referred to above.24,40,80,86  Interestingly, the vast majority of outcomes (281 of 444) were 
reported in single studies only, meaning that none of these outcomes would be amenable 
to any form of research synthesis such as meta-analysis.  This implies that that there is 
potentially a large amount of research waste in the existing literature as it is difficult to 
pool or compare results from different studies in any meaningful way. 
I supplemented the systematic review with focus groups, in order to reduce the likelihood 
that I would miss key outcomes simply because they had not been reported in previous 
research in my patient population.  In doing so I revealed five additional outcomes for 
consideration.  This phenomenon of discovering outcomes which have not been the topic 
of previous research is common to other core outcome set development projects and 
highlights the need for this mixed-methods approach to creating a list of possible 
outcomes to take to a consensus process.74,75 
5.2.4 Core outcome sets – coming to consensus 
The final core outcome sets contained 11 short-term and 11 medium-term items.  These 
sets are similar in size to other core outcome sets mentioned above , which had 5 
outcomes in tooth decay in children, 19 in head and neck cancer, 12 in colorectal cancer 
and 10 oesophageal cancer resection.24,40,41,80  One of the interesting things about the 
final list of core outcomes is that one of them (Effective communication between 
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healthcare team and patient/carers) came from the focus groups, having not been found 
in any previous literature on patients undergoing amputation.  This again highlights the 
benefits of the mixed-methods approach which we have taken. 
A further interesting feature of my core sets is that the consensus meeting added back in 
two of the outcomes which had not received enough support in the Delphi survey.  One 
of these – deterioration of the other leg – was on the borderline of being accepted by the 
Delphi survey, so the inclusion of this item is perhaps not controversial.  The other 
outcome – psychological morbidity (such as anxiety and depression) – is more 
controversial, as it was voted out after the second round of the Delphi so did not make it 
into the final round of voting.  The process of reaching consensus has been done in a 
number of ways in the literature.  Some studies do not have a consensus-meeting at all 
and simply publish the results of the Delphi survey as the core set.80  Some bypass the 
Delphi survey stage altogether and discuss all outcomes from outcome discovery at a 
consensus meeting.24  A systematic review of core outcome set development reports 
found that 9 of the 19 development processes held face-to-face consensus meetings and 
that each one used a slightly different method.87  The commonest general approach 
appears to be to have a discussion phase where every member is encouraged to 
contribute, followed by a voting phase where proposals raised during the discussion 
phase may be voted on, which is how I designed our consensus meeting. The COMET 
handbook recommends that both a consensus survey and a face-to-face meeting should 
be held, but does not proscribe the precise methodology to be used in either step.69 
5.3 Implications for practice 
5.3.1 Predictors of peri-operative risk 
I have identified 11 parameters which are independently associated with increased risk of 
in-hospital mortality, and a further 12 parameters which are associated with the 
secondary outcomes.  Some of these factors, such as age and co-morbidity, are not 
modifiable in any meaningful sense.  Some, such as white blood cell count and creatinine 
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may be modifiable in the peri-operative period through a short period of pre-operative 
optimisation, though it is possible that these factors are simply reflective of the advanced 
clinical state of the patient.  If so, they would only be modifiable by treating the patient 
much earlier in the disease process.  Likewise, modification of other factors such as 
whether the patient is admitted as an emergency, are also only possible through changing 
the patient population presenting for amputation.  This is clearly a significant challenge 
and may require significant changes to the way patients with peripheral arterial disease 
and diabetes are cared for. 
I am optimistic, however, that in the UK we have already begun to put the pieces in place 
which may help with this.  There is a growing movement internationally to develop ‘limb 
salvage’ services, incorporating multi-disciplinary clinics and rapid referral pathways.88  
There is mounting evidence that these services result in lower major amputation rates.89  
For many centres, this is a radical shift in the way in which foot ulceration is managed.  
Traditionally, patients have mainly been seen only by non-specialist district nurses, whose 
rôle was to change soiled dressings.  As a result, the recognition that a wound was failing 
to heal and that decisions needed to be made about further revascularisation, continuing 
conservative management, or amputation were not made until the next scheduled 
outpatient appointment, often several months later.  Addressing this problem is 
challenging.  One idea which is currently being trialled in some UK centres is a 
combination of education and the establishment of a ‘hot-foot’ line, which allows 
community nurses easy access to urgent specialist review for any wound which is failing 
to heal or has become a cause for concern.90  Evaluation of the efficacy and effectiveness 
of this strategy, alongside its cost-effectiveness is still lacking.  The recent GIRFT (Getting 
It Right First Time) report on Vascular Surgery in England supports the development of 
these services and has further led to the development of an ambitious Quality 
Improvement Framework by the Vascular Society of Great Britain and Ireland.91,92  This 
quality improvement framework sets ambitious targets of two days between referral and 
assessment for severe limb ischaemia or foot sepsis and seven days for stable disease.92  
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While the principal goal of these services is limb preservation, the added benefit is that 
patients without reasonable limb salvage options can have early discussions about the 
option of amputation.  By doing so, we have the opportunity to perform a higher 
proportion of amputations on an elective basis when patients are not acutely septic or 
malnourished from the effects of chronic sepsis and/or pain, which is likely to have 
consequent benefits in terms of improved survival and reduced complications.  My risk 
model suggests that an elective patient with a white cell count 5x109 cells/L lower and 
5kg heavier would have 2.8 times the odds of survival to hospital discharge when 
compared with an identical patient admitted as an emergency with reciprocal changes in 
white cell count and weight. 
5.3.2 A prognostic model of risk 
The development of an accurate model of peri-operative risk is also important for 
practice.  As I have discussed in Chapter 2, it could be used to aid counselling and 
decision-making, either in clinic or at the bedside, by quantifying the probability of the 
patient surviving to hospital discharge, and I have developed a web calculator for easy 
use in clinic which is available from www.ambler.me.uk/Vascular.  The General Medical 
Council (GMC) advice on consent states that ‘discussions with patients should focus on 
their individual situation and the risk to them.’93  As previously highlighted, surgeons are 
poor at estimating individual patient risk.62,63 The lowest-risk 10 percent of patients had 
estimated in-hospital mortality risk of 0-1.2%, while the highest risk 10 percent had an 
estimated risk of death exceeding 22%.   
With this wide range of absolute risks, I feel that the information gained from a risk 
calculator is essential if we are to satisfactorily individualise risk estimates in the way 
suggested by GMC guidance.  As the choice between amputation and conservative 
management is often the choice between amputation and palliation, it is even more 
important that these discussions are conducted in the context of reliable risk estimates.  
One possible use of this calculator might be in highlighting those patients who are 
unlikely to have a good outcome from amputation.  For example, an underweight 85-
year-old patient with sepsis who would need an above knee amputation would have a 
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low chance of surviving amputation.  Rather than intervening, which entails a high chance 
of prolonged and greater morbidity and eventual (unavoided) death, it may be better to 
consider and discuss palliative management, having now identified them accurately with 
this prognostic model. 
Previous procedures to the amputated limb were associated with reduced mortality 
rates.  While it is possible that having had previous procedures is a surrogate for ‘fitness’ 
in some way, it may also be that intervention to facilitate healing at a trans-tibial rather 
than trans-femoral level might have multiple benefits, both in terms of improved short-
term outcomes and also in terms of the improvement in long-term functional outcomes.  
Supporting this hypothesis is the fact that 51% of patients with a previous procedure had 
a trans-tibial amputation, whereas only 43% of patients without a previous procedure 
had a trans-tibial amputation.  While it is possible that some of the effect seen for trans-
tibial amputation is due to unmeasured confounding, the association was strong even 
when all measured confounders were taken into account in multivariate modelling 
(adjusted odds ratio for in-hospital mortality 0.61, 95% C.I. 0.52-0.72). 
The other area where accurate risk estimates are potentially important is in routine 
surgical audit.  In 2013, publication of surgeon-specific outcome data became compulsory 
in England for key index procedures in nine surgical specialties.94  The problems 
associated with the publication of unadjusted outcomes were highlighted by the first 
specialty to report outcomes – Vascular Surgery – where newspapers immediately 
reported on high unadjusted mortality rates.95 These were subsequently revealed to be 
well within the normal range once case mix adjustment had been performed.95,96  While 
not without its problems, publication of outcomes has been shown, time and again, to be 
followed by improvement in those outcomes – a Hawthorne-like effect.  As a result, 
publication of outcomes is unlikely to be discontinued.  It is important, therefore, that 
this is done in as constructive a way as possible, and the availability of an accurate 
method for calculating individual patient risk could be used to reduce problems such as 
the penalisation of surgeons who take on higher risk cases in the future, by facilitating 
appropriate risk adjustment. 
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5.3.3 Core outcome sets – development of the ‘long list’ of outcomes 
The huge number of outcome measures revealed by the systematic review highlights the 
need for core outcome sets in order to improve the efficiency of research.  Resources for 
research studies are limited and it is therefore critical that attention is paid to the 
outcomes which matter most to patients, carers and healthcare professionals.  In 
addition, the focus groups revealed several outcomes which had not previously received 
attention in research studies.  There was evidence of huge inefficiency in the research 
which has been done into improving outcomes for amputee patients.  This inefficiency 
must be addressed if we are to make adequate progress in improving outcomes for these 
unfortunate patients. 
5.3.4 Core outcome sets – coming to consensus 
It is clear from the broad range of outcomes in both short- and medium-term core 
outcome sets that there is a plethora of different issues facing amputee patients.  In the 
short-term, there are issues relating to the amputation stump itself in terms of healing, 
infection, pain and whether the patient needs to go back to theatre for further surgery, 
such as revision of the amputation stump.  There are care-related issues such as peri-
operative complications (in Chapter 2 I showed that respiratory, cardiac and renal 
complications are all common following amputation), need for re-admission to hospital 
and effective communication with the healthcare team.  Mortality is also common and 
both the fact of and the cause of death are short-term core outcomes.  The possibility of 
deterioration of the other leg is also a concern.  Given the life-changing nature of major 
limb amputation it is not surprising that the psychological health of this patient group is 
an important concern.  In the medium-term, in addition to the stump-related issues 
mentioned above, more functional outcomes predominate such as mobility, independent 
living and overall quality of life.   
Improving outcomes for amputee patients will require a multifaceted approach.  At 
present, the British Association of Chartered Physiotherapists in Amputee Rehabilitation 
(BACPAR) have produced guidance on the interventions that may be performed in 
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amputee rehabilitation, but this is more of a long list of possibilities than a short-list of 
recommended rehabilitation techniques or therapies.97  The Vascular Society of Great 
Britain and Ireland has also produced a quality improvement framework for patients 
undergoing amputation.8  This covers many of the areas measured by the core outcome 
sets I have developed, but fails to cover issues of communication or psychological 
morbidity.  The core sets I have developed therefore highlight important outcomes which 
are not well covered by existing guidelines. 
5.4 Limitations of the project 
5.4.1 Predictors of peri-operative risk 
Limitations of my work on identifying predictors of peri-operative risk include the fact 
that the case completion rate in the NVR is only around 60%.17  While this is a dramatic 
improvement over the situation 10 years ago, when only half this number of cases was 
entered,98 there exists the possibility that the non-submitted cases might be 
systematically different from submitted cases.  This would introduce bias into my results.  
The UK National Vascular Registry reports for the past two years have highlighted the fact 
that case ascertainment rates vary widely between Vascular Networks.17,38  It is possible 
that many of the missing data relate largely to institutional and administrative factors 
rather than patient-related factors.   
In addition to missing cases (patients), there was also a degree of missing data items 
within otherwise completed cases.  Most data collection items in the NVR are 
compulsory. Of those that are not, missing data rates ranged from around 10% for ECG 
findings up to 36% for pre-operative haemoglobin level.  While this sounds like a high 
level of missing data it is important to realise that there were still over 6000 cases in the 
registry where haemoglobin level was recorded. This means that the multiple imputation 
methodology has large amounts of data from which to calculate the likely values for the 
missing items.  Multiple imputation methodology is the gold-standard method for 
handling missing data in clinical research.56 It is preferred over complete case analysis, 
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where cases with missing items are discarded, and single value imputation methods, as it 
makes use of all available data and also allows information on the uncertainty about the 
true values of missing data to be used to correct P-values and confidence intervals, 
allowing these to be calculated reliably.  Sensitivity analysis using only complete cases 
gave similar results (Table 2.4 on page 29), so there was no evidence that the imputation 
process introduced significant bias. 
Validation of data within the NVR is also lacking.  This is a general criticism of registry-
based studies, as to my knowledge, no national registry of major lower limb amputation 
cases has been rigorously validated.  The Swedish Vascular registry (SwedVasc) and the 
Hungarian registry have been validated (and reasonable levels of validity identified), 
although the former only for aortic aneurysm repair and carotid surgery while the latter 
also for infra-inguinal arterial reconstruction.99,100  Plans are in place for a validation 
exercise of the UK NVR in 2020, but this also may not include the major lower limb 
amputation subset. 
A further weakness of this study is due to limitations of the variables recorded in the NVR.  
For example it is increasingly recognised that frailty is an important risk factor for peri-
operative complications, including mortality.45  Dependent functional status has been 
shown in other work to be important for predicting mortality in patients undergoing 
amputation.12,14,16  However, until recently no measure of frailty or functional status has 
been recorded in the NVR.  A measure of frailty was added to the NVR dataset in January 
2019, which will allow further investigation of this factor in the future. 
I have modelled in-hospital mortality, as that is the audit standard within the UK Vascular 
Registry.  Unfortunately, this is different from many other national audit databases such 
as SwedVasc, which reports 30-day mortality.  As I have highlighted in Chapters 3 and 4, 
inconsistency in outcome reporting presents difficulties for clinical audit and research, as 
it makes pooling of information between studies (meta-analysis) challenging.  This further 
justifies the development of core outcome sets, which I have developed in Chapters 3 and 
4 of this thesis. 
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Finally, I only used data from the UK.  This makes extrapolation of these results to other 
healthcare settings questionable.  One of the things which makes international studies 
difficult is that different registries report both different outcomes and different baseline 
characteristics.  Some work has been undertaken to establish a core minimum 
information set for patients with both acute and chronic limb ischaemia.82,101  This work 
complements the work I have done in Chapters 3 and 4 on core outcome sets by 
establishing consensus on the other data which registries should collect. 
5.4.2 A prognostic model of risk 
Any risk model is only reliable if the data used to generate it are reliable.  Therefore, all 
the comments above about missing cases, missing data within cases, missing parameters 
and the lack of external data validation are also relevant to the risk model I have 
developed.  While the apparent discrimination of the model is good on internal 
validation, it is entirely possible that the introduction of other unmeasured parameters 
might result in a different model with improved discrimination.  Examples of these might 
be functional status and frailty.  As mentioned previously, dependent functional status 
has been shown in several other studies to be a good predictor of poor outcome.12,14,16  It 
is possible that if this were recorded in the data and used to generate the risk prediction 
model, a different optimal model may have been selected by the automatic parameter 
selection method.  In addition, around 40% of cases were missing from the database.  The 
availability of the additional data would most likely have led to improvements in the 
model by improving the precision of parameter estimates.  It is also possible that other 
parameters might have come out as more important as a result of this. 
A second limitation is the lack of external validation of the model.  I can therefore only 
talk about the ‘apparent’ discrimination and calibration of the model, as it is possible that 
overfitting has resulted in optimistic estimates of the C-statistic.  Poor discrimination and 
calibration of models when tested on external data is an established problem in risk 
prediction,102 so assessment of the true discrimination and calibration of the model will 
need to be assessed in future work.  I guarded against overfitting by using the stringent 
Schwarz-Bayes criterion to determine whether parameters should be included in the 
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model, and the fact that the model is based on data from almost 10,000 cases makes it 
unlikely that the sample is unrepresentative.  One option would have been to use only a 
subset of the data to generate the model and to validate it on the remaining data.  This 
approach is efficient in terms of avoiding the need for a second validation study, but 
inefficient in terms of model generation, as it results in a model with poorer estimates of 
the parameters than would have been possible if all of the data were used.  Studies which 
perform validation using a subset of available data have also been criticised by the UK 
National Institute for Health and Care Excellence (NICE) as validation was performed on 
data which could not be truly regarded as ‘unseen’.65  I therefore feel that it is better to 
generate the best possible model using all of the available data and to defer validation to 
a follow-up study.  By using truly unseen data for validation, we then also get more 
reliable estimates of the discrimination and calibration of the model in practice. 
Finally, though the model is good at discriminating between patients who die in hospital 
and those who are discharged alive, it is much less good at predicting morbidity 
outcomes.  This is not unexpected as the model has been optimised to predict in-hospital 
mortality.  In addition, even models developed specifically to predict morbidity outcomes 
had C-statistics which were not as good as the C-statistic for the model for in-hospital 
mortality when assessed against that outcome.  It is possible that the difficulty with 
predicting morbidity outcomes could be related to under-reporting of complications.  This 
phenomenon is well reported in other large healthcare administrative databases such as 
NHS England’s Hospital Episode Statistics publications.21,103  Data on in-hospital mortality 
are far more likely to be accurate.  It is possible, therefore, that under-reporting of 
complications is making it more difficult to predict these outcomes. 
5.4.3 Core outcome sets – development of the ‘long list’ of outcomes 
There are some limitations to the process used to develop the long list of outcomes for 
the core outcome sets.  Firstly, although screening of search results was done by two 
independent people and discrepancies were then resolved by careful examination of the 
studies, discussion and reference to a senior author, outcome extraction was largely done 
by only a single individual.  I and one other person extracted outcomes from 10% of 
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studies independently, compared results and came to a consensus.  We then repeated 
this for a further 10% of studies.  Results from this second 10% were very similar, so we 
then extracted outcomes from the remaining studies independently – I extracted from a 
further 50% of studies and the other reviewer extracted from the remaining 30% of 
studies.  As there was not duplicate extraction from these studies it is possible that we 
may have missed some previously studied outcomes.  I feel that any deficiencies from this 
are likely to have been minimal, owing to the number of studies and outcomes identified, 
and compensated for by the fact that I went on to hold focus groups to supplement the 
outcomes revealed by the systematic review, and I also allowed participants in the Delphi 
survey to suggest additional outcomes in the first round. 
A further deficiency is the limited size of the focus groups, with only three patients and 
three carers represented.  I did invite a much larger number of participants but found it 
difficult to get engagement from patients.  Those who did not agree to attend either cited 
a lack of interest in the process or difficulties with transportation.  While I provided 
wheelchair-suitable transport from patients’ homes to the venue, some patients still felt 
that it was a lot of effort to get to and from the venue and so were unwilling to attend.  I 
did, however, manage to get engagement from all major stakeholder groups apart from 
orthopaedic surgeons.  In our area, few orthopaedic surgeons are involved in major limb 
amputation so it may be that they felt it was not particularly relevant to their practice. 
A final limitation is that there is no objective way of reducing the outcomes from the 
systematic review and the themes from the focus groups to domains.  I used a recognised 
system to categorise the outcomes in order to help me in this process, making the 
process somewhat more objective.68  The system I developed was also checked carefully 
with both my thesis supervisors and the PLACEMENT trial management group in order to 
reduce bias introduced by this process as much as possible.  The inherently subjective 
nature of this process does, however, mean that it is possible that the way in which 
outcomes were grouped, and the wording used for the domains, may have introduced 
bias.  I am hopeful that allowing participants in the Delphi to suggest new 
outcomes/domains in round one will also have minimised the effect of this. 
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5.4.4 Core outcome sets – coming to consensus 
Limitations also exist in the consensus process for core outcome set development.  The 
first of these is in the number of patients and carers who completed the survey.  The 
study team invited all of the amputee patients they came across in clinical practice.  I 
invited all of the patients recruited to the PLACEMENT trial who had given consent to be 
approached for further qualitative work, by sending out letters of invitation and also by 
telephoning.  Despite this, only ten patients and one carer completed the first round of 
the consensus survey, with seven patients and one carer completing all three rounds, 
compared with 112 healthcare professionals who completed the first round and 83 who 
completed all three rounds.  Healthcare professionals did represent many different 
professions, including surgeons, anaesthetists, physicians, nurses, prosthetists, 
physiotherapists, occupational therapists and clinical psychologists, so it is inevitable that 
there would be a larger number of healthcare professionals than patients and carers.  I 
attempted to reduce the impact of this imbalance by retaining outcomes which were 
rated highly by either healthcare professionals or patients/carers in round one of the 
survey and also presenting separate response histograms when asking participants to rate 
outcomes in rounds two and three of the Delphi survey.  As I did not feel that there was 
an entirely natural way to weight responses from the different groups, I took the 
pragmatic decision to weight all responses equally, as I was concerned that if I gave equal 
weight to each group rather than to every individual, that individual views from patients 
or carers would carry a disproportionate amount of weight. 
A further limitation is that health service commissioners and policymakers were not 
invited to participate in the consensus process.  It is possible that the outcomes which 
commissioners and/or policymakers view as ‘core’ may be different from those which 
healthcare professionals, patients and carers view as ‘core’.  In hindsight, this may have 
been an oversight: neither I nor my advisors thought of this point when devising the study 
protocol. 
Finally, the fact that I allowed the face to face meeting to modify the results from the 
(much larger) consensus survey could be considered a limitation.  I added two outcomes 
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which had not been rated as ‘core’ to both short- and medium-term core sets, and 
modified the wording of one of the outcomes slightly in order to highlight that pain in the 
phantom limb (pain experienced by an amputee patient which appears to be coming from 
the part of the body which has been amputated) should be considered when reporting 
medium-term pain.  One of the outcomes added (development of problems with the 
other leg) was on the threshold for acceptance from the Delphi survey.  The other added 
outcome (psychological morbidity: anxiety or depression) was not even rated in round 3 
of the survey, having not received enough support in round 2 to be carried forward.  It 
was successfully argued by the clinical psychologist on the panel that this was because 
only one clinical psychologist responded to the Delphi survey, so their voice had not been 
‘heard’ in the survey. 
5.5 Future directions 
I approached this project with the hope that through identifying predictors of poor 
outcomes, developing a risk model and developing core outcome sets I would then be 
able to produce recommendations for standardising research and for a programme of 
quality improvement for the care of amputee patients.  Having now successfully achieved 
those objectives, I find, however, that I have become aware of more questions than 
answers and have come to realise that a further large programme of work is required 
before such firm recommendations can be drawn up.  I will look at each part of the 
project in turn and lay out some of the key work which is still necessary. 
5.5.1 Predictors of peri-operative risk 
Many of the comments already raised in this Chapter require further work.  Firstly, more 
work is needed to assess whether the new frailty parameter in the NVR is a good 
predictor of outcome in amputee patients.  Frailty has been shown to predict outcomes in 
a general cohort of vascular surgery patients,45 as well as more specifically in abdominal 
aortic aneurysm repair and lower limb revascularisation.104  While functional dependence 
has been shown in other studies to be predictive of outcome in patients undergoing 
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amputation,12,14,16 there has not to my knowledge been any work looking at the similar 
but related concept of frailty.  In addition, the NVR has chosen to use a bespoke four-
point frailty score rather than an established (validated) measure of frailty such as the 
Edmonton Frail Scale.105  As a result, it is not currently known whether this four-point 
scale will be a useful prognostic indicator for vascular patients.  Further work is required 
to assess the utility of this measure as a prognostic indicator and the relationship it has to 
outcomes such as in-hospital mortality or length of stay. 
Secondly, the data in the NVR have never been subjected to external validation in terms 
of either formal linkage with routinely collected data such as English Hospital Episode 
Statistics or the Welsh Secure Anonymised Information Linkage datasets.  In fact, no 
amputation registry has ever been subjected to this rigorous process of external data 
validation.  Both the Hungarian and Swedish national vascular registries have been 
validated for patients undergoing abdominal aortic aneurysm repair or carotid 
endarterectomy, but this process has not been undertaken for the amputation subsets of 
these registries.99,100  In order to provide confidence that the results of analysis from the 
amputation subset of the NVR are valid, I believe that it is necessary to undertake such a 
project. 
Finally, I have suggested above that it is possible that limb-salvage services may improve 
outcomes for amputee patients as well as for the patients where limb salvage is 
successful.  This is unknown at present but there are good reasons (discussed above) to 
believe that it might be the case.  This is not something that lends itself to a randomised 
trial, as the very presence of an active limb-salvage service in a hospital is likely to have 
an impact on any patients who might be randomised to ‘usual care’.  Unfortunately, this 
means that this is an area of practice where running a randomised controlled trial would 
be difficult, so high-quality ‘level one’ evidence may never, therefore, exist.  The next best 
thing would be a comparison with historical controls, perhaps matched using a propensity 
scoring approach.  A brief search of the literature around modern limb-salvage services 
revealed only one study looking at results before and after implementation of the new 
service, and this focused (understandably) on limb salvage rather than the outcome for 
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amputee patients.89  While this was not a systematic review, it highlights the fact that 
there is much work still to be done in this area. 
5.5.2 A prognostic model of risk 
The prognostic model I have developed needs to be externally validated.  This could be 
done using data from the NVR over the next two years (which became available in 
December 2019).  Once the performance of the model has been validated on new data it 
will then be possible to accurately risk adjust outcomes and to develop benchmarks for 
unit performance which could then be used as part of a quality improvement process 
designed to drive up standards. 
I discussed the unavailability of a measure of frailty within the NVR over the study period 
and the introduction of a new measure of frailty into the NVR dataset above.  Once it has 
been established whether this new frailty measure is predictive of outcome it will be 
important to evaluate whether the addition of this measure significantly improves the 
discrimination of the model I have developed. 
In addition to this, an accurate risk prediction model for in-hospital mortality is a 
reasonable first step in prognostication for patients undergoing major lower limb 
amputation.  However, the standard short-term mortality endpoint used in most of the 
world is 30-day mortality rather than in-hospital mortality.  In order to accurately 
compare results in the UK with those of other healthcare systems so that we might learn 
lessons from both good and bad performance, it is therefore necessary to standardise the 
measurement of this outcome.  This can be achieved through linkage of the NVR to the 
UK death registry maintained by the Office for National Statistics.  This linkage would also 
allow longer term outcomes such as mortality at one year to be modelled.  To my 
knowledge, only one model exists which predicts mortality at one year following lower 
limb amputation.106  This model was developed using data from the USA Veterans Affairs 
Surgical Quality Improvement Programme and found a mortality rate at one year of 
28.8% for patients undergoing above the ankle amputation.  It is therefore questionable 
how much benefit the approximately 20% of patients who survive to hospital discharge 
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but who then die within the first year after surgery are getting from their amputation, as 
there is little work which has been done looking at the quality of life of amputee patients 
in the first year following amputation or their satisfaction with their health status.  I 
therefore think that mortality at one year may be an important measure to be able to 
discuss with patients. 
5.5.3 Core outcomes 
I have developed core outcome sets which are applicable both to studies focussed on 
short-term outcomes such as post-operative pain, and medium-term outcomes such as 
prosthetic rehabilitation.  To my knowledge, this is the first time that core outcome sets 
for studies of patients with the same condition but for different durations have been 
developed.  This is important in conditions such as major lower limb amputation where 
recovery to steady state following surgery takes a long time, as it makes the core sets 
more applicable.  I was not surprised to discover that while there was some overlap 
between the two core sets, with four outcomes common to both the short-term and 
medium-term sets, the majority of outcomes in the two core sets were actually different, 
as the importance of outcomes such as immediate perioperative complications reduces 
with time, whereas the importance of outcomes such as independent living increases.  
This highlights the need to consider the appropriate timing of core sets in future research. 
The final core sets include a wide range of outcomes, from hard clinical outcomes such as 
mortality, to softer outcomes which are more difficult to measure and lend themselves to 
patient report such as social re-integration (participation in work and social activities).  
Further work is needed to identify the best way to measure these outcomes.  Part of this 
must include the development of a multidimensional patient reported outcome measure 
(PROM).  There are currently several PROMs which measure mobility and function in 
prosthesis users, and two others which measure mobility alone in all amputee patients 
(ongoing, unpublished work).  There are no PROMS which are designed to measure 
multiple domains of health-related quality of life in amputee patients which are 
applicable to both prosthesis users and those who do not mobilise with a prosthesis (who 
represent approximately 60% of amputee patients).107  A new PROM is therefore needed 
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to adequately capture disease-specific health-related quality of life, which would then 
need to be assessed for face and construct validity as well as reliability and 
responsiveness.108 
In addition to the patient-reported outcomes in the core set there are some clinician-
assessed outcomes such as wound healing and infection.  There are multiple definitions 
for these, so there is need for consensus on the best way to measure them.  Putting this 
together with a newly designed and validated PROM, it would then be possible to define 
a core measurement set to go alongside the core outcome set I have developed.  This 
would require a further consensus process.  With these two pieces, if we can encourage 
trialists and registries to adhere to these standards we will finally be able to realise the 
goal of efficient future amputation research by ensuring that we measure the outcomes 
which are most important to patients, carers, professionals and the health service in a 
consistent manner.  Standardisation of reporting is as least as important in national 
registries as it is in clinical trials, as observational studies require adjustment for 
confounding influences and results become more robust if it is possible to pool data from 
multiple registries. This requires standardisation of the collection of confounding 
variables as well as outcomes, but with such standardisation it would also be possible to 
perform correction for confounding factors at scale in a uniform way across multiple 
registries. This is much needed work, as we saw in Chapter 2 the problems related to the 
generation of prognostic models from different national registries which collected data 
about different risk factors.  Work has already begun in this direction in vascular surgery, 
though not for patients undergoing amputation.82 
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5.6 Conclusions 
The objectives of this thesis were: 
1.  
a. To identify the principal risk factors for peri-operative mortality and 
morbidity in patients undergoing MLLA using routinely collected national 
data. 
b. To use these risk factors to develop a prognostic model for peri-operative 
mortality, again using routinely collected national data. 
2.  
a. To develop an exhaustive list of outcomes for research and service 
evaluation involving patients undergoing major lower limb amputation as a 
result of complications of peripheral vascular disease.  
b. To establish consensus on core outcome sets for both short-term and 
medium-term research and service evaluation involving patients 
undergoing MLLA for complications of peripheral vascular disease, using 
the list developed in 2.a. above as a starting point.   
In the preceding sections of this chapter I have highlighted the ways in which I have 
achieved these goals, highlighting some limitations and areas where further work is 
needed. 
Major lower limb amputation is a mutilating procedure, which is performed for end-stage 
peripheral vascular disease when surgeon and patient agree that it is the best option to 
either prolong life or improve its quality.  As it is viewed by many as a ‘failure’ of surgical 
reconstruction, research has mainly been focussed on prevention. In order to improve 
outcomes for this group of individuals, we must accept the fact that sometimes it is the 
best option available, and work to make it the best option that it can be.  The 
components of my thesis have sought to tackle this in different ways.  It is my hope that 
by highlighting the predictors of perioperative mortality and morbidity in these patients 
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that it will stimulate researchers to develop interventions which might improve these 
outcomes.  By developing a model for predicting perioperative mortality risk it is my hope 
that this will enable clinicians to better inform patients and their relatives about the 
expected outcomes of surgery.  By developing core outcome sets I have highlighted the 
outcomes which matter the most, so should receive attention for those designing both 
interventional trials and quality improvement projects, allowing future studies to be more 
focussed.  Finally, by defining the list of outcomes which should be reported by all of 
these studies, different studies will become more comparable, so that effective 
interventions will be identified more readily and implemented widely, and research waste 
minimised.  
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Appendix A. Thematic framework for core 
outcome sets focus groups 
 
Aim: To identify outcomes for patients following major lower limb amputation 
Data: 4 qualitative focus groups with patients, carers and health care professionals, fully 
transcribed verbatim. 
Analysis: Thematic analysis. Focus Group 1 with mixed health care professional group = 
blue font, Focus Group 2 with patients and carers = red font, Focus Group 3 with health 
care professionals (medics) = black font, Focus Group 4 with physiotherapist health care 
professionals = green font 
Overview of themes 
1. Quality of life 
2. Social functioning 
3. Psychological/ biopsychosocial factors 
4. Illness representations 
5. Communication 
6. Financial issues 
7. Amputation type 
8. Wound healing 
9. Pain 
10. Rehabilitation 
11. Mobility: Prosthesis 
12. Mobility: other mobility aids 
13. Returning home 
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14. Falls  
15. Readmissions 
16. Clinical state 
17. Fate of other limb 
18. Risk reduction behaviour 
19. Mortality 
 
The thematic framework is presented in full on the following pages.
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 Theme Suggested sub-themes Comments Outcomes 
1.  Quality of life 1.1 Body image  Body image 
1.2 Comfort • Free of pain and complications Pain in amputation stump/phantom 
pain/prosthesis comfort and fitting 
1.3 Independence • Return to previous e.g. whether can only use 1 room 
in the house, whether leading an “active life”, 
whether carers needed at home 
Level of independent mobility or function 
achieved/independent living/ability to return to 
work 
2.  Social functioning 2.1 Social goals 
 
• Relates to personalised individual patient’s goals 
both social e.g. going away to their caravan/holiday 
home, going out for meal, going out for drink, 
pushing grandchild in pram, walking daughter down 
church aisle at her wedding, walking into lounge on 
Christmas day with grandchildren  
Participation in social activities 
2.2 Practical goals • Relates to practical goals e.g. filling car with petrol, 
shopping (reaching high shelves, pushing trolley), 
Independent living 
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access to buildings, getting taxis, getting on 
aeroplane. Mobility e.g. are they able to get out of 
house, are they able to move around house 
2.3 Relationships • Relationships affected (“I wasn’t a nice person to 
know”) 
Coping strategies and psychological adaptation 
2.4 Hobbies and exercise • Hobbies and exercise: Golf, working in shed, cycling, 
Zumba fitness class, getting into garden  
Level of independent mobility or function 
achieved 
2.5 Personal care • Personal care: cooking for self, shaving self, getting 
up to go toilet, getting own drink of water, 
housework 
Level of independent mobility or function 
achieved 
2.6 Personal space • Ability to have ‘personal space’ Independent living 
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2.7 Social support • Existence and use of social network/social support Participation in social activities  
2.8 Driving • Patient able/allowed to drive. Patient has gained 
“the blue badge” for parking 
• Suggested that this might be more of a concern for 
family members 
Participation in social activities/Independent 
living 
2.9 Sexual activity • Not mentioned spontaneously but only mentioned 
briefly in relation to literature review prompts 
Sexual activity 
3.  Psychological/ 
biopsychosocial 
factors  
3.1 Managing expectations 
 
• Managing expectations and feeling psychologically 
prepared. Will depend on whether elective vascular 
or orthopaedeic patient (e.g. patient doing own 
research before surgery, time for visit from nurse, 
read leaflet, visit unit/talk to surgeon in advance) /  
Coping strategies and psychological adaptation 
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• Being prepared might involve psychologist, CBT 
counselling, chronic pain counselling, pain 
management programme 
3.2 Negative • Grief/bereavement/loss for the future, depression, 
anger, anxiety, disappointment, shock, frustration, 
regret, guilt/forgiving self, blame, sadness, fear (and 
fear of unknown/pain), uncertainty (e.g. could 
amputation have been avoided?), emotional trauma 
Coping strategies and psychological 
adaptation/Anxiety or depression 
3.3 Positive  • hope for a new start, positive mood, motivated, 
euphoria/elation, self-belief, confidence 
•  
Coping strategies and psychological adaptation 
3.4 Recognising ‘difference’ • Physical: Phantom sensations/forgetting haven’t got 
leg (try to cross legs, think can still feel feet) 
Phantom sensations or pain/falls 
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3.5 Family perspective • How will family cope Not covered – Impact on family/loved ones 
4.  Illness representations 4.1 Narrative around amputation • Patient beliefs around what has happened to them. 
(see Weiman Model Common Sense Model).  
• E.g. Amputation can be seen as positive by some 
patients if have experienced pain previously, or if 
had experienced “nibbling”, or if had had “smelly 
open wound” which required frequent visits to 
hospital and restricted social functioning. Some 
patients wish they had had the amputation earlier. 
“amputation is not always a failure” 
• Could amputation have been avoided? 
• Not being treated like “an invalid” 
• Dealing with other people’s 
reactions/stigma/staring/derogatory 
Satisfaction with situation 
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5.  Communication  5.1 Patient and health professional 
communication 
 
• In terms of patient: being listened to, involved in 
decision making, given opportunity to ask questions, 
interaction with surgical team, being ‘understood’ 
and understanding what was going to happen, 
empowering patient 
• Individual patient goal setting (theory of care 
owners’ model) 
• Terminology - asking the patient what they want to 
call the residual limb  
• Empathy from health care professionals 
• Continuity of care (‘knowing’ the patient) 
• Will depend on whether elective vascular or 
orthopaedeic patient 
Not covered – two new outcomes: 
• Shared decision making. 
• Effective 
communication 
between healthcare 
team and patient/carers 
5.2 Multi-disciplinary communication • MDT meeting amongst health professionals Compliance with guidelines for care 
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6.  Financial issues 6.1 Return to work • Suggested that this might be more of a concern for 
family members 
• Not only about financial concerns but may also be 
psychological issue relating to positive mood, 
independence etc. 
Ability to return to work 
6.2 Financial worries • Loosing home, cost of adapting home Cost of treatment 
7.  Amputation type 7.1 Amputation technique 
 
• ‘Good’ and ‘bad’ amputation  
• Amputation technique – long posterior flap or skew 
flap – will have impact on mobility and rehabilitation 
e.g. prosthesis fitting e.g. months of dressings being 
changed and months of attending outpatients 
appointments. Different perspectives – to surgeon 
could be failure of treatment but in terms of 
General stump or wound problems 
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rehabilitation could save months. Positioning of scar 
line 
7.2 Level of amputation • Level of amputation (i.e. through, below or above 
knee) – different perspectives – to surgeon could be 
failure of treatment but in terms of rehabilitation 
could save months (will also impact on time until can 
go home – if home not already adapted, above knee 
amputation might mean cannot go home to existing 
accommodation) 
Prosthesis use/satisfaction with 
situation/prosthesis comfort and fitting/Time 
until mobile with temporary or definitive 
prosthesis/Length of stay 
7.3 Shape of residual limb • Shape of residual limb (can be changing shape for up 
to 12 months afterwards). Fixed flexion deformity. 
“Stump volume reduction”? 
Stump swelling/joint contractures 
8.  Wound healing 8.1 Wound healing • wound healing (or prolonged wound healing, deep 
or surface healing, strength of wound, scarring, skin 
Problems with amputation stump healing 
  
175 
grafting) and on amount of energy required to walk, 
stitches removal 
9.  Pain 9.1 Level of pain • Free of pain? Is the pain controllable? (Pain should 
be controllable but relies on the patient telling 
health professional) 
• Chronic pain, does the pain escalate. 
• For some even 12 months later residual limb may be 
changing – complex. Need to consider time periods. 
• Pain will be categorised/asked about at different 
time periods  
– post operative setting: are you in pain? Is it 
mild/moderate/severe? 
• Later is pain persistent? What does it feel like? 
Where is it coming from? 
Pain in amputation stump 
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9.2 Residual limb pain 
 
 Pain in amputation stump 
9.3 Nerve pain/neuroma  Pain in amputation stump/peripheral nerve 
problems 
9.4 Wound pain/surgical site pain • e.g. Pressure ulcer Pain in amputation stump 
9.5 Sepsis pain  Pain in amputation stump 
9.6 Phantom limb pain • Phantom limb pain deals with emotional and 
physical aspects 
Phantom sensations or pain 
9.7 Arterial pain  Pain in amputation stump 
9.8 Walking pain • (e.g. muscle cramps) Pain in amputation stump 
9.9 Prosthesis pain  Pain in amputation stump/problems with skin 
of amputation stump/prosthesis comfort and 
fitting 
9.10 Pain management: Medication • Referral to others for pain e.g. pain team, GP, plastic 
surgery, psychology, 
• OTC e.g. paracetamol 
• Opiates e.g. Morphine. Side effects e.g. vomiting 
• Type of anaesthetic Side effects e.g. vomiting 
Amount of painkillers needed 
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• Co-codamol 
• Gabapentin 
9.11 Pain management: non-medication • Are patients supplementing due to pain (e.g. 
cannabis use) 
• Other ways of handling pain e.g. handling 
techniques, massage, laser or mirror box therapy 
Not covered – use of drugs or therapies which 
have not been prescribed 
10.  Rehabilitation  10.1 Rehabilitation • Continuity of care (confidence, trust, building 
relationships) 
• Peer support 
• Time out of bed  
• Rehabilitation generally and self-awareness and 
setting realistic goals for mobility 
Amount of physiotherapy during rehabilitation/ 
time taken to complete rehabilitation 
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11.  Mobility: prosthesis 11.1 Prosthesis comfort • Generally and length of time able to wear prosthesis 
comfortably, being able to bear weight for different 
lengths of time 
prosthesis comfort and fitting 
11.2 Prosthesis look •  Prosthesis use/satisfaction with situation/prosthesis comfort and fitting 
11.3 Prosthesis function • Walking gait ‘normal’ or acceptable, Stairs, steps, 
indoor/outdoor walking, walking on slopes, getting 
up if fall, walking various distances, picking up 
objects off floor, carrying objects, Taking on and off 
prosthesis 
Prosthesis use/characteristics of gait with 
prosthesis 
11.4 Overall satisfaction with prosthesis • prosthesis won’t fit sometimes, satisfaction/overall 
experience of using limb daily 
Prosthesis use/satisfaction with 
situation/prosthesis comfort and fitting 
11.5 Time to walking • Patient’s desire to walk (walking training) Time until mobile with temporary or definitive prosthesis 
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11.6 Time to start physiotherapy  • Required equipment available: Suitable footwear 
(e.g. insoles), early walking aid (inflatable), 
compression sock, Frame. Sticks. Crutches. 
• Self-awareness and setting realistic goals 
Amount of physiotherapy during 
rehabilitation/Need for mobility 
aids/satisfaction with situation/prosthesis 
comfort and fitting 
12.  Mobility: other 
mobility aids  
 
12.1 Use of crutches • Frame. Sticks. Crutches. Patients have desire to be at 
same level as others (rather than lower down as in 
wheelchair).  
Need for mobility aids 
12.2 Use of wheelchair • Indoor/outdoor wheelchair. Stump board. Slide 
board 
Need for mobility aids 
12.3 Mobility scooter •  Need for mobility aids 
12.4 Transfers  • Transfers (shower, toilet, bed, car, wheelchair) Need for mobility aids 
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13.  Returning home 13.1 Length of hospital stay • Will be influenced by needing to have the house 
altered, whether a catheter is still in, whether 
amputation was above the knee or not 
• Managing wound as outpatient 
Length of time in intensive care/acute 
hospital/rehabilitation 
14.  Falls  14.1 Experiencing falls  Falls 
14.2 Injury as a result of falls  Falls 
15.  Readmissions  
 
15.1 Readmission relating to surgery • Whether there has been a need for revision surgery 
or not. In 10 post-operative days (short term) or 
after (mid-term?) 
Need for re-admission to hospital after 
discharge 
15.2 Other hospital visits  • Difficult having to go to so many different appointments Not covered – Number of outpatient 
appointments 
15.3 Revision surgery  Need for further operation on stump 
16.  Clinical state 
compared to pre-
operative state 
16.1 Clinical state • Medical stability. Improvement in clinical state. 
Before surgery patient may have been very unwell 
Overall perioperative complications/stroke/ 
myocardial Infarction (heart attack) during 
surgery or follow-up 
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e.g. toes removed, sleeplessness, septic, low 
functioning therefore loss of muscle, and reduction 
in stamina and fitness. 
• Co-morbidity will affect timescale in which to try and 
achieve patient’s goals 
• Operation clinical success (but people still need 
support) 
• Without amputation might be dead 
• Extra energy needed for walking could trigger other 
health problems e.g. stroke, heart attack, vascular 
dementia 
17.  Fate of other limb 17.1 Amputation of other leg • Pressure on other limb due to desire to walk. May 
have to stop walking due to risk on other leg 
Need for amputation of other leg 
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17.2 Deterioration of other leg • Blisters, strain on other knee/hip. Deterioration of 
other limb (may be worsened by longer hospital 
stay, pressure ulcer), Pressure heel sores 
Development of problems with the other leg 
18.  Risk reduction 
behaviour 
18.1 Risk reduction behaviour • Smoking cessation 
• Diabetic control 
• Drug abuse 
• Homeless status 
Diabetic control, use of unprescribed drugs and 
discharge destination already covered.  Smoking 
cessation can be included in Compliance with 
guidelines for care 
19.  Mortality  19.1 Mortality  Death within a specified period of time after 
operation, or while still in hospital after initial 
amputation/length of survival after amputation 
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Appendix B – Publications and Presentations 
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Much of the content of Chapter 2 was published in the European Journal of Vascular 
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Much of the method described in Chapters 3 and 4 was published as a protocol in Trials.  
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Ambler GK, Bosanquet DC, Brookes-Howell L, Thomas-Jones E, Waldron CA, Edwards AGK, 
Twine CP.  Development of a core outcome set for studies involving patients undergoing 
major lower limb amputation for peripheral arterial disease: study protocol for a 
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